-More than 10 million RT-PCR SARS-CoV-2 tests manufactured -Test kits being distributed to over 80 countries -Production capacity trebled to more than 2 million tests per day; set to rise further to meet demand &nbsp; SAN JOSE, Calif.,&nbsp;April 20, 2020&nbsp;/PRNewswire/ --Global genomics leader BGI Group has announced it has produced more than 10 million of its Real-Time SARS-CoV-2 tests, which are authorized under US FDA-EUA, and is distributing them to more than 80 countries around the world. BGI Group is also helping partners to set up emergency testing laboratories in the US, Europe,&nbsp;Middle East&nbsp;and&nbsp;Asia, bringing population-scale detection and diagnosis of COVID-19 to the world. &nbsp; <img class="wp-image-13550 " src="https://www.bgi.com/wp-content/uploads/sites/2/2020/04/Doctors-with-MGI-instrument-Paris.jpg" alt="" width="849" height="637"/> Doctors with MGI equipment at AP-HP hospital group in Paris BGI Group is meeting the demand for testing kits by trebling production and working with governments to launch emergency laboratory solutions. MGI, part of the BGI Group, confirmed an agreement with the French Health Ministry to provide equipment and materials to 19 hospitals throughout&nbsp;France&nbsp;to enable COVID-19 testing of 2 million people, while BGI Genomics confirmed it will provide 1 million RT-PCR tests for diagnosis of COVID-19. BGI Genomics is one of the few companies globally that has products recognized as officially approved or authorized for use in China, the European Union, the United States, Japan and Australia. BGI's RT-PCR Test for SARS-CoV-2 has been granted approval or authorization for emergency use by the US FDA, Europe's CE-IVD, China's NMPA, Japan's PMDA and Australia's TGA. "The most critical thing for all of us at BGI is to help bring this pandemic under control. We are working with governments and institutions globally to achieve this mission," says&nbsp;Yin Ye, CEO of BGI Genomics. BGI Group started out at the forefront of the fight against COVID-19 in&nbsp;China&nbsp;and is now spearheading a worldwide response, deploying not only test kits but also laboratory robots to automate sample preparation and powerful sequencers to track virus mutations. In&nbsp;Wuhan, BGI Group set up its first Huo-Yan or "Fire Eye" Laboratory in five days. This 2,000 square-meter automated Biosafety Level-2 PCR testing laboratory can perform 10,000 tests a day. A comprehensive solution for rapidly scaling up diagnostic testing, the Fire Eye model is now being implemented around the world. The laboratories combine the best of BGI Group expertise.&nbsp; The laboratory equipment is produced by MGI, a part of the BGI Group focused on sequencing tools and lab automation. Sequencing plays a number of roles in the fight against COVID-19, explains&nbsp;Duncan Yu, President of MGI. "It helped identify the virus that caused COVID-19 and can track new strains of the virus as it mutates and the speed of those changes." In&nbsp;Sweden, BGI Group has been working with the&nbsp;Karolinska Institute&nbsp;to build a Fire Eye lab in&nbsp;Stockholm. It will perform both virus detection and scientific research for comprehensive monitoring of virus mutations. In&nbsp;Kansas City, BGI Group formed an innovative partnership with local business leaders and The&nbsp;University of Kansas&nbsp;Health System. The business leaders provided funding to help protect their local community and provide 50,000 test kits, along with lab automation equipment. The BGI Group has a long history of responding to public health crises, including decoding the genome of the SARS virus in 2003, then developing the virus detection kit in 96 hours, and helping fight the Ebola outbreak in 2014 in&nbsp;West Africa. SOURCE BGI Group

BGI Group Helping Over 80 Countries for Timely COVID-19 Detection and Intervention

<img src="https://cdn.it.bgi.com/source/14d1dd0c4bd58c87451d60284436032.png" alt="14d1dd0c4bd58c87451d60284436032.png" data-href="" style=""/>We are excited to meet you in person at ASHG in Washington DC this year! &nbsp;As a global multi-omics service provider, we are excited to announce the following programs at ASHG this year: Booth Exhibition:Come talk to us at our booth #309 to learn about our multi-omics analysis solution, a unique integration of NGS and mass spectrometry services. We have been the trusted DNBSEQ™ sequencing service provider in US since 2017 to support the genetics research community. Our US-based team allows additional integration of proteomics and metabolomics into a comprehensive portfolio of omics services for the academic and biopharma industries. Lunch Workshop:<img src="https://cdn.it.bgi.com/source/Speaker Graphic-2.png" alt="Speaker Graphic-2.png" data-href="" style="">We’ve had the distinct honor of supporting two incredible researchers in the genomics field. Our two talks “The Additional Impact of Genetic Ancestry over Self-reported Race/Ethnicity to Prevalence of KRAS Mutations and Allele-specific Subtypes in Non-small Cell Lung Cancer” and “Full-Length RNA and RNA Velocity in Single Cells” will highlight the innovative genomic approaches that identify and treat a variety of diseases. Dr. Xin-An Wang from Harvard University specializes in population and molecular environmental health. She will give a talk on the additional impact of genetic ancestry over self-reported race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer (NSCLC). The interplay between self-reported race and/or ethnicity (SIRE) and genetically inferred ancestry (GIA) on KRAS mutations and allele-specific subtypes is largely unknown. Dr. Wang and her team analyzed patients from the Chinese OrigiMed (OM) cohort and Boston Lung Cancer Survival (BLCS) cohort all of whom had well-annotated baseline covariates including age at diagnosis, sex, clinical stage, SIRE, cancer histology and smoking status. Their findings reveal factors that can contribute to more accurate diagnostics and clinical decision-making, ultimately benefiting diverse patient populations of NSCLC. Dr. Tang received his Ph.D. in Biochemistry from the University of Nevada, Reno (UNR). He served as research assistant professor and co-director of Nevada Center of Single Cell Research. Dr. Tang published over 25 articles in highly ranked international scientific journals in the fields of spermatogenesis and novel genome sequencing technologies. He also served as editor for Biology of Reproduction and re-viewers for Nature Communications, PIOS ONE, Cell Communication and Signaling (CCS). Dr. Tang currently serves as R&amp;D director at BGI-Tech Global. Dr. Tang will deliver a talk on “Full-Length RNA and RNA Velocity in Single Cells.” During his presentation, he will introduce the differences between PacBio-based HIT-scISOseq and Nanopore-based FLOUR-seq. He will also discuss why RNA velocity software has become the most popular choice." These two lead scientists will present featured topics in Room 143AB of Walter E. Washington Convention Center from 12:00 PM to 1:00 PM on Saturday, Nov 4th. Lunch will be provided for free! <a href="https://cdn.it.bgi.com/source/us-special-promotion-for-2023-ashg-20-off-20230928.pdf" target="_blank">Special Promotions:</a>We are glad to start offering our special fall promotions at ASHG. Visit BGI booth #309 to receive a 20% discount on our DNBSEQ™ NGS services and additional offers!<img src="https://cdn.it.bgi.com/source/final513.png" alt="final513.png" data-href="" style="">

Join us at ASHG 2023 (Booth #309)

<img src="https://cdn.it.bgi.com/source/bannerimageresized.png" style="max-width:100%;" contenteditable="false"/> The countdown is on and we cannot
wait to see you at AACC 2023!This year, we are thrilled to present SENTIS and
PMseq early access programs. SENTIS™ Cancer+
Discovery Panel offers one of the market’s most
comprehensive and accurate NGS-based testing solution for identifying
actionable mutations in cancer. It covers 688 cancer-related genes and
interrogates the most common types of alterations, including SNVs, indels, CNVs,
and fusions in solid tumors. SENTISTM Hereditary
Cancer Panel focuses on genes associated with a predisposition to cancer. By analyzing germline
mutations in 79 genes&nbsp;associated with&nbsp;24 types of hereditary
cancer,&nbsp;including breast, ovarian, colorectal, prostate, and stomach
cancer, the panel helps identify cancer-causing mutations, guiding treatment
decisions and further testing for at-risk individuals. 













PMseqTM is a powerful high-throughput
sequencing technology that detects and identifies suspected pathogenic
microorganisms in infected specimens. It provides comprehensive reports for rapid
and accurate detection of difficult- and critical-to-detect infections, and
promotes the rational use of antibiotics under Antibiotic Stewardship Programs
(ASP) with insights of antimicrobial resistance and susceptibility (AMR).<table border="0" width="100%" cellpadding="0" cellspacing="0" style="text-align:center;"><tbody><tr><th>Exhibit Location and Hours</th></tr><tr><td>Anaheim Convention
Center, Anaheim, CA.</td></tr><tr><td>July 25th&nbsp;(Tuesday): 9:30 a.m. – 5:00 p.m.</td></tr><tr><td>June 26th&nbsp;(Wednesday): 9:30 a.m. – 5:00 p.m.</td></tr><tr><td>June 27th&nbsp;(Thursday): 9:30 a.m. – 12:00 p.m.</td></tr></tbody></table><table border="0" width="100%" cellpadding="0" cellspacing="0"><tbody><tr><th>Booth Exhibition</th></tr></tbody></table><table><tbody>
 <tr>
 <td>
 <img src="https://cdn.it.bgi.com/source/orso.jpg" style="max-width:100%;" contenteditable="false"/>
 </td>
 <td>
 Visit
 us&nbsp;at&nbsp;booth #915, tell us about your projects, and get to
 know what’s new with BGI and our SENTIS and PMseq early access programs. Not
 to forget, we will be handing out our popular BGI stuffed polar bears and mobile phone stands to our visitors (while supply lasts)!&nbsp;
 </td>
 </tr></tbody></table>

Join BGI at AACC 2023 (Booth #915)

<img src="https://cdn.it.bgi.com/source/insidenewsimage.png" style="max-width:100%;" contenteditable="false"/>The countdown is on and we cannot
wait to see you at ASM 2023!This year, we are thrilled to present PMseqTM,
our pathogen metagenomics sequencing solution. 







PMseqTM is direct high-throughput
sequencing of infected specimens, through microbial-specific database
comparison and intelligent algorithm analysis, obtaining species information of
suspected pathogenic microorganisms, and providing comprehensive and in-depth reports
for rapid and accurate detection of difficult- and critical-to-detect
infections, and promoting the rational use of antibiotics under Antibiotic
Stewardship Programs (ASP) with insights of antimicrobial resistance and
susceptibility (AMR).<table border="0" width="100%" cellpadding="0" cellspacing="0"><tbody><tr><th>Exhibit Location and Hours</th></tr><tr><td>George R. Brown Convention Center, Houston, TX</td></tr><tr><td>June 16th (Friday): 10:00 a.m. - 5:00 p.m.</td></tr><tr><td>June 17th (Saturday): 10:00 a.m. - 5:00 p.m.</td></tr><tr><td>June 18th (Sunday): 10:00 a.m. - 4:00 p.m.</td></tr></tbody></table><table border="0" width="100%" cellpadding="0" cellspacing="0" style="text-align:center;"><tbody><tr><th>Booth Exhibition</th></tr><tr><td> <img src="https://cdn.it.bgi.com/source/orso.png" contenteditable="false" style="font-size: 14px; max-width: 100%;"/> Visit
us&nbsp;at&nbsp;booth #1722, tell us about your projects, and get to
know what’s new with BGI and our PMseqTM early access program. Not to
forget, we will be handing out our popular BGI stuffed polar bears and mobile phone
stands to our visitors (while supply lasts)!&nbsp;</td></tr></tbody></table>

Join BGI at ASM 2023 (Booth 1722)

<img src="https://cdn.it.bgi.com/source/bannerasm.png" style="max-width:100%;" contenteditable="false"/> The countdown is
on and we cannot wait to see you at ASMS 2023! This year, we are thrilled to present a&nbsp;complete line of mass
spectrometry services from our laboratory in San Jose, California, for all your
research and drug development needs. Our state-of-the-art mythology can help
simplify the challenge of proteomic analysis, metabolomics analysis
and biologics characterization. We provide services for biomarker
discovery, drug target deconvolution, mechanism of action (MOA), candidate
ligand screening, and comprehensive characterization of biologics.<img src="https://cdn.it.bgi.com/source/servicesprovided.jpg" style="max-width:100%;" contenteditable="false"/>We look forward
to offering you our special <a href="https://genomics.bgi.com/multiomics-promotion">promotion</a> for:●&nbsp;Proteome +
Transcriptome Correlation Analysis 
●&nbsp;Metabolome + Metagenomic Survey Correlation Analysis 
●&nbsp;Quantitative Proteome + Phosphoproteome Correlation Analysis&nbsp;Don’t forget to meet our
scientists in poster sessions (10:30 am to 2:30 pm) to learn about our novel
research in proteomics and metabolomics:&nbsp;&nbsp;June 5 (Monday)MP 587: Multi-species of Benchmarking
Phospho-DIA Comparison of Commercial Sample Prep KitsPresenter: Billy Newton, BGI Americas,
San Jose, California MP 575: A Bio-Zr Based Enrichment for
the Phosphopeptides from Human and Animal TissuesPresenter: Qidan Li, BGI-Shenzhen, ChinaJune 6 (Tuesday)TP 484: A High-Efficiency Method for Simultaneous
Quantification of Seven Classes of PhytohormonesPresenter: Lingyun Chen, BGI-Shenzhen,
ChinaTP 485: Targeted Metabolic Analysis of Bile
Acids in Biological Samples by Ultra-performance Liquid Chromatography Tandem Mass
Spectrometry







































Presenter: Yun Zhao, BGI-Shenzhen, China

BGI Americas at 2023 ASMS Conference in Houston 

<img src="https://cdn.it.bgi.com/source/metagenomic banner 202203 small_4.jpg" width="767.6" height="266.45"/> BGI has been providing world-class metagenomic sequencing services for more than&nbsp;10 years.&nbsp;We&nbsp;have processed over&nbsp;96,000 samples&nbsp;from partners across the world on our own DNBSEQTM&nbsp;technology platforms and have published more than&nbsp;70 papers&nbsp;in the world's leading journals.For a limited time, we are offering 60% off for our metagenomic sequencing services, including both library construction and sequencing: <h3>US$69 for 5Gb clean data US$99 for 10Gb clean data</h3> Key Terms and Conditions:- This promotion can not be accumulated with any other offer. - The promotion terms are only eligible for contracts signed before June 30th, 2022. - This promotion includes library construction and sequencing. - Sequencing performed on DNBSEQTM, PE150. -This promotion is for metagenomic sequencing 5Gb and 10Gb packages only. - Additional terms may apply, contact us for details. <a href="mailto:%20info@bgi.com" target="_blank">Contact us</a>&nbsp;or visit our&nbsp;<a href="https://services.bgi.com/bgi-metagenomic-sequencing-promotion" target="_blank">promo page</a>&nbsp;for more details!

BGI offers 60% Off for Metagenomic Sequencing Services

<img src="https://cdn.it.bgi.com/source/mmexport1646388169929.jpg" style="max-width:100%;" contenteditable="false"/>CAMBRIDGE, Mass.&nbsp;– Mar. 2,
2022 – BGI Americas Corporation, US subsidiary of BGI Genomics Co.
Ltd.&nbsp;(300676.SZ), one of the world’s leading multi-omics companies, today
announced an agreement with Science Exchange, a marketplace that helps scientists
accelerate their research by providing an all-in-one digital platform to
source, order, manage, and pay for R&amp;D services.<a></a><a></a>BGI will now
offer a 5% discount when contracting any of its Next Generation Sequencing
Services, such as whole genome sequencing, RNA sequencing, exome sequencing,
and other sequencing services, through the Science Exchange Marketplace. The partnership will allow users to take
advantage of the discounts by simply requesting a quote from BGI through
Science Exchange, and the 5% discount will automatically be added to the
quote.&nbsp; Science Exchange customers can
access the BGI storefront <a href="https://www.scienceexchange.com/labs/bgi-genomics">here</a>.About BGI Americas CorporationBGI Americas Corporation is
one of the leading providers of genomics and proteomics services in the
Americas Region as part of BGI Genomics, a public company listed on the
Shenzhen Stock Exchange. Established in 2010, BGI Americas has grown to include
a presence in Boston and San Jose, serving a wide range of customers in
genetics research, drug R&amp;D and diagnostics. BGI brings over 20 years of
genomics experience to its customers and collaborators based on a broad array
of leading technologies, including&nbsp;proprietary DNBSEQ™ genetic sequencing
platforms, economies of scale, and expert bioinformatics resources. BGI is
committed to advancing genetic research, technologies, and applications to
benefit humankind.About Science ExchangeThe
Science Exchange SaaS-enabled marketplace helps scientists accelerate their
research by providing an all-in-one digital platform to source, order, manage,
and pay for R&amp;D services. Scientists get instant access to our network of
3,500+ CROs, CMOs, and academic labs that are already contracted and qualified
so projects can start without the delays caused by contract negotiations and
provider onboarding. We automate repetitive administrative tasks, purchasing
workflows, and payment processing. Our analytics are top-notch so you can
dissect your outsourcing spend and view trends critical to your business. Our
solutions are trusted by the world’s top life sciences organizations, saving
thousands of hours and millions of dollars in costs while helping to advance
drug discoveries. For more information, please visit <a href="http://scienceexchange.com">http://scienceexchange.com</a> Media Contact:
Anthony Tong, Ph.D. 
Director of Marketing 
BGI Americas Corporation 
<a href="mailto:anthony.tong@bgi.com">anthony.tong@bgi.com</a> 
&nbsp; 
Chris Zan 
Head of Supplier Business
Development 
Science Exchange 
<a href="mailto:Chris.Zan@scienceexchange.com">Chris.Zan@scienceexchange.com</a>

BGI Americas Partners with Science Exchange to Offer 5% Discount of its Next Generation Sequencing Services

Partnership delivers high-volume, cost-efficient, low-pass whole genome sequencing for human genetics and other applications. NEW YORK and CAMBRIDGE, Mass.&nbsp;– Jan. 10, 2022 /PRNewswire/ – <a href="https://www.gencove.com/?gclid=Cj0KCQiAzfuNBhCGARIsAD1nu--6PoYhWVH_EXQlPDe7dcUoKk1yRgbS2706SRqjVEdqrUXWfYBdDLkaAhPzEALw_wcB">Gencove</a>, a pioneer of low-pass whole genome sequencing (LPWGS) analysis, and BGI Americas Corporation, US subsidiary of BGI Genomics Co. Ltd.&nbsp;(300676.SZ), one of the world's leading multi-omics companies, today announced the extension of the subscription and joint marketing agreements. The partnership combines BGI’s sequencing services from proprietary DNBSEQ™ sequencing technology with Gencove’s analysis platform so that high-capacity, cost-efficient whole genome information can be made more accessible and actionable.&nbsp;Both companies are united by a common goal of providing genomic information for a healthier and more sustainable world.“Improving hardware cost, speed, and capacity is one part of the equation”, said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove. “Sequencing large populations generates massive amounts of data. We knew that for genomics to be universally applicable, we needed to help interpret that data to support scientific discovery.”Gencove developed&nbsp;a unique software platform that makes whole genome sequencing fast, affordable, and the data more understandable. Gencove’s technology platform is called low-pass whole genome sequencing (LPWGS). Requiring less DNA per sample and using any sequencing machine, the whole genome is read but fewer times. In a step called imputation, the lower depth reads are compared to a fully characterized reference genome. The data is further analyzed depending on the customer’s needs, but the result is highly accurate with reliable genomic information.“Gencove’s platform helps us fulfill our mission of providing the highest quality genomic data at industry-leading&nbsp;pricing”, said Charles Bao, Ph.D., General Manager of BGI Americas. “The combination of DNBSEQ™ technology-based&nbsp;sequencing with Gencove’s software brings personalized medicine and bio-sustainability much closer to reality. Since BGI and Gencove launched our combined LPWGS solution more than three years ago, we have seen successful adoption and application by many of our customers across a wide range of human, plant, and animal research.”With over 20 years of experience, BGI Genomics is one of the world’s leading providers of genomic sequencing services and proteomic services. The company provides highly affordable, integrated services across a broad range of applications, including:●&nbsp;Basic research for human, plant, animal, and microbial species●&nbsp;Drug discovery and development ●&nbsp;Agriculture and biodiversity preservation and sustainability&nbsp;The partnership means academic institutions, biotechnology, diagnostic, and pharmaceutical companies all over the world can utilize the scale and efficiency of low-pass whole genome sequencing from two trusted leaders in genomics. About GencoveWith additional threats to human health and the challenge of feeding the world’s growing population, demand for genomic information has skyrocketed. Historically, DNA processing options fell into two categories: low-throughput and costly options such as whole genome sequencing, and high-throughput but limited technologies like genotyping arrays. To help scientists make life-saving discoveries, Gencove combines low-pass whole genome sequencing (reading the DNA at shallow depths) with a proprietary software-as-a-service (SaaS) computation layer. The result is a fast, high-volume, and cost-sensitive sequencing solution. As evidence of the technology’s value, the company has hundreds of customers and the largest genomics service providers in the world partner with Gencove.&nbsp; For more information visit: <a href="http://www.gencove.com/">www.gencove.com</a>&nbsp;and follow us on <a href="https://www.linkedin.com/company/gencove/mycompany/">LinkedIn</a>&nbsp;and <a href="https://twitter.com/Gencove">Twitter</a>. About BGI Americas CorporationBGI Americas Corporation is one of the leading providers of genomics and proteomics services in the Americas Region as part of BGI Genomics, a public company listed on the Shenzhen Stock Exchange. Established in 2010, BGI Americas has grown to include a presence in Boston and San Jose, serving a wide range of customers in genetics research, drug R&amp;D and diagnostics. BGI brings over 20 years of genomics experience to its customers and collaborators based on a broad array of leading technologies, including &nbsp;proprietary DNBSEQ™ genetic sequencing platforms, economies of scale, and expert bioinformatics resources. BGI is committed to advancing genetic research, technologies, and applications to benefit humankind.ContactsFor Gencove:Kristi Ashton, 650.224.8231kristi.ashton@gencove.comFor BGI Americas:Anthony Tong, 617.500.2741 <a href="mailto:anthony.tong@bgi.com">anthony.tong@bgi.com</a>For BGI Genomics (Global markets excl. Americas):Matt Poulter<a></a><a href="mailto:matt.poulter@bgi.com">matt.poulter@bgi.com</a>

BGI and Gencove Extend Agreement to Offer Low-Pass Whole Genome Sequencing and Analysis Service to Advance Global Health and Sustainability

<h3 class="article-sub-headline">Collaboration between two biotech companies signals BGI’s increased focus on fostering partnerships with organizations in the diagnostics space</h3> <time datetime="2021-06-29T14:00:00Z">June 29, 2021 10:00 ET</time> | Source: <a href="https://www.globenewswire.com/en/search/organization/BGI%2520Americas">BGI Americas</a> CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- <a title="BGI Americas" href="https://www.globenewswire.com/Tracker?data=afnuPCJskfYnIQpp0uxc6pt5Wh5UYnqIS4NtL3eP9TjR_rIJ0le4tQQqyRdwjsfozghagihe6irKcE14GUT-eg==" target="_blank" rel="nofollow noopener noreferrer">BGI Americas</a>, a global leader in diagnostic testing, today announced a partnership with Advaite, a Pennsylvania-headquartered biotech company, as well as the launch of <a title="dxpartnerships.com" href="https://www.globenewswire.com/Tracker?data=secfag-U7Li5DZ6O8K2msLv25OIEyjiC9L8nGTHvzZ0kI_Q6QXa05NLnjb8lMfsrTLLElh_Sv5ZPqKGg7OK0hVwhYCmrie8NLrn_WuS_4Ig=" target="_blank" rel="nofollow noopener noreferrer">dxpartnerships.com</a>, a hub for diagnostics companies seeking partnerships through licensing, original equipment manufacturer (OEM) or distribution agreements. The partnership will add Advaite’s <a title="RapCov™ Rapid COVID-19 Test" href="https://www.globenewswire.com/Tracker?data=NdbO4qUoWXYxTSR1bStTkSnw3gMKwCUV9BOvCF-lmnPrPGiYOUYUe3PbzHlwUZK8j4-_YpKtwYpim-6rJRRE_uJfQgnvvqFekAE1yGqKt4CwJKX7rmoUjCmBv3btmx6YYRYe3Ii0c-uaxgW0Y6TKZw==" target="_blank" rel="nofollow noopener noreferrer">RapCov™ Rapid COVID-19 Test</a> to BGI’s growing portfolio of diagnostic testing solutions. The Advaite test is a CLIA-waived, lateral flow immunoassay for the qualitative detection of immunoglobulin G (IgG) antibodies to the SARS-CoV-2 virus in human fingerstick whole blood samples. One of the first U.S.-manufactured point-of-care serology tests for which the Food and Drug Administration has granted for emergency use authorization, the RapCov™ Rapid COVID-19 Test is simple to use and delivers highly accurate results in 15 minutes by eliminating the requirement to send the sample to a laboratory. The partnership allows BGI to combine Advaite’s proprietary handheld test with its <a title="Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2" href="https://www.globenewswire.com/Tracker?data=RjJtWR2Ce7X-X0L992JxzQgFPqz91pTMLIMdbYEdZXLWXBq6hxDnz-Tu9Z8gyPLjDZLOo-56-1HuiA-xi20fYc2rcT_2N_WEAncBde0GonyyzTf11AgF93zbH4MXfKbGaedjE20nH4al2sJkJGob05p9El-Ubzjp0QU9PJ7lFeigvma0d0qmw2egQePeyjzM0Yu7HDp7yFnyfBIZz_nVhw==" target="_blank" rel="nofollow noopener noreferrer">Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2</a>, providing hospital systems and other health care facilities with both central laboratory and point-of-care CLIA-waived testing solutions. “Our rapid antibody test kits provide an ideal solution for screening mass populations and help patients determine whether they were once infected with the disease without knowing,” said Karthik Musunuri, CEO of Advaite. “Partnering with BGI to supply hospitals and other health care facilities with our innovative tests was a no-brainer in helping fight this ongoing pandemic.” The COVID-19 pandemic has underscored the global need for manufacturing and distribution of accessible and accurate diagnostic testing devices, and BGI’s launch of <a title="dxpartnerships.com" href="https://www.globenewswire.com/Tracker?data=secfag-U7Li5DZ6O8K2msBW5_agNnZyQgtDoTSrJTmAo9_t_mcD2QKFD4k6fgmkVd7xPJ6Hyv6Yhp7zFSpI_Mk_KocjAeW6x_cobRJA3MRE=" target="_blank" rel="nofollow noopener noreferrer">dxpartnerships.com</a> enables the company to partner with a broad range of organizations in the diagnostics testing space to advance diagnostic solutions. With proven commercial expertise and an established global footprint, partnering with BGI enables an organization to quickly and efficiently commercialize its in vitro diagnostic solutions. “As one of the world’s largest suppliers of COVID-19 testing reagents and automation systems, we are thrilled to partner with Advaite to bring their groundbreaking testing solution to market and help stop the spread of the deadly coronavirus,” said Craig Hoechstetter, director of corporate development at BGI. “Not only does quick and easy testing alert individuals whether they are infected, it also enables them to get treated faster and take the necessary steps to minimize the spread of the virus to their colleagues, friends and families, ultimately saving lives. By offering end-to-end high-quality molecular and serology tests, we are providing a synergistic solution to tackling this pandemic head on by being one step ahead of the virus.” To partner with BGI, visit <a title="dxpartnerships.com" href="https://www.globenewswire.com/Tracker?data=secfag-U7Li5DZ6O8K2msLwahqqCsd7XG-TlZbiAx3fF1hDQmQ_7SmatHwNRDp0_zY-d3UfSP9ssxdyyGou5Yz0-BSb0aNccvM-z4VbdJsg=" target="_blank" rel="nofollow noopener noreferrer">dxpartnerships.com</a>. For more information about BGI and the RapCov™ Rapid COVID-19 Test, visit <a title="bgi.com/us" href="https://www.globenewswire.com/Tracker?data=tVLoQUfNQ1wORLubiLKfTrcB4mEuADtXYjC3c6JbzBK3UKyY3wPatptxue0H7hjICvFzBs8u8Yy8W2UPKTkn2A==" target="_blank" rel="nofollow noopener noreferrer">bgi.com/us</a>. &nbsp; About BGI Americas Corporation BGI Americas Corporation is the leading provider of genomics and proteomics services in the Americas Region as part of BGI Genomics, a public company listed on the Shenzhen Stock Exchange. Established in 2010, BGI Americas has grown to include presence in Boston and San Jose, serving a wide range of customers in genetics research, drug R&amp;D and diagnostics. In response to the COVID-19 pandemic in 2020, BGI Americas introduced its diagnostic solutions to the north and south American markets, and initiated its in vitro diagnostics business. BGI brings 20 years of genomics experience to its customers and collaborators. We are committed to advancing genetic research, technologies and applications to benefit the mankind. &nbsp; About Advaite ADVAITE Inc. is a Malvern, Pennsylvania-headquartered biotech company focused on developing novel therapeutics and diagnostics to help patients suffering from a variety of debilitating diseases. The word “Advaite” means “one without a second,” unrivaled or unique. At ADVAITE, our team aspires to be just that. Currently, ADVAITE Inc. is focused on developing novel point-of-care assays to help combat the modern world’s deadliest disease, COVID-19. With a high-complexity CLIA laboratory based in Chicago, Illinois, and an expanded state-of-the-art R&amp;D facility in Malvern, Pennsylvania, ADVAITE is continuously innovating, developing and commercializing best-in-class point-of-care tests to address this pandemic and help impact large populations. &nbsp; About RapCov™ Rapid COVID-19 Test The ADVAITE RapCov™ Rapid COVID-19 Test is a lateral flow immunochromatographic assay for the qualitative detection of IgG antibodies to SARS-CoV-2 in human fingerstick whole blood specimens. Testing of fingerstick whole blood specimens is limited to laboratories certified under CLIA, that meet the requirements to perform high, moderate or waived complexity tests. Testing of fingerstick whole blood specimens is authorized for use at the POC, i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. &nbsp; <ul> 	<li> <h6>This test has not been FDA cleared or approved, but the FDA has authorized it for emergency use by authorized laboratories;</h6> </li> 	<li> <h6>This test has been authorized only for detecting the presence of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and</h6> </li> 	<li> <h6>The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.</h6> </li> </ul> <h6></h6>

BGI announces strategic partnership with Advaite in the US, and launches a diagnostics partnership forum

The formal launch of the BGI/Natera Signatera Assay is the next step towards achieving global access to personalized ctDNA testing AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=1668959029&amp;u=http%3A%2F%2Fwww.natera.com%2F&amp;a=Natera%2C+Inc." target="_blank" rel="nofollow noopener noreferrer">Natera, Inc.</a> (NASDAQ: <a class="ticket-symbol" href="https://www.prnewswire.com/news-releases/natera-and-bgi-genomics-announce-commercial-launch-of-the-bginatera-signatera-assay-in-china-301319176.html#financial-modal" data-toggle="modal">NTRA</a>), a pioneer and global leader in cell-free DNA (cfDNA) testing, and<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=371287518&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=%C2%A0" target="_blank" rel="nofollow noopener noreferrer"> </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=888626500&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=BGI+Genomics+Co.%2C+Ltd." target="_blank" rel="nofollow noopener noreferrer">BGI Genomics Co., Ltd.</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2264705084&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=%2C" target="_blank" rel="nofollow noopener noreferrer">,</a> (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China. Natera's Signatera® assay, now offered in partnership with BGI,1 has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease (MRD) up to two years earlier than standard imaging. The test is now available in China under the Chinese brand name "<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=276910199&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=%E5%8D%8E%E8%A7%81%E5%BE%AE" target="_blank" rel="nofollow noopener noreferrer">华见微</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2570353821&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=%C2%AE" target="_blank" rel="nofollow noopener noreferrer">®</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=1482659449&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=-" target="_blank" rel="nofollow noopener noreferrer">-</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2810814723&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=%E8%82%BF%E7%98%A4" target="_blank" rel="nofollow noopener noreferrer">肿瘤</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2072665964&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=MRD" target="_blank" rel="nofollow noopener noreferrer">MRD</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2403841452&amp;u=https%3A%2F%2Foncology.bgi.com%2Fhuajianwei.html&amp;a=%E5%AE%9A%E5%88%B6%E5%8C%96%E6%A3%80%E6%B5%8B" target="_blank" rel="nofollow noopener noreferrer">定制化检测</a>" - 华见微 (Hua Jian Wei for short). "We're excited to bring this revolutionary technology to clinicians and patients in China," said John Fesko, chief business officer at Natera. "Partnering with BGI also enables Natera to offer our pharma partners truly global clinical trial services." In March 2019, Natera and BGI Genomics entered into a partnership to commercialize Natera's Signatera test in China,1 and after two years of technology transfers and validation, the BGI/Natera Signatera Assay (华见微) is now officially available in the country. The assay can help facilitate innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions. Pharmaceutical companies can access this assay in China through the BGI-Natera partnership, which offers unique opportunities for companion diagnostic registration in both China and the U.S. "BGI is committed to promoting precision medicine and cancer prevention with cutting-edge technologies. Signatera can detect recurrence earlier and help clinicians optimize treatment decisions, thus bringing greater survival benefits for patients. In partnership with Natera, we are pleased to introduce Signatera into China and provide this innovative technology that incorporates MGI sequencing platforms for clinical oncology and drug development in a reliable and affordable manner," said Shida Zhu, general manager of BGI Oncology. About Natera <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=1640480404&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3034263-1%26h%3D1273922838%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2976603-1%2526h%253D3037276919%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2921670-1%252526h%25253D1587813196%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2837094-1%25252526h%2525253D2305986283%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D2818126-1%2525252526h%252525253D3703159391%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D2676832-1%252525252526h%25252525253D4130479052%252525252526u%25252525253Dhttp%2525252525253A%2525252525252F%2525252525252Fwww.natera.com%2525252525252F%252525252526a%25252525253DNatera%2525252526a%252525253DNatera%25252526a%2525253DNatera%252526a%25253DNatera%2526a%253DNatera%26a%3DNatera&amp;a=Natera" target="_blank" rel="nofollow noopener noreferrer">Natera</a> is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=4255778355&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3034263-1%26h%3D1712116155%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2976603-1%2526h%253D406175958%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2921670-1%252526h%25253D3170652573%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2837094-1%25252526h%2525253D2528648270%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D2818126-1%2525252526h%252525253D2717552065%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D2676832-1%252525252526h%25252525253D2185316474%252525252526u%25252525253Dhttp%2525252525253A%2525252525252F%2525252525252Fwww.natera.com%2525252525252F%252525252526a%25252525253D%252525252525C2%252525252525A0natera.com%2525252526a%252525253Dnatera.com%25252526a%2525253Dnatera.com%252526a%25253Dnatera.com%2526a%253Dnatera.com%26a%3Dnatera.com&amp;a=%C2%A0" target="_blank" rel="nofollow noopener noreferrer"> </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=4171892541&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3034263-1%26h%3D1712116155%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2976603-1%2526h%253D406175958%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2921670-1%252526h%25253D3170652573%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2837094-1%25252526h%2525253D2528648270%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D2818126-1%2525252526h%252525253D2717552065%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D2676832-1%252525252526h%25252525253D2185316474%252525252526u%25252525253Dhttp%2525252525253A%2525252525252F%2525252525252Fwww.natera.com%2525252525252F%252525252526a%25252525253D%252525252525C2%252525252525A0natera.com%2525252526a%252525253Dnatera.com%25252526a%2525253Dnatera.com%252526a%25253Dnatera.com%2526a%253Dnatera.com%26a%3Dnatera.com&amp;a=natera.com" target="_blank" rel="nofollow noopener noreferrer">natera.com</a>. Follow Natera on<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=1584247903&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3034263-1%26h%3D1926413164%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2976603-1%2526h%253D2978446137%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2921670-1%252526h%25253D3883770696%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2837094-1%25252526h%2525253D2648637082%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D2818126-1%2525252526h%252525253D2455241333%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D2676832-1%252525252526h%25252525253D4200851928%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fwww.linkedin.com%2525252525252Fcompany%2525252525252Fnatera%2525252525252F%252525252526a%25252525253D%252525252525C2%252525252525A0LinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=%C2%A0" target="_blank" rel="nofollow noopener noreferrer"> </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=3630599626&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3034263-1%26h%3D1926413164%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2976603-1%2526h%253D2978446137%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2921670-1%252526h%25253D3883770696%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2837094-1%25252526h%2525253D2648637082%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D2818126-1%2525252526h%252525253D2455241333%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D2676832-1%252525252526h%25252525253D4200851928%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fwww.linkedin.com%2525252525252Fcompany%2525252525252Fnatera%2525252525252F%252525252526a%25252525253D%252525252525C2%252525252525A0LinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn" target="_blank" rel="nofollow noopener noreferrer">LinkedIn</a>. Natera Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners' efforts to develop and commercialize product offerings, including obtaining regulatory approvals, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers, or our expectations regarding our strategic operations. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2684330480&amp;u=https%3A%2F%2Finvestor.natera.com%2F&amp;a=%C2%A0" target="_blank" rel="nofollow noopener noreferrer"> </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2176024808&amp;u=https%3A%2F%2Finvestor.natera.com%2F&amp;a=www.natera.com%2Finvestors" target="_blank" rel="nofollow noopener noreferrer">www.natera.com/investors</a> and<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=1004919615&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2398906-1%26h%3D1723542246%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&amp;a=%C2%A0" target="_blank" rel="nofollow noopener noreferrer"> </a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3208081-1&amp;h=2696299085&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2398906-1%26h%3D1723542246%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&amp;a=www.sec.gov" target="_blank" rel="nofollow noopener noreferrer">www.sec.gov</a>. source: <a href="https://www.prnewswire.com/news-releases/natera-and-bgi-genomics-announce-commercial-launch-of-the-bginatera-signatera-assay-in-china-301319176.html">Cision</a>

BGI Genomics and Natera Announce Commercial Launch of the BGI/Natera Signatera Assay in China

<div> </div>CAMBRIDGE, Mass. — June 15, 2021 — <a href="https://www.bgi.com/us/" style="font-size: medium;">BGI Americas Corporation</a>, a leading provider of genomics and proteomics services in the Americas as part of BGI Genomics Co. Ltd. (300676:Shenzhen), today announced a collaborative agreement with Champions Oncology (NASDAQ:CSBR), a leading global oncology data-driven solutions provider, to offer their respective customers end-to-end proteomics and multiomics solutions for oncology biomarker discovery and validation. &nbsp; As part of the collaboration, BGI’s Mass Spectrometry Center in San Jose, California, will be responsible for sample preparation as well as generation and analysis of proteomics and metabolomics data using the laboratory’s cutting-edge mass spectrometers. BGI’s customers will have access to <a href="https://www.championsoncology.com/software-solutions/lumin-bioinformatics-software?hsCtaTracking=89d95139-e98f-409e-9b87-e2e6af28ff30%7Cfc6b2a0b-f232-46ca-9bee-160e78a8d9d1" style="font-size: medium;">Champions’ Lumin Bioinformatics platform</a>, a unique and sophisticated data visualization software featuring over 25,000 multiomic datasets, to visualize and process their proteomics data and leverage large proteomics datasets available throughout the platform in order to perform advanced analytics. Champions Oncology will also leverage the mass spectrometry services from BGI to further enhance the characterization of its patient-derived xenograft (PDX) bank with proteomic and metabolomic profiling datasets. This fully streamlined analysis workflow and the multiomics-characterized PDX model assets aim to address the needs of a variety of drug discovery and development projects by customers in the biopharmaceutical space. Built in 2019, BGI’s state-of-the-art Mass Spectrometry Center offers specialized expertise in proteomics and biologics characterization, including native MS analysis of biomolecules, to support North American customers in basic life science research, pharmaceutical research and drug development, and translational medicine. The laboratory, combined with BGI’s global genomics laboratory infrastructure, allows BGI Americas to provide one of the industry's most comprehensive multiomics service portfolios, including proteomics, metabolomics, genomics, transcriptomics and epigenomics. The quality of BGI’s laboratory service and the company’s know-how in proteomics analysis were recently recognized in an international performance assessment and standardization study published in <a href="https://www.nature.com/articles/s41467-020-18904-9" style="font-size: medium;">Nature Communications</a>. “For years, BGI has worked with leading companies in the biopharmaceutical space, providing unmatched multiomics analysis services to support precision medicine studies and drug development at different phases,” said Siqi Liu, Ph.D., co-founder and global head of BGI’s Proteomics Center. “Leveraging deep expertise and 25 years of experience serving the biopharmaceutical and biotechnological industries, I am confident that this strategic partnership will deliver the unique information that customers truly need to make a difference in the fight against cancer.”&nbsp; For more information about BGI Americas, visit <a href="https://www.bgi.com/us/" style="font-size: medium;">bgi.com/us</a>. For more information about Champions Oncology, visit <a href="https://www.championsoncology.com/" style="font-size: medium;">championsoncology.com</a>. About BGI Americas Corporation<div> BGI Americas is the Americas-based subsidiary of BGI Genomics providing genomics and proteomics services. BGI is the world’s largest genomics organization, providing a wide range of genetic tests and sequencing and proteomic services across more than 66 countries. The company, which was founded in 1999 as a research organization to support the Human Genome Project, focuses on research, diagnostics and applications in the health care, pharmaceutical, conservation and environmental fields. BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications. For more information, visit <a href="https://www.bgi.com/us/">https://www.bgi.com/us/</a>. </div><div>About Champions Oncology, Inc.</div><div> Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based discovery platforms, unique oncology software solutions, and innovative and proprietary experimental tools such as in vivo, ex-vivo and biomarker platforms. For more information, please visit <a href="http://www.ChampionsOncology.com" style="font-size: medium;">www.ChampionsOncology.com</a>. Media Contact: Anthony Tong, Ph.D. Director of Product Management, BioPharma BGI Americas Corporation <a href="mailto:anthony.tong@bgi.com" style="font-size: medium;">anthony.tong@bgi.com</a> Rachel Bunting, MS, MBA Sr. Director, Head of Marketing Champions Oncology, Inc. <a href="mailto:Marketing@championsoncology.com" style="font-size: medium;">Marketing@championsoncology.com</a></div>

BGIA partners with Champions Oncology to offer mass spectrometry-based proteomics and multiomics data analysis solutions

Recent reports in certain international media outlets have focused on BGI’s outreach in the U.S. at the outbreak of the COVID-19 pandemic in January 2020, making misleading claims about the company. BGI strongly denies baseless allegations that are not supported by any evidence. In response to recent media requests, we have provided a detailed statement that addresses many of the misleading claims put forward, but the media has chosen only used selected parts of our statement. In order to communicate clearly our position on these media reports, we are reposting our statement in full: Founded in 1999, BGI is an organization that has for years demonstrated social responsibility, ethics and global collaboration. Our role is to provide research consultation, tools and services in genomic sciences to benefit human health and wellbeing. Our employees have rushed into danger zones to help during public health emergencies around the world. Because of this commitment, our COVID-19 tests are now welcomed globally. It was in the same spirit of reaching out to help that we approached the United States, particularly earlier in 2020 when solutions were limited in the US and urgent action was needed. In addition to this statement, it is important to note that we offer solutions that the U.S. Food and Drug Administration (FDA) has authorized. BGI does not have access to either patient samples or test data. The FDA granted Emergency Use Authorization (EUA) for BGI’s SARS-COV-2 test after receiving initial authorization on March 26, 2020 (<a href="https://www.fda.gov/media/136473/download">link</a>) (updated on January 28, 2021). BGI does not have access to either patient samples or test data. Our RT-PCR test kit for SARS-COV-2 is a test for the viral RNA, not for the patient’s DNA. The only BGI products sold directly in the United States are the FDA authorized RT PCR diagnostic reagents for SARS-COV-2 detection, nucleic acid extraction equipment and reagents. These are supplied to clinical laboratories that perform COVID-19 testing. It is not possible for us to share something that we do not have. BGI pays particular attention to complying with scientific ethics and personal privacy protection at all times, with zero tolerance for any violations of ethics and privacy, and strictly prohibits any business that violates human rights. BGI does not condone and would never be involved in any human rights abuses. BGI has never been involved in the collection, storage or analysis of personal genetic information with the potential for or the purpose of violating human rights. This is the case in the past, present – and in the future. BGI’s mission is to apply genomics technology to improve public health. At the time of the inclusion of the two BGI subsidiaries on the U.S. Commerce Department’s Entity List, BGI released a statement on July 21, 2020 (<a href="https://www.bgi.com/global/company/news/statement-regarding-bgis-subsidiaries-being-added-to-uss-entity-list/">link</a>). Finally, there has been speculation about the financial backing the company has received. As a leading company in the genomics sector, we are able to obtain lines of credit on commercial terms from a wide range of financial institutions, and we are able to repay these in full. Throughout its history, BGI has demonstrated social responsibility, ethics and global collaboration, and our employees, have rushed into danger zones to help during public health emergencies around the world, including SARS in 2003, avian flu in 2004, E.coliO104 in 2011 and Ebola in 2014. BGI was founded in 1999 for the purpose of participating in the internationally renowned Human Genome Project, which achieved history-changing breakthroughs in great part because of a commitment to open sharing and collaboration, which remain today basic tenets of the science of genomics and integral to BGI's philosophy and mission.

Statement Regarding Misleading Media Reports about BGI

Join our webinar on November 12 to learn how <a href="https://kashilab.com/">Kashi Clinical Laboratories</a> has quickly operationalized a custom saliva SARS-CoV-2 testing protocol by leveraging the BGI/MGI’s clinical lab partnership program. Featured speakers are Dr. Zahra Kashi (CEO/Founder) and Mrs. Dena Balbach (Chief Business Officer).

They will discuss an advanced approach that has enabled their high-complexity genetic testing laboratory to operationalize in COVID-19 molecular testing within weeks and the continued innovations that are required to help combat the deadly novel coronavirus.

Their discussions will also include:
<ul>
 	<li>Adoption of automation that enabled high-throughput, accurate testing</li>
 	<li>How they implemented a saliva-based collection protocol - the game changer for pathogen surveillance testing</li>
 	<li>Direct-to-consumer saliva testing - the next step to extend community coverage</li>
 	<li>Expansion of testing capacity through pooled samples</li>
 	<li>Partnership roles contributed by BGI and MGI</li>
</ul>
&nbsp;

<a href="https://youtu.be/sk6WZoQuNSo">Click here to watch the webinar</a>

High-Throughput SARS-CoV-2 Detection with Custom Saliva-Based Collection Protocol

Shenzhen, China., Nov 17, 2020 - BGI Genomics (SZSE:300676) today announced that the Real-time Fluorescent RT-PCR Kit for Detecting 2019-nCoV received registration by National Sanitary Surveillance Agency of Brazil (ANVISA) as a Class III In-vitro Diagnostic device. The kit is manufactured by BGI Biotechnology (Wuhan), a wholly-owned subsidiary of BGI Genomics. BGI’s highly sensitive test can return results within three hours. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in throat swab and Bronchoalveolar Lavage Fluid (BALF) samples. BGI has been on the forefront of fight against COVID-19 from the very beginning of the pandemic. BGI was among the first few companies to have developed diagnostic tests that received emergency authorizations from China’s National Medical Products Administration (NMPA) on January 26, 2020. Up to now, the product has received global emergency authorizations including CE-IVD, US FDA, Japan PMDA, Australia TGA, Health Canada, and included in WHO’s Emergency Use Listing. ANVISA approved the RT-PCR kit as a medical device till 2030 in Brazil. It is BGI’s first such product eligible for distribution in Brazilian market.

BGI COVID-19 RT-PCR Kit Receives Brazil ANVISA Registration

Dr. Tony Mazzulli, Microbiologist-in-Chief, and Ms. Christine Bruce, Administrative Director from the Department of Microbiology, will discuss the rapid scaleup of testing capacity to address the spread of virus throughout the population with the loss of epidemiologic risk factors such as travel history.

You will learn:
<ul>
 	<li>How the changes in testing criteria and government policy quickly increase testing demand</li>
 	<li>How the lab testing capacity is going to expand from 650 to 17,500 tests per day</li>
 	<li>The role of MGISP-960 and MGISTP-7000 automation systems in driving the lab to deliver the largest testing capacity in Ontario</li>
</ul>
&nbsp;

Also, Dr. Rod Bremner, Senior Scientist at Lunenfeld-Tanenbaum Research Institute, will explain how the BGI SARS-CoV-2 RT-PCR and MGI robotic systems are being used to help develop POC and lab-based tests and to initiate a clinical trial to monitor infection rates in a hospital research institute.

You will learn:
<ul>
 	<li>A clinical trial that assesses whether photodynamic therapy might reduce patient viral load</li>
 	<li>A clinical trial using robotic testing that assesses “2nd wave” infections in research institutes</li>
 	<li>How POC tests, being developed with LAMP or Toehold switches, compare to gold standard BGI tests</li>
</ul>
&nbsp;

Watch the webinars:

<a href="https://youtu.be/33JQqbu_4SU">Rapid Expansion of COVID-19 Testing Capacity</a>

<a href="https://youtu.be/47yyDyO_eaQ">Point of Care Lab-Based Diagnostics to Track COVID-19 Spread</a>

&nbsp;

Release date: 10/23/2020

Transforming COVID-19 Testing and Research in Sinai Health System/University Health Network

<img class="alignnone wp-image-15321 aligncenter" src="https://www.bgi.com/wp-content/uploads/sites/2/2020/10/pic1-233x300-1.png" alt="" width="403" height="517" />

Join Erik Bogaard, Founding Partner of <a href="https://www.taskforcelab.com/">Task Force Lab</a> (TFL), as he explains how the BGI/MGI <a href="https://www.bgi.com/us/bgi-mgi-covid-19-clinical-lab-partnership-program/">COVID-19 Clinical Lab Partnership Program</a> has accelerated population-level testing to help fight the on-going pandemic.

He will discuss how his organization leverages high-accuracy technology available in local warehouses to offer 24- to 48-hour turnaround times so their customers can get back to normal activity safely.

From this webinar, you will learn:

• The program’s nuts and bolts as well as immediate and long-term program benefits
• TFL’s full service, on-site COVID-19 testing solution in different sectors
• A case study in athletes/staff testing for 2020 AVP Champions Cup Series

Watch the webinar: <a href="https://youtu.be/hLBrV9w8CcQ">https://youtu.be/hLBrV9w8CcQ</a>

Release date: 10/9/2020

&nbsp;

Fighting COVID-19 in the Real World – How Task Force Lab Gets People Back to Work

BGI &amp; MGI provide founding member Task Force Lab (TFL) immediate access to US FDA EUA COVID-19 testing equipment and reagents to ramp up capacity and reduce turnaround times SAN JOSE, Calif.,&nbsp;Sept. 22, 2020 -- BGI and MGI announced a <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2925246-1&amp;h=1940727588&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2Fbgi-mgi-covid-19-clinical-lab-partnership-program%2F&amp;a=clinical+lab+partnership+program" target="_blank" rel="nofollow noopener noreferrer">clinical lab partnership program</a>&nbsp;designed to accelerate population-level testing to help fight the on-going pandemic. The companies are leading global suppliers of COVID-19 (SARS-CoV-2) RT-PCR test kits and automated sample preparation systems, including sample transfer and viral RNA extraction. The program empowers accredited labs with high-quality, readily available technology so they can focus on maximizing productivity. "In addition to delivering a world-class technology solution for COVID-19 testing programs like TFL's, we are pleased to assure our partners that they have access to near limitless testing supplies, both extraction and detection, at a crucial time during this pandemic," said&nbsp;Jeremy Nickolenko, Head of Global Commercial Partnerships for BGI-MGI. "Lack of testing reagents in this country is a myth. Having high-accuracy technology available in local warehouses now has helped TFL and other lab partners offer 24- to 48-hour turnaround times so their customers can get back to normal activity safely." The program is now open for accredited labs to join and includes benefits such as: <ul> 	<li>Continuous Supply of Critical Reagents</li> 	<li>Immediate Access to EUA COVID-19 Assay</li> 	<li>Lab Automation to Maximize Throughput</li> 	<li>Premier Customer &amp; Technical Support</li> </ul> Task Force Lab, a founding member of the program, is bringing full service, concierge testing directly to customers. "We started TFL to address the shortage of COVID-19 testing and we're thrilled to be partnered with BGI and MGI to provide our full service, on-site testing solution in an effort to create a safe environment for clients in a number of sectors, including government, sports, nursing homes, schools and universities, production studios, and so on," said&nbsp;Erik Bogaard, Co-Founder, Task Force Lab. "Given our unique approach towards not overbooking lab capacity and our coordination of on-site sample collection, TFL is perfectly positioned to provide clients with the convenience and guaranteed turnaround time needed to protect their communities." Task Force Lab recently announced a partnership with the Association of Volleyball Professionals (AVP) to facilitate and lead all testing procedures for the 2020 AVP Champions Cup Series. In order to provide reliable diagnostic testing, TFL via a CLIA certified and CAP accredited clinical laboratory, processed results in around 24 hours allowing the AVP to provide the best possible testing protocols to athletes and staff. "Our partnership with TFL not only brought to the table experience in COVID-19 testing, but true collaborative partners who facilitated and led all logistics within a time-frame that allowed us the best possible safety standards were met," said&nbsp;Al Lau, Chief Operating Officer, AVP. "TFL delivered on all fronts and I'm pleased to have found partners that share our same values, integrity and commitment to the cause." TFL uses the BGI RT-PCR Kit for detecting SARS-CoV-2 as well as the MGI viral RNA extraction system (MGISP-960 liquid handler plus MGIEasy Automated Extraction Kits), all covered by the US FDA emergency use authorization (EUA). Combined, this scalable, high-throughput workflow solution enables TFL to meet all current and future testing demand. The BGI RT-PCR kit was among the first COVID-19 molecular assays to be authorized by the US FDA. For more information, contact BGI-MGI:&nbsp;Jeremy Nickolenko Email:&nbsp;<a href="mailto:jnickolenko@mgiamericas.com" target="_blank" rel="nofollow noopener noreferrer">jnickolenko@mgiamericas.com</a>&nbsp; Phone: +1.608.444.2049

Clinical Lab Partnership Program Provides Ready Supplies and Reliable Support for COVID-19 Testing

Statement&nbsp;Regarding BGI’s&nbsp;subsidiaries being added to US’s Entity List On 20th July US Eastern time, The US Department of Commerce's Bureau of Industry and Security (BIS) issued updates to the Entity List, which includes two of BGI Group’s subsidiaries: Beijing Liuhe BGI and Xinjiang Silk Road BGI. Beijing Liuhe BGI provides commercial Sanger sequencing services for researchers and scientists conducting basic scientific research related to disease. None of this work includes personally identifiable information or violations of privacy or human rights. There is no basis for inclusion on the list of entities or for how its services or products could be used with respect to the allegations made. The “Xinjiang Silk Road BGI” subsidiary mentioned was established in November 2016 and has not carried out any actual business so far. It was formed for local business development, but the business did not move forward and the company is not operating. The specific reasons for being included in the Entity List&nbsp;have not yet been properly communicated and BGI is currently analyzing and evaluating the potential impacts of this decision. BGI is driven by technological innovation, focused on precision medical research and reducing the impact and harm of major diseases on humans. The company strictly abides by all international business practices and laws and regulations, conducts business operations in compliance with regulations on a global scale, and is committed to making positive contributions to public health in various countries and regions. BGI will respond to this matter professionally and will work openly and transparently with all relevant parties in response to this decision.&nbsp;&nbsp;BGI is confident that it can continue to protect the interests of its customers, partners, investors and employees to the maximum.

Statement Regarding BGI’s subsidiaries being added to US’s Entity List 

In early April, after experiencing negative impacts to its U.S. business resulting from the COVID-19 pandemic, BGI Americas Corp. applied for a PPP loan to help cover local salaries and prevent layoffs of U.S. employees. Although the company qualified at that time to receive these funds, BGI Americas announced it has returned the money to the U.S. government. After BGI Americas applied for the funds, the U.S. Small Business Administration and Treasury Department issued new guidance clarifying that the loans were not intended for companies with access to the equity market. BGI Genomics, the parent company of BGI Americas, is a public company listed on the Shenzhen stock exchange. BGI’s decision takes into consideration this new guidance, as well as the current challenges facing large and small business recovery in the United States. BGI aims to do the right thing. BGI Americas’ business is managing under these difficult circumstances, and does not want to distract from the U.S. government’s need to prioritize recipients when funds are limited and other small businesses are in greater need. We remain fully committed to protecting the jobs of our U.S. employees.

BGI Americas Returns PPP Loan

CAMBRIDGE, MA, June 16, 2020 – BGI Americas Corporation, the US subsidiary of BGI Genomics, is helping the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle to support COVID-19 testing in Uganda. BGI is donating its RT-PCR test kits to Fred Hutch for use by its affiliate (Hutchinson Center Research Instiute-Uganda or HCRI-Uganda) in cooperation with the Uganda Cancer Institute (UCI) in Kampala, Uganda. As the pandemic continues to spread rapidly to an increasing number of countries around the world, outbreaks have now been detected in many resource-limited countries in sub-Saharan Africa. Fred Hutch has a long-standing collaboration with the UCI to conduct research, provide training, and support clinical care at the UCI-Fred Hutch Cancer Center in Kampala, a facility with world-class laboratories and molecular diagnostic capabilities operated by HCRI-Uganda. In response to the outbreak of COVID-19 in Uganda in late March, Fred Hutch and the UCI proposed establishing testing capacity at the UCI-Fred Hutch Cancer Center. “Our goal with the UCI has always been to develop high-impact diagnostic tools and therapies for low-resource settings,” said Dr. Edus H. Warren, program head of Fred Hutch’s Global Oncology program. “BGI Americas’ generous support will help accelerate Fred Hutch’s infectious disease experts to better understand how COVID-19 is spreading across sub-Saharan Africa.” “We are very glad to support Fred Hutch to bring this much needed testing capability to sub-Saharan Africa,” said Charles Bao, General Manager of BGI Americas. “We are committed to doing everything we can to help countries around the world fight this pandemic.” Uganda currently has only one central laboratory performing PCR-based testing for SARS-CoV-2, the novel coronavirus that causes COVID-19 disease. The Uganda Ministry of Health (MOH) has identified an urgent need to scale up viral testing at additional laboratories in the country and to secure reliable test assays. BGI has donated 2,000 of its RT-PCR tests for detecting SARS-CoV-2 to help establish the initial testing capacity in Kampala. BGI has been on the forefront of testing for SARS-CoV-2 and supporting emergency response efforts around the world. BGI’s RT-PCR Test for Detecting SARS-CoV-2 is one of the most reliable and widely used testing methods available, with over 20 million tests already performed. In 2020, BGI’s testing kit for SARS-CoV-2 received emergency approval from China’s National Medical Products Administration (NMPA) on January 26, followed by the European CE-IVD marking on February 24, the U.S. FDA-issued Emergency Use Authorization (EUA) on March 26, and the World Health Organization (WHO) Emergency Use Listing (EUL) process on May 11. It is now being distributed to more than 100 countries. BGI and Fred Hutch envision that testing services can be expanded in Kampala to serve the greater needs of Uganda and also to build on existing networks with other institutions in sub-Saharan Africa to coordinate SARS-CoV-2 laboratory testing strategies across the region.

BGI Americas Donation Supports COVID-19 Testing at  Fred Hutchinson Center in Uganda

May 10, 2020, BGI Europe A/S, a subsidiary of BGI Genomics today announced that its Real-time fluorescent RT-PCR kit for detecting 2019-nCoV was listed in the World Health Organization Emergency Use Listing (EUL). On January 30, 2020, WHO declared the outbreak of COVID-19 to be a public health emergency of international concern, and initiated EUL for In vitro diagnostics (IVDs) Detecting SARS-CoV-2 Nucleic Acid. There are five SARS-CoV-2 detection kit providers listed in WHO's EUL till now. Among them, BGI is the first Chinese company to be listed in EUL as qualified provider of WHO's in vitro diagnostic procedures. BGI’s highly-sensitive RT-PCR testing kit, which can return results within three hours, detects the RNA of SARS-CoV-2 extracted from a wide range of respiratory samples. It features <ul> 	<li>High sensitivity: Limit of detection as low as 100 viral copies/mL</li> 	<li>High specificity: No cross-reactivity with 54 human respiratory pathogens</li> 	<li>Ease to use: All-inclusive with pre-mixed reaction reagents</li> 	<li>Easy interpretation: Analysis of one target with well-defined controls</li> </ul> “BGI’s RT-PCR kit is one of the most widely recognized molecular products for SARS-CoV-2 detection by global regulatory agencies,” said Yin Ye, CEO of BGI Genomics. “It is another testament to our strong commitment to enabling safe and effective COVID-19 testing on a global scale.” BGI’s RT-PCR Test for Detecting SARS-CoV-2 is one of the most reliable and widely used testing methods available, with over 20 million tests already performed, covering more than 80 countries and regions around the world. In 2020, BGI’s testing kit for SARS-CoV-2 received emergency approval from China’s National Medical Products Administration (NMPA), followed by the European CE mark, the U.S. FDA Emergency Use Authorization (EUA), Japan’s PMDA approval, Australia’s TGA approval, and Health Canada Authorization. For more information please contact: info@bgi.com

BGI’s Real-time Fluorescent RT-PCR Kit for Detecting 2019-nCoV was Listed in the Emergency Use Listing of WHO

TORONTO, May 6, 2020&nbsp;– BGI Genomics announced today that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 in the Canadian market. The testing kit is part of an integrated solution that includes automated extraction methods to support fast and accurate detection of SARS-CoV-2 around the world. BGI Genomics and MGI, members of the BGI Group, are jointly providing a high throughput, clinically validated workflow to address major bottlenecks for large-scale COVID-19 testing. The solution includes BGI’s Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2, which is the authorized device by Health Canada, as well as MGI’s MGIEasy Nucleic Acid Extraction Kit and MGISP-960RS Automated Sample Preparation System. Both BGI and MGI have existing local entities and business operations in Canada, allowing the companies to deploy immediate local resources for establishing supply chain and customer service to ensure successful adoption of the testing solution in clients’ laboratories. “BGI’s RT-PCR kit is one of the most widely recognized molecular products for SARS-CoV-2 detection by global regulatory agencies,” said Yin Ye, CEO of BGI Genomics. “It is another testament to our strong commitment to enabling safe and effective COVID-19 testing on a global scale.” BGI’s highly-sensitive RT-PCR testing kit, which can return results within three hours, detects the RNA of SARS-CoV-2 extracted from a wide range of respiratory samples. The kit is validated on a number of RT-PCR instruments with broad adaptability. It features <ul> 	<li>High sensitivity: Limit of detection as low as 100 viral copies/mL</li> 	<li>High specificity: No cross-reactivity with 54 human respiratory pathogens</li> 	<li>Ease of use: All-inclusive with pre-mixed reaction reagents</li> 	<li>Easy interpretation: Analysis of one target with well-defined controls</li> </ul> The authorization includes MGI’s MGIEasy Nucleic Acid Extraction Kit as a validated method for viral RNA extraction, which is currently in abundant supply worldwide and addresses a severe sample preparation bottleneck for widespread testing. In addition, MGI’s robotic sample preparation system significantly improves throughput and reproducibility. The combination of the MGI products enable processing of 192 samples in 80 minutes, a major increase in productivity compared to manual processing. “The integrated SARS-CoV-2 testing workflow offers our customers unique ability to scale testing efforts in Canada,” added Stephen Rogers, BGI/MGI’s Country Manager in Canada. “BGI and MGI are committed to supporting Canadian labs with our tools to tackle the COVID-19 pandemic.” The integrated solution of MGI sample preparation with BGI’s RT-PCR kit is part of a comprehensive solution BGI Group has introduced for rapidly scaling up diagnostic testing — the&nbsp; Huo-Yan or “Fire Eye” labs. The Fire Eye Laboratory model that demonstrated its early success in Wuhan, China, where the virus was first identified, is now being implemented in Europe, the Middle East, Asia and around the world. Fire Eye laboratories combine the best of BGI Group expertise, with the most recent labs launched in Saudi Arabia and Australia. BGI Genomics currently has a manufacturing capacity of 2 million RT-PCR tests per day and is fulfilling international orders from more than 80 countries and regions around the world. BGI’s RT-PCR Test for Detecting SARS-CoV-2 is one of the most reliable and widely used testing methods available, with over 20 million tests already performed. In 2020, BGI’s testing kit for SARS-CoV-2 received emergency approval from China’s National Medical Products Administration (NMPA) on January 26, followed by the European CE-IVD marking on February 24, the U.S. FDA-issued Emergency Use Authorization (EUA) on March 26, Japan’s PMDA approval on March 27, and Australia’s TGA approval on April 10. About BGI Genomics Co Ltd. BGI&nbsp;was founded in 1999 with the vision of using genomics to benefit humanity and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications. BGI Genomics is an independent division of BGI Group and was listed on the&nbsp;Shenzhen Chi-Next exchange in&nbsp;July 2017. BGI Genomics’ goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI’s own DNBSEQ technology platforms, economies of scale, and expert bioinformatics resources. BGI Genomics also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. More information:&nbsp;<a href="http://www.bgi.com/">www.bgi.com</a> About MGI MGI, a subsidiary of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI produces sequencing instruments, reagents, equipment and related products to support life science research, agriculture, medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include sequencing, mass spectrometry, medical imaging and laboratory automation. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all. More information:&nbsp;<a href="https://en.mgitech.cn/">https://en.mgitech.cn/</a>

BGI Receives Health Canada Authorization to Supply SARS-CoV-2 RT-PCR Test in Canadian Market

Total lab solution addresses major bottlenecks for large-scale COVID-19 testing - Automated liquid handling solution improves testing throughput and efficiency - Expanded accessibility of test kits by broader models of PCR machines and sample types - Adding viral RNA extraction kit type removes a key sample preparation bottleneck - Integrated workflow replicates global success of BGI's Fire Eye Laboratory model &nbsp; CAMBRIDGE, Mass., April 24, 2020 -- BGI Genomics. Co. Ltd. (SZSE:300676) today announced that it has received authorization from the U.S. Food and Drug Administration (FDA) for expanding its offering of SARS-CoV-2 RT-PCR Test under emergency use authorization to include the RNA extraction kit and automated liquid handling system made by MGI, as well as additional PCR systems and sample types. BGI now provides a total lab solution for large-scale COVID-19 testing. Inclusion in the EUA of MGI's viral RNA extraction kit, which is currently in abundant supply in the US, addresses a severe sample preparation bottleneck for widespread testing. In addition, MGI's robotic sample preparation system significantly improves throughput and reproducibility. MGI's MGIEasy Nucleic Acid Extraction Kit and MGISP-960RS Automated Sample Preparation System enable processing of 192 samples in 80 minutes, a major increase in productivity compared to manual processing. "We now have a one-stop, total solution that makes it easier to ramp up large-scale, community-based testing," said Yin Ye, CEO of BGI Genomics.  He added that the integrated BGI/MGI solution has been effectively used first in China and later on in many countries scaling up testing laboratories to perform up to 50,000 tests a day. The expanded FDA EUA label also increases the accessibility of test kits to include more types of PCR instruments -- besides Thermo Fisher's ABI 7500 Real-Time PCR System, now ABI 7500 Fast, QuantStudio 5 and Roche LightCycler 480, are also approved for use with BGI's test. The FDA also expanded the label of the kit to cover more respiratory sample types. Now throat (oropharyngeal) swabs, nasopharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal washes, nasal aspirates and bronchoalveolar lavage fluid (BALF) sample are all compatible with BGI's RT-PCR kit. More flexibility in sample types will increase the clinical utility of the kit to overcome the other testing bottleneck caused by a shortage of sample collection kits. The amendment announced today expands options for viral RNA extraction from Qiagen's QIAamp Viral RNA Mini Kit to cover MGI's MGIEasy Nucleic Acid Extraction Kit. The kit offers comparable performance along with high throughput and addresses the current supply shortage of extraction kits in the US market. The Centers for Medicare &amp; Medicaid Services (CMS) on April 15, 2020 announced that Medicare will nearly double payment for lab tests that use high-throughput technologies to rapidly diagnose large numbers of COVID-19 cases. At a time when the United States still urgently needs to enhance its capacity for community COVID-19 testing, the integrated workflow delivered by BGI will allow clinical laboratories to effectively adopt high-throughput testing solutions. The integrated solution of MGI sample preparation with the BGI RT-PCR kit is part of a comprehensive solution BGI Group has introduced for rapidly scaling up diagnostic testing -- the  Huo-Yan or Fire Eye labs. The Fire Eye Laboratory model that demonstrated its early success in Wuhan, China, is now being implemented in Europe, Middle East, Asia and around the world. Fire Eye laboratories combine the best of BGI Group expertise, with the most recent labs launched in the UAE and Sweden. BGI Genomics and its US subsidiary, BGI Americas Corp., announced on March 27, 2020 that the FDA had issued EUA for its RT-PCR kit for detecting SARS-CoV-2. It was the first FDA authorized RT-PCR product for COVID-19 testing manufactured in China. BGI Genomics currently has a manufacturing capacity of 2 million tests per day and is fulfilling international orders from more than 80 countries and regions around the world. BGI’s RT-PCR Test for SARS-CoV-2 is one of the most reliable and widely used testing methods available, with over 2 million tests already performed. In addition to the US FDA, BGI’s RT-PCR Test for SARS-CoV-2 has been granted emergency authorization or approval by Europe’s EMA, China’s NMPA, Japan’s PMDA and Australia’s TGA. About EUA The Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV has not been FDA cleared or approved. However, the FDA can issue an EUA to permit use of certain medical products that may be effective in diagnosing, treating or preventing a disease or condition, as in the case of the novel coronavirus when the secretary of the U.S. Department of Health and Human Services (HHS) declares a public health emergency. HHS Secretary Alex Azar declared an emergency for COVID-19 on January 31. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. About BGI Genomics Co Ltd. BGI was founded in 1999 with the vision of using genomics to benefit humanity and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications. BGI Genomics is an independent division of BGI Group and was listed on the Shenzhen Chi-Next exchange in July 2017. BGI Genomics' goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry's broadest array of leading technologies, including BGI's own DNBSEQ™ technology platforms, economies of scale, and expert bioinformatics resources. BGI Genomics also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. More information: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2786348-1&amp;h=1951879781&amp;u=http%3A%2F%2Fwww.bgi.com%2F&amp;a=www.bgi.com">www.bgi.com</a> About MGI MGI, a subsidiary of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI produces sequencing instruments, reagents, equipment and related products to support life science research, agriculture, medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include sequencing, mass spectrometry, medical imaging and laboratory automation. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all. More information: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2786348-1&amp;h=3908704659&amp;u=https%3A%2F%2Fen.mgitech.cn%2F&amp;a=https%3A%2F%2Fen.mgitech.cn%2F">https://en.mgitech.cn/</a> SOURCE BGI Group

BGI Expands EUA Label for SARS-CoV-2 RT-PCR Test with MGI Automated Extraction Methods and Additional PCR Systems

SAN JOSE, CA, March 30, 2020 -- Global genomics leader BGI Group is providing SARS-CoV-2 test kits, automated sample preparation equipment and viral RNA extraction reagent to enable the diagnosis of new coronavirus cases in the Kansas City region through an innovative partnership with local business leaders and The University of Kansas Health System. Responding to a request by a group of business leaders to quickly build additional testing ability for their community,  BGI immediately mobilized its team to provide a total solution for COVID-19, including BGI Genomics’ Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV and MGI’s MGISP-960 High-throughput Automated Sample Preparation Systems. Once availability was confirmed, the Kansas City business leaders quickly committed to purchasing 50,000 BGI Genomics’ tests and MGI’s equipment. BGI Genomics’ Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV, the virus which causes COVID-19, has been used to diagnose more than 1 million individuals worldwide and is currently being distributed to more than 70 countries and regions. BGI’s technology has been deployed on the front lines of fighting the novel coronavirus in China, and the company aims to bring its experience and testing capability at scale to speed detection efforts across the US. “We want to help the American people and support the Kansas City community to fight the spread of this disease with rapid, accurate testing capabilities that have proven to be very effective in China,” said Yongwei Zhang, BGI Group Vice President and Americas CEO. “We are so impressed with the speed at which the local community took action, and we are ready to provide our full support to this and other communities affected by the current pandemic.” BGI Genomics. Co. Ltd. (SZSE:300676) and its US subsidiary BGI Americas Corp., announced on March 18, 2020, that its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 is commercially available in the United States. BGI’s detection kit is eligible to be used immediately to expedite clinical testing for the novel coronavirus, based on updated guidance from the U.S. Food and Drug Administration (FDA). On March 27, BGI announced that the FDA had issued an Emergency Use Authorization (EUA) for its RT-PCR kit for detecting SARS-CoV-2. In Kansas City like many areas, the community has been challenged by the availability of COVID-19 test kits and the impact the virus is having on their community. “Our company had four employees who were suffering from symptoms of the coronavirus, but due to the relative lack of available testing at the time, they were concerned about their health,” said Nathaniel Hagedorn, CEO of NorthPoint Development, who worked alongside fellow business leaders Andy Deister, CEO of Russell Stover Chocolates; Dave Cummings, CEO of Tradebot; Taimoor Nana, CEO of MTAR; and Tyler Nottberg, CEO of US Engineering, to get the test kits to Kansas City. They initially researched what China and South Korea had successfully done to create much wider testing availability, searched for the companies that provided tests kits, and reached out to BGI. The group also engaged The University of Kansas Health System, one of the Kansas City region’s leading healthcare institutions and only academic medical center. Working around the clock with the Kansas City leaders, BGI was able to deliver the first equipment and test kits on March 22 and secure shipments of automated equipment and other supplies for delivery next week. The University of Kansas Health System is currently processing the materials and equipment, and coordinating when, where and how the tests and associated capabilities will be available. “It is remarkable what was achieved so quickly,” said Mr. Deister, CEO of the Russell Stover Chocolate Company. “This, however, is just the beginning and there is a long way yet to go. We are all working hard to support and protect our community.” “Working together we were able to bring the best ideas and the best technology to support our local community,” said Mr. Hagedorn. “We appreciate the efforts of BGI to help make this happen. Businesses can make a big difference, and our country needs effective leadership at this time.”

BGI Helps Kansas City Community Scale Up COVID-19 Testing

Battle-proven test used over 1 million times will accelerate clinical testing in United States <ul> 	<li>BGI’s test now has global approvals or authorizations through US FDA, Europe’s CE-IVD, and China’s NMPA</li> 	<li>Kits are currently being distributed to more than 70 countries and regions worldwide</li> 	<li>Highly sensitive, rapid test with 3-hour turnaround time</li> </ul> &nbsp; CAMBRIDGE, MA, March 27, 2020 – BGI Genomics. Co. Ltd. (SZSE:300676) and its US subsidiary BGI Americas Corp. today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its RT-PCR kit for detecting SARS-CoV-2. BGI’s highly sensitive test can return results within three hours. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in bronchoalveolar lavage fluid (BALF) and throat swabs. “The authorization of our diagnostic test for COVID-19 in the US will provide high-quality, high-volume testing capabilities to the US, and enable medical professionals to respond quickly to diagnose patients, preventing further spread of infection,” said Ye Yin, CEO of BGI Genomics. “As one of the first responders to the outbreak in China, we quickly scaled up our production and have deployed large numbers of kits for testing in China and globally in countries where our test kit has been approved or authorized. We are committed in bringing rapid, accurate testing capabilities&nbsp; on a massive scale to bolster detection efforts throughout the United States and globally in order to fight the spread of this disease.” Advantages of BGI’s test include: <ul> 	<li>High sensitivity– Limit of Detection at 100 copies/mL in BALF and 150 copies/mL in throat swabs</li> 	<li>High specificity – No cross-reactivity with 54 human respiratory pathogens</li> 	<li>Fast TAT – Sample to result in 3 hours</li> 	<li>Ease &nbsp;of use – All inclusive with pre-mixed reaction reagents</li> 	<li>Easy interpretation – Analysis of one target with well-defined controls</li> </ul> BGI has been on the forefront of testing for SARS-CoV-2. Following the outbreak of the novel coronavirus in China, BGI was among the first few companies to have developed diagnostic tests that received emergency approval from China’s National Medical Products Administration (NMPA) on January 26, 2020, followed by CE-IVD marking on March 2, 2020.&nbsp; BGI currently has a daily manufacturing capacity of 600,000 reactions and is actively scaling up to meet rapidly growing global demand. As of March 22, BGI has produced a total of 4.72 million tests. The company has performed over 500,000 SARS-CoV-2 tests in its own central laboratories in China and is distributing its SARS-CoV-2 detection kits to more than 70 countries and regions around the world. BGI has donated over 130,000 tests since the beginning of the outbreak to regions and countriesmost in need of testing. BGI’s Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV is the first FDA-authorized product manufactured in China. It is also BGI's first FDA-authorized medical device. BGI is bringing its full genomics expertise and resources to the fight against the 2019 novel coronavirus throughout the world. BGI’s long history of timely response to public health crisis events dates back to 2003, when the company decoded the genome of the SARS coronavirus and developed the virus detection kit within 96 hours. During the 2014 West African Ebola outbreak, &nbsp;BGI quickly set up a front-line laboratory in Sierra Leone and helped to develop virus detection kits. &nbsp; About EUA The Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV has not been FDA cleared or approved. However, the FDA can issue an EUA to permit use of certain medical products that may be effective in diagnosing, treating or preventing a disease or condition, as in the case of the novel coronavirus when the secretary of the U.S. Department of Health and Human Services (HHS) declares a public health emergency. HHS Secretary Alex Azar declared an emergency for COVID-19 on January 31. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. &nbsp; About BGI Genomics Co Ltd. BGI was founded in 1999 with the vision of using genomics to benefit humanity and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications. BGI Genomics is an independent division of BGI Group and was listed on the Shenzhen Chi-Next exchange in July 2017. BGI Genomics' goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry's broadest array of leading technologies, including BGI's own DNBSEQ™ technology platforms, economies of scale, and expert bioinformatics resources. BGI Genomics also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. More information: www.bgi.com. &nbsp; <img class="alignnone wp-image-12939 " src="https://www.bgi.com/wp-content/uploads/sites/2/2020/03/Kit-Box.png" alt="" width="449" height="319"/>

BGI’s Real-Time SARS-CoV-2 Test to Detect Novel Coronavirus  Receives FDA Emergency Use Authorization

Rapid and Scalable RT-PCR Assay is Pending Approval for Emergency Use Authorization <ul> 	<li>BGI’s test already has approvals through CE-IVD and China’s NMPA</li> 	<li>Kits are currently being distributed to more than 50 countries and regions worldwide</li> 	<li>Highly sensitive and quick test with 3-hour turnaround time</li> </ul> &nbsp; CAMBRIDGE, MA, March 18, 2020 -- BGI Genomics. Co. Ltd. (SZSE:300676) and US subsidiary BGI Americas Corp., today announced that its Real-Time Fluorescent RT-PCR test for detecting SARS-CoV-2 is now commercially available in the United States. With the updated guidance from FDA issued on March 16, BGI’s detection kit is eligible to be used immediately to expedite clinical testing for the novel coronavirus. BGI is submitting a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its SARS-CoV-2 test and expects to receive formal EUA in the near future. BGI has been in regular communication with the FDA about its testing data since submitting information to the agency more than a week ago. “We appreciate the FDA’s move to open up the market for our diagnostic test kits,” said BGI Genomics CEO Yin Ye. “Our goal is to deploy our maximum capability to support efforts to contain the virus worldwide. Our technology has been put to the test on the front lines of fighting this novel coronavirus outside the US. We are now bringing rapid and accurate testing capability at scale to bolster detection efforts throughout the US and help more patients receive accurate diagnosis.” BGI has been on the forefront of testing for SARS-CoV-2. Following the outbreak of the novel coronavirus in China, BGI was among the first few companies that developed the diagnostic test that received emergency approval from China’s National Medical Products Administration (NMPA) on January 26, 2020, followed by CE-IVD marking on March 2, 2020. &nbsp;BGI quickly scaled up manufacturing and currently has a daily capacity of up to 300,000 reactions per day. BGI has performed over 500,000 SARS-CoV-2 tests in its own central laboratories in China and is distributing its SARS-CoV-2 detection kits to more than 50 countries and regions around the world. BGI is bringing its full genomics expertise and resources to the fight against the 2019 novel coronavirus around the world. BGI’s long history of responses to public health crisis events includes decoding the genome of the SARS virus in 2003 and developing the virus detection kit in 96 hours, and helping fight the Ebola outbreak in 2014 in West Africa, where BGI quickly set up a front-line laboratory in Sierra Leone and helped the local team to develop Ebola virus detection kits. &nbsp; About EUA The Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV has not been FDA cleared or approved. However, the FDA can issue an EUA to permit use of certain medical products that may be effective in diagnosing, treating or preventing a disease or condition, as in the case of the novel coronavirus when the secretary of the U.S. Department of Health and Human Services (HHS) declares a public health emergency. HHS Secretary Alex Azar declared an emergency for COVID-19 on January 31. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

BGI’s RT-PCR SARS-CoV-2 Test Now Commercially Available for Clinical Use in the United States

On February 5, the Huo-Yan Laboratory, an emergency test laboratory run by BGI and designed to handle 10,000 samples daily to detect 2019-nCoV, officially started trial operation in Wuhan. The lab will greatly increase the speed of testing novel coronavirus cases so that suspected infections can be eliminated or confirmed as soon as possible. The Huo-Yan or “Fire Eye” laboratory was jointly established by the Wuhan Municipal Government, Wuhan East Lake High-Tech Development Zone, CCCC Second Harbor Engineering Company, Shanghai Nori Laboratory Equipment Co., and BGI. The East Lake High-Tech Development Zone provided the site, BGI led the design and operation, the Second Harbor Engineering Company led the construction, and Shanghai Nori provided a large amount of laboratory equipment. Overcoming the 2019-nCoV epidemic requires rapid and accurate detection and diagnosis. Precise nucleic acid testing is an important basis for clinical diagnosis and discharge of recovered patients, as well as ending isolation of contacts. The laboratory will provide scientific support for the detection of suspected cases and the examination of high-risk populations, and help relieve the worry and panic among the community. The 2,000-square-meter laboratory includes 1,000 square meters of testing laboratory area strictly designed as a P2 laboratory (Second Level of Biosafety) and equipped with high-throughput sequencing equipment manufactured by MGI. It also has 30 B2 biological safety cabinets, a series of 12 automated nucleic acid extraction platform, separate sample preparation rooms, reagent storage rooms and office areas. On January 29, the East Lake District Government of Wuhan responded quickly and implemented the site support provided by the East Lake High-Tech Development Zone. BGI collaborated with the Second Harbor Engineering Company to complete the laboratory site survey. On January 30, BGI completed the design of the laboratory, and the Second Harbor Engineering Company officially launched the laboratory construction on January 31. With the voluntary work of 279 employees from Second Harbor and Shanghai Nori in an all-out push, the main laboratory construction was completed in just five days. The Huo-Yan Laboratory will provide sufficient testing capabilities for Wuhan and surrounding cities, and provide support for the diagnosis of patients, the screening of high-risk groups, the identification of suspected cases, the isolation of positive infections, and the protection of healthy people. The laboratory also received instrument donations from Xi'an Tianlong Technology Co. and Tiangen Biochemical Technology (Beijing) Co., a donation of 2 million yuan from the Henan Youth Development Foundation (for clinical testing and related research and development) and a donation of 1 million yuan from IDG Capital for laboratory construction. <img src="https://en.mgitech.cn/Uploads/detail/2020-02-06/5e3b8c8def3bb.jpg" alt="" /> BGI and the CCCC Second Harbor Engineering Company teams at the inauguration ceremony of the Huo-Yan Laboratory in Wuhan <img src="https://en.mgitech.cn/Uploads/detail/2020-02-06/5e3b8cc3cc2f9.jpg" alt="" /> (Photo courtesy of CCCC Second Harbor Engineering Co., Ltd., photo by Li Anhui)

New Emergency Detection Laboratory Run by BGI Starts Trial Operation in Wuhan, Designed to Test 10,000 Samples Daily

January 28, 2020 BGI is bringing its full genomics expertise and resources to the front lines in the fight against the 2019 novel coronavirus. BGI has scaled up production of its new real-time fluorescent RT-PCR kits for detecting the virus, known as 2019-nCoV, donating 20,000 kits to support the response in Wuhan and Hubei Province. The test can issue results in a few hours. BGI has now released about than 50,000 test kits to hospitals and disease control centers around China. BGI Chairman and Co-Founder Wang Jian and a team of employees arrived in Wuhan January 25 to lead BGI’s emergency response. During the Chinese New Year holiday, the company set up an emergency coordination center in Wuhan to mobilize efforts and expand the manufacturing capacity, with staff working around the clock to produce the testing kits and arrange storage, transportation and other logistics. BGI said its teams from Wuhan, Shenzhen, Tianjin and other cities where it has offices or laboratories are on standby to provide the fastest response to frontline efforts. <img src="https://www.bgi.com/wp-content/uploads/sites/2/2020/01/图片1-300x224.png" alt="" width="300" height="224" class="alignnone size-medium wp-image-12504" /> In addition to the rapid detection kit based on RT-PCR technology, BGI has also developed a metagenomic sequencing detection kit (2019-nCoV nucleic acid detection kit- combinatorial Probe-Anchor Synthesis sequencing method) to monitor mutations. The metagenomic sequencing kit can identify and diagnose other coronaviruses, including new coronaviruses and respiratory tract infections, and achieve rapid detection of viral sequences. The combination of RT-PCR and BGI metagenomics solution PMseq® can detect both known and novel microorganisms, in addition to 2019-nCoV. The two coronavirus detection kits and the ultra-high-throughput DNBSEQ-T7 sequencing system and analysis software have officially passed the emergency approval procedures of the National Medical Products Administration (China’s FDA), becoming the first batch of officially tested products to fight the outbreak. Two of the powerful DNBSEQ-T7 sequencers, produced by BGI subsidiary MGI, have been deployed to Wuhan. <img src="https://www.bgi.com/wp-content/uploads/sites/2/2020/01/图片2.png" alt="" width="276" height="254" class="alignnone size-full wp-image-12505" /> BGI has been working with various Chinese authorities, including the Chinese Center for Disease Control and Prevention, to deliver detection kits to various hospitals and local disease control centers. BGI is the third-party collaborator authorized by China’s National Health Commission in detecting the 2019-nCoV virus in China. Further, BGI is also engaged with relevant organizations overseas to supply the test kits and offer additional pathogen detection solutions using next generation sequencing technology. International delivery has started, as the kits are equipped with English manuals and offer online training programs. On January 24, a Chinese citizen in Brunei, suspected of 2019-nCoV infection, was diagnosed negative as the first international case using the BGI kit. Building on its experience during SARS and other epidemics, BGI is actively participating in 2019-nCoV pathogen research and providing technical support. In 2003, BGI successfully sequenced the SARS virus in less than 20 hours, and developed an enzyme immunoassay test kit in 96 hours. In 2011, BGI successfully and rapidly developed a free diagnostic kit for the Enterohaemorrhagic Escherichia Coli (EHEC) epidemic that broke out in Germany. All scientific data and information was made immediately and openly available to the international community, laying an important scientific foundation to control the epidemic. <img src="https://www.bgi.com/wp-content/uploads/sites/2/2020/01/图片3-300x273.png" alt="" width="300" height="273" class="alignnone size-medium wp-image-12506" />

BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan

BGI Develops Real-Time Fluorescent RT-PCR kit for detecting the 2019 Novel Coronavirus Press Release, January 23, Shenzhen, China As widely reported in the media, a new coronavirus has been identified in China, which has been given the name “2019 novel coronavirus” or “2019-nCoV.” Building on BGI’s history of developing solutions for rapid pathogen detection, BGI has developed a real-time fluorescent RT-PCR kit for detecting the 2019 Novel Coronavirus. The kits have already been issued to many hospitals and disease control centers. Coronaviruses are a family of viruses, circulating mainly among animals, including camels, cats and bats. Rarely, animal coronaviruses can evolve and infect people and then spread between people such as seen with <a href="https://www.cdc.gov/coronavirus/mers/index.html">MERS</a> and <a href="https://www.cdc.gov/sars/index.html">SARS</a>. 2019-nCoV is a new strain of virus that has not been previously identified in humans. As of 24:00on January 22(GMT+8), a cumulative total of 571 cases with 17 deaths caused by new coronavirus have been reported in China. Cases have also been reported in 6 other countries, including Thailand (2),Japan (1), the Republic of Korea (1), Australia (1), United States (1) and Singapore (7). In response to this situation, and immediately after the occurrence of unexplained pneumonia on December 31, 2019,BGI successfully developed a Real-Time Fluorescent RT-PCR kit for detecting 2019-nCoV, which can issue results in a few hours. BGI has been working with relevant Chinese authorities including the Chinese Center for Disease Control and Prevention, through which the kits have been issued to various hospitals and local disease control centers. BGI is also engaged with relevant organizations in Hong Kong and Taiwan, the Brunei Ministry of Health, the Thailand ministry of public health, the National Medical Research Center of Nigeria (NIMR), the National Institute of Infectious Diseases of the National Health Laboratory of South Africa (NICD), to supply the test kits and offer additional pathogen detection solutions using next generation sequencing technology. Further, alarge number of kits are being urgently sent around the world to cope with the mass migration of people during the Chinese New Year. The development of the 2019-nCoV detection kit builds upon BGI’s previous experience developing rapid diagnostic solutions for pathogen detection. For example, in April 2003, BGI successfully sequenced the SARS virus in less than 20 hours, and developed an enzyme immunoassay test kit in 96 hours. In 2011, BGI successfully developed a diagnostic kit for the Enterohaemorrhagic Escherichia Coli (EHEC) epidemic that broke out in Germany. All scientific data and information was made available to the international community, laying an important scientific foundation to control the epidemic. About BGI Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life. For queries, please contact media@genomics.cn

BGI Develops Real-Time Fluorescent RT-PCR kit for detecting the 2019 Novel Coronavirus

<h4></h4>
<img class=" wp-image-12335" src="https://www.bgi.com/wp-content/uploads/sites/2/2019/12/workhshop.png" alt="BGI- PAG XXVIII Workshop" width="832" height="282" />
<h4></h4>
<h4 style="text-align: center">Advanced NGS Technologies for Phylodiversity Research, </h4>
<h4 style="text-align: center">Agricultural Trait Discovery and Molecular Breeding</h4>
Date: Tuesday, January 14, 1:30 - 3:40 PM
Location: Golden West
Snacks and beverages will be provided
<img class="alignnone size-full wp-image-12341" src="https://www.bgi.com/wp-content/uploads/sites/2/2019/12/workshop.png" alt="" width="2125" height="993" />
<h2></h2>
&nbsp;
<h2>More Inspiration</h2>
<h2>from BGI Poster Presentation at PAG</h2>
<img class="alignnone size-full wp-image-12374" src="https://www.bgi.com/wp-content/uploads/sites/2/2019/12/poster-ID.png" alt="" width="1589" height="129" />

We are looking forward to seeing you in San Diego to discuss exciting new Genomic Solutions for your research.

Put Booth #418 on your list for inspiration!

BGI offers a complete line of NGS services, and the world’s broadest portfolio of Whole Genome Sequencing services including <a href="https://www.bgi.com/us/sequencing-services/dna-sequencing/whole-genome-sequencing/" target="_blank" rel="noopener">True PCR-free WGS</a>, <a href="https://www.bgi.com/us/sequencing-services/dna-sequencing/low-pass-whole-genome-sequencing-2/" target="_blank" rel="noopener">Low-pass WGS</a>, and <a href="https://www.bgi.com/us/sequencing-services/plant-animal-microbial-dna-sequencing/plant-animal-de-novo-whole-genome-sequencing-2/" target="_blank" rel="noopener">Long-read Whole Genome Sequencing</a>.

We support your research projects: From single sample to large-scale population studies, we are at your service!

&nbsp;

BGI will be at the Plant and Animal Genome XXVIII in San Diego

BGI Americas Opens Mass Spectrometry Center in California Mass spec services for proteomics research and biologic drug characterization complement BGI genomics services &nbsp; San Jose, Calif., &nbsp;(May 31, 2019) – BGI Americas, a leading genomic services company, announced today at the American Society of Mass Spectrometry conference (ASMS) that it has opened a state-of-the-art Mass Spectrometry Center at its research facility in San Jose, California. The new center gives BGI customers a resource for a range of mass spectrometry services for proteomics and drug characterization and offers synergies with genomics data analysis. BGI, headquartered in Shenzhen, China, has a strong track record in the business of providing analytical services, including mass spectrometry, to a global customer base. The new San Jose-based Mass Spectrometry Center extends that expertise to North American customers in pharmaceutical drug development, basic life science research and translational medicine. The new Mass Spectrometry Center investment signifies a global extension of multi-omics solutions for the scientific community. Additional mass spectrometry services will become available throughout the year. BGI co-founder and chief mass spectrometry scientist, Dr. Siqi Liu, described BGI’s most recent push as an opportunity to stand at the forefront of proteomics by allowing researchers to integrate sequencing and mass spectrometry data to explore the basic chemical codes that underpin all biology. Dr. Charles Bao, general manager of BGI Americas adds, “Our operations based in San Jose can better address the demand from our North American customers and leverages existing BGI know-how in mass spectrometry.” “The experienced Mass Spec team at BGI has been very helpful with advice for my projects and has generated great data in a short time,” says BGI customer Lei Wang, professor at The University of California, San Francisco. Dr. Wang adds, “They have proven to be an important resource for our projects, and we are looking forward to more collaborations in the near future.” In addition to proteomics, the San Jose Mass Spectrometry Center will provide specialized expertise in state-of-the-art biologics characterization, including first-in-class support for non-denaturing mass spectrometry or “native MS” analysis of biomolecules. The commercially available native MS services at BGI are supported by an experienced San Jose-based scientific team that includes laboratory director Dr. Guanghui Han and product manager Dr. Aaron Bailey, who share a history of successful collaboration while previously employed at Genentech and Thermo Fisher, respectively. &nbsp; About BGI Americas <a href="https://www.bgi.com/us/">BGI Americas</a>&nbsp;is a subsidiary of BGI Genomics, which is a publicly traded entity listed on the Shenzhen Stock Exchange in China. BGI Americas provides comprehensive sequencing, mass spectrometry and bioinformatics services for basic and translational research as well as pharmaceutical drug development in North, Central and South America.&nbsp;The company helps customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies, including BGI’s innovative DNBseq™ sequencing technology. BGI’s global customers benefit from a vast scientific expertise and massive sequencing capacity in state-of-the-art service laboratories, including a CAP/CLIA laboratory in Hong Kong. For more information, visit&nbsp;<a href="https://www.bgi.com/us/">https://www.bgi.com/us/</a>

BGI Announces Mass Spectrometry Services from new Mass Spec Center in San Jose

The newest addition to the BGI pharma solutions offers pharmaceutical companies a customized solution that has played a key role in the global clinical trials and development of the first innovative anti-ovarian cancer precision medicine. Cambridge, MA (April 1, 2019) – BGI Americas today announced the launch of Hereditary Cancer Panel (HCP) to support global clinical trials of anti-cancer drugs using BGI’s DNBSEQTM next-generation sequencing technology. The panel was launched at the American Association for Cancer Research (AACR) Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia. HCP is a hereditary cancer assay designed to identify known and emerging tumor biomarkers for 17 cancer types. The assay identifies germline variants covered in full exome regions of up to 115 target genes by the MGISEQ-2000 and Illumina HiSeq 2500 and 4000 systems. One unique feature of the  HCP is the comprehensive coverage of BRCA1/2 gene mutations in a proprietary database that is first in China. The database, BGI Hereditary Cancer Genetic Database v1.0, integrates results from more than 30,000 clinical tests and demonstrates a high consistency rate between automated database and manual interpretations as well as a low percentage of Variant of Unknown Significance (VUS) for BRCA1/2 gene mutations. Inherited genetic mutations play a significant role in 5% to 10% of all cancers. In particular, the germline mutations in BRCA1/2 genes lead to DNA damage repair deficiency and genetic instability of cells. PARP (Poly ADP-Ribose Polymerase) inhibitor (PARPi) potentially exploits DNA damage repair deficiencies such as BRCA mutations to preferentially kill cancer cells. Clinical studies have shown that the first PARPi is highly potent and has a dual mechanism of action to induce tumor cell death by blocking PARP enzyme activity and trapping PARP on the sites of DNA damage. The clinical utility of HCP and pharma experience have proved that BGI is uniquely positioned to offer pharma partners a “China solution” in co-developing precision medicine worldwide: <ul> 	<li>Contributions to a landmark BRCA research and a PARPi development for ovarian and breast cancers: BGI was selected as the BRCA testing lab in China and provided BRCA testing for the first nationwide germline BRCA mutation prevalence study in Chinese ovarian cancer patients (1) and multiple PARPi phase III global clinical studies (2-4) to enable the development of innovative precision medicine for ovarian and breast cancer patients.</li> 	<li>Proprietary and high-performance germline BRCA-mutated database: More than 30,000 clinical tests were performed in house at BGI to develop a database with BRCA genotypes for the Chinese population, in addition to integrating the database with other public genetic databases such as HGMD and ClinVar. The consistency rate between automated database and manual interpretations is over 99.3% in double-blind tests. The percentage of VUS for BRCA1/2 gene mutations is only 3.1%.</li> 	<li>Reliable companion diagnostics assays: HCP has been clinically validated at BGI’s CAP-accredited and CLIA-certified laboratory in Hong Kong. The assay is currently reviewed for accelerated IVD approval by the China National Medical Products Administration (NMPA). This experience provides a companion diagnostics roadmap for BGI’s future pharmaceutical partnerships worldwide, especially in China.</li> </ul> “BGI has a successful track record with the hereditary cancer panel, supporting multiple PARPi clinical trials in China,” said Charles Bao, Ph.D., General Manager of BGI Americas. “The past successes have demonstrated our strength and commitment to driving healthcare innovation through the development and global commercialization of precision medicine. I am optimistic that the hereditary cancer panel will lead to more approvals of anti-cancer drugs.” For additional product and availability information, please visit: <a href="https://www.bgi.com/us/pharma-solutions/translational-oncology/hereditary-cancer-panel/">https://www.bgi.com/us/pharma-solutions/translational-oncology/hereditary-cancer-panel/</a> <ol> 	<li>1Int J Gynecol Cancer 2017; 27: 1650-1657</li> 	<li>Lancet Oncol 2017; 18: 1274-1284</li> 	<li>N Engl J Med 2017; 377: 523-533</li> 	<li>N Engl J Med 2018; 379: 2495-2505</li> </ol> &nbsp; About BGI Americas <a href="https://www.bgi.com/us/">BGI Americas</a> provides comprehensive sequencing and bioinformatics services for basic and translational research as well as pharmaceutical drug development in North, Central and South Americas. We help our customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBSEQ™ sequencing technology. Our customers also benefit from BGI’s vast scientific expertise and massive sequencing capacity in state-of-the-art service laboratories, including our CAP/CLIA laboratory in Hong Kong. For more information, visit <a href="https://www.bgi.com/us/">https://www.bgi.com/us/</a>. &nbsp; Media Contact Information: Anthony Tong, Ph.D. BGI Americas +1 617 500 2741 <a href="mailto:anthony.tong@bgi.com">anthony.tong@bgi.com</a> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;

BGI Americas Launches Hereditary Cancer Panel for Global Drug Trials

Prof Hon-Ming Lam from The Chinese University of Hong Kong teamed with BGI Genomics and other experts to complete the first reference-grade wild soybean genome, published in Nature Communications Soybean is an economically important crop first domesticated in China. Wild soybeans contain genes that could be used to improve agronomic traits of cultivated soybean, including stress tolerance, seed protein and secondary metabolite contents, etc. Until recently, genomic research of soybean relied solely on the reference genome of the cultivated soybean Williams 82, thus hindering the discovery of genetic information that are specific to wild soybeans. Prof Hon-Ming Lam from The Chinese University of Hong Kong has led a team of experts from BGI Genomics, UK, USA, Japan and Korea to build and decode the first high-quality wild soybean reference genome, providing an important tool to facilitate the mining of gene resources from wild soybeans. The findings were published as a research article entitled “A reference-grade wild soybean genome” in Nature Communications. BGI Genomics provided the sequencing service and participated in the assembly of this new genome. The team adopted a combination of high-end technologies, including PacBio sequencing, Bionano Genomics optical mapping (OM), and Hi-C sequencing, to assemble the wild soybean W05 genome at chromosome scale. The assembled genome is 1,013.2 Mb in size with contig N50 3.3 Mb. Compared with the existing Williams 82 reference genome, the contig N50 shows a 17 times improvement. Based on the ample amount of RNA-seq data and PacBio Isoseq data, a total of 55,539 protein-coding genes were annotated. Making use of this newly assembled genome, researchers were able to identify the structural differences between wild and cultivated soybean genomes. For example, a translocation between chromosome 11 and chromosome 13 was found. Such translocation may affect the breeding between wild and cultivated soybeans and QTL analyses in the affected regions, which has a strong impact on breeding strategies. In addition, researchers discovered a large genomic inversion in the I locus which controls the seed coat color. This inversion explained the long mystery of the switching from dark seeds to yellow seeds during soybean domestication. In combination with the OM technology, the wild soybean reference genome could have an even wider scope of application. Researchers made use of the new reference genome to assemble and analyze OM data from wild and cultivated soybeans of different origins. The translocation between chromosome 11 and chromosome 13 and the inversion in the I locus seem to be common phenomena in different accessions. Moreover, researchers also noticed a reduction in the number of genes encoding anti-nutrient proteins in cultivated soybeans, possibly as a result of human selection. The release of this wild soybean reference formed a solid foundation for comparative genomic studies of legumes and soybean improvement programs. It expedites the investigations of genomic information and important traits of wild soybeans, facilitates the continuous improvement of soybean cultivars, and hence extends the habitats of soybean cultivation and contribute to sustainable agriculture. Read the full study here: https://www.nature.com/articles/s41467-019-09142-9 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;

Researchers from the Chinese University of Hong Kong, BGI Genomics and others report the first high-quality chromosome-scale reference genome for wild soybean

<table width="100%"><tbody><tr><td width="50%"></td><td width="50%"></td></tr></tbody></table> &nbsp; <table width="100%"><tbody><tr><td width="100%"> <table width="100%"><tbody><tr><td> <h4>Flow Pharma will use BGI’s DNBSEQ™ NGS technology for therapeutic vaccine development</h4> </td></tr></tbody></table> </td></tr></tbody></table> &nbsp; <table width="100%"><tbody><tr><td width="100%"> <table style="height: 2987px" width="730"><tbody><tr><td> <h5>NEWARK, Calif., and CAMBRIDGE, Mass., February 28, 2019 –&nbsp;<a href="http://www.flowpharma.com/">Flow Pharma Inc.</a>, a San Francisco Bay Area biotechnology company focused on personalized vaccine development, announced today that it has selected <a href="https://www.bgi.com/us/">BGI Americas</a> Inc. to provide the sequencing services required for all FlowVax neoantigen-based personalized therapeutic cancer vaccines under development by Flow Pharma.</h5> The first two Flow Pharma products under development are FlowVax HPV for the treatment of cervical cancer and FlowVax BreastCA for the treatment of breast cancer. FlowVax Breast CA will be a personalized therapeutic vaccine requiring patient-specific gene sequencing. “The exciting new area of personalized therapeutic cancer vaccines requires rapid, accurate genomic and transcriptomic sequencing. BGI Americas is unique in providing next generation sequencing services using its own unique DNBSEQ™ sequencing technology based on combinatorial probe-anchor synthesis (cPAS), linear isothermal rolling-circle replication and DNA nanoball (DNB) technology,” said Victor Zhang, Ph.D., CEO of BGI Americas. “BGI has a strong track record supporting the therapeutic and biomarker development of top biopharma and biotech companies. Our DNBSEQ technology has been validated by leading academic centers and industry users and will deliver strong value in our collaboration with Flow Pharma.” “In order to make a personalized therapeutic cancer vaccine, you have to know the genomic information of the patient’s tumor as well as that of the patient. Speed and accuracy are both critical. Once we have these gene sequences, we can use AI-augmented bioinformatics tools to quickly identify tumor targets for T-cell attack and then rapidly load these targets into a FlowVax vaccine customized for that particular patient.” Said <a href="http://www.flowpharma.com/team.html">Lu Wang, Ph.D.,</a> Flow Pharma bioinformatics team leader “We have spent a decade developing the FlowVax vaccine platform. FlowVax is optimized to simultaneously deliver multiple unmodified peptide targets for killer T-cell attack. Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying our regulatory pathway,” said <a href="http://www.flowpharma.com/team.html">Charles Herst, Ph.D.,</a> Flow Pharma chief science officer. “Personalized FlowVax therapeutic vaccines can be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.” “We believe that BGI’s DNBSEQ NGS platform is the best in class for the rigorous requirements of personalized therapeutic cancer vaccine development. The fact that BGI Americas provides professional and competitive genomic sequencing services along with experience and knowledge in supporting drug development, allows us to become a full-stack company in the space without the time and expense required to bring gene sequencing technology in-house,” said <a href="http://www.flowpharma.com/team.html">Reid Rubsamen, M.D.,</a> CEO of Flow Pharma. &nbsp; About BGI Americas <a href="https://www.bgi.com/us/">BGI Americas</a> provides comprehensive sequencing and bioinformatics services for basic and translational research as well as pharmaceutical drug development in North, Central and South America. We help our customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies, including our own innovative DNBSEQ™ sequencing technology. Our customers also benefit from BGI’s vast scientific expertise and massive sequencing capacity in state-of-the-art service laboratories, including our CAP/CLIA laboratory in Hong Kong. For more information, visit&nbsp;<a href="https://www.bgi.com/us/">https://www.bgi.com/us/</a> BGI Americas is a subsidiary of BGI Genomics, which is a publicly traded entity listed on the Shenzhen Stock Exchange in China. &nbsp; About Flow Pharma <a href="http://www.flowpharma.com/">Flow Pharma, Inc.</a> is a San Francisco Bay Area based, biotechnology company using artificial intelligence to guide selection of neoantigen peptide targets on cancer cells or virus-infected cells for attack by the patient’s own, native immune system. These peptides can then be loaded into the FlowVax platform for administration by injection. <a href="http://www.flowpharma.com/">Flow Pharma, Inc.</a> is preparing to test therapeutic cancer vaccines targeting neoantigens found in various cancers. Neoantigens are small peptide markers expressed on cancer cells as a result of a cancer-causing viral infection or mutation of the DNA in normal cells. Media Contact BGI Americas Louis Sintasath, Sr. Director, Business Development BGI Americas, Inc. One Broadway Cambridge, MA 02124 (858) 344 8398 <a href="mailto:Louis.Sintasath@bgi.com">Louis.Sintasath@bgi.com</a> www.bgi.com Media Contact Flow Pharma Reid Rubsamen, CEO Flow Pharma, Inc. 39655 Eureka Drive Newark, California 94560 (925) 708-8000 <a href="mailto:rrubsamen@flowpharma.com">rrubsamen@flowpharma.com</a> <a href="http://www.flowpharma.com">www.flowpharma.com</a> Investor Relations Flow Pharma Flow Pharma, Inc. 39655 Eureka Drive Newark, California 94560 (760) 564-7400 <a href="mailto:ir@flowpharma.com">ir@flowpharma.com</a> <a href="http://www.flowpharma.com">www.flowpharma.com</a></td></tr><tr><td> <table style="height: 17px" width="700"><tbody><tr><td width="214"></td><td width="214"></td><td width="214"></td></tr></tbody></table> </td></tr></tbody></table> </td></tr></tbody></table> <table width="100%"><tbody><tr><td width="100%"> <table width="100%"><tbody><tr><td>Forward Looking Statements This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc and BGI Genomics. (“the Companies”), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Companies, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Companies’ future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Companies cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Companies undertake no obligation to update these statements after the date of this release, except as required by law, and also take no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc. or BGI Genomics. &nbsp;</td></tr></tbody></table> </td></tr></tbody></table> &nbsp; <table width="100%"><tbody><tr><td width="100%"></td></tr></tbody></table> &nbsp; &nbsp;

BGI Selected as sequencing partner for development of Flow Pharma Personalized Cancer Vaccines

For the first time, BGI is attending the ACMG Annual Clinical Genetics Meeting.

We’re excited to present our global NGS services and share some significant development at booth #636.

BGI offers a complete portfolio of turn-key NGS services for basic and translational research, pharmaceutical drug discovery and the support of clinical trials.

We look forward to seeing you to discuss how we can assist you with world-class DNBseq™ NGS services, designed to support your research and clinical testing without breaking the bank.

BGI will be at the 2019 ACMG meeting in Seattle

Researchers from BGI-Shenzhen, the South China University of Technology, and elsewhere have isolated almost 6,500 bacterial representatives from fecal samples donated by 155 healthy individuals, using 11 types of growth media to culture the gut bacteria under anaerobic conditions in the lab. From there, the investigators turned to 16S ribosomal RNA sequencing, as well as whole-genome sequencing for almost 1,800 isolates, to produce 1,520 high-quality draft genomes for bacteria from 388 species clusters spread across the bacterial phylogenetic tree, including 264 new reference genomes in 134 species clusters. The strains are now part of the China National GeneBank and may be useful for studies that aim to alter microbiota functions, as novel probiotics, or for verification of disease-associated bacterial markers. Learn more about our commercial services for <a href="https://www.bgi.com/us/sequencing-services/rna-sequencing-solutions/16s18s-its-sequencing/">16S sequencing </a>or <a href="https://www.bgi.com/us/sequencing-services/plant-animal-microbial-dna-sequencing/plant-animal-and-microbe-whole-genome-resequencing/">bacteria WGS services.</a> <a href="https://www.nature.com/articles/s41587-018-0008-8">Or read the study.</a> &nbsp; <img class="size-full wp-image-10295" src="https://www.bgi.com/wp-content/uploads/sites/3/2019/02/Screen-Shot-2019-02-05-at-10.31.41.png" alt="BGI Nature Biotech Study" width="584" height="508" /> 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses &nbsp;

1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses

We're excited to be in Atlanta for AACR. Come say hi at booth #1643 and learn how we can support your cancer research with our world-class sequencing services. We will introduce a new Hereditary Cancer Panel to support your biomarker discovery or cancer research will and present a workshop on Biomarker-driven precision medicine. Scroll down for the details...


<hr />

<h5>Be Inspired! At our Spotlight Theater Seminar<img class="wp-image-6350 alignright" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/PAG-lightbulb.png" alt="BGI at PAG lightbulb" width="90" height="135" /></h5>
Attend our educational seminar to be inspired by leaders in cancer genomics to learn about the application of NGS tools in precision cancer treatment.

&nbsp;
<h4 style="text-align: center">Case Studies of Biomarker-Assisted Patient Stratification for Oncology Precision Medicine</h4>
<h6></h6>
<h6></h6>
<h6 style="text-align: center">Sunday, March 31, 2019</h6>
<h6 style="text-align: center">3:30-4:30 PM</h6>
<h6 style="text-align: center">Spotlight Theater C on the exhibit floor</h6>
<img class="size-full wp-image-9494 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2019/01/9.png" alt="" width="108" height="100" />

Biomarker testing and companion diagnostic development for precision medicine
Yu-Zhen Liu, Ph.D.
Global Diagnostic Expert, Precision Medicine &amp; Genomics, Global R&amp;D, AstraZeneca
<div class="layoutArea">
<div class="column">

<img class="size-full wp-image-9495 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2019/01/10.png" alt="" width="110" height="104" />Refining the Precision Medicine for Pancreatic Cancer
Lei Zheng, MD, Ph.D.
Co-Director, the “Precision Medicine Center of Excellence” for Pancreatic Cancer, Johns Hopkins University School of Medicine

&nbsp;

</div>
</div>

<hr />

<h5>Introducing Hereditary Cancer Panel</h5>
Our Hereditary Cancer Panel offers flexible solutions for applications including biomarker discovery, patient enrollment, risk evaluation and screening. Flexibility in reporting options for up to 115 genes, based on BGI’s comprehensive proprietary database, allow you to scale a solution to fit your needs and budget.

Hereditary Cancer Panel samples are processed in our CAP accredited and CLIA certified service laboratory

<hr />

<h5>Meet Our Scientists</h5>
Following a rich history of contribution to Genomic Science, BGI scientists will be presenting a variety of posters during this AACR meeting:
Non-invasive detection of aberrant DNA methylation in colorectal cancer by multiplex methylation specific PCR

<h6>[Lili Ye, Chunting Zheng] et al.  <a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/5991" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
Development of a cfDNA based trans-omics approach for early cancer detection

<h6>[Yuying Wang] et al.  <a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/5985" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
Comprehensive analysis of immune evasion in breast cancer by single-cell RNA-seq
<h6>[Jianhua Yin, Hanlin Zhou] et al.  <a href="https://www.abstractsonline.com/pp8/#!/6812/presentation/4362" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
Analysis of the tumor microenvironment in seven cancer types by single-cell RNA-seq
<h6>[Michael Dean] et al.  <a style="font-family: inherit;font-size: 12px;background-color: #ffffff" href="https://www.abstractsonline.com/pp8/#!/6812/presentation/4370" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
Intratumor heterogeneity of non-small-cell lung cancer with EGFR
<h6>[Sitan Qiao, Xin Zhao, Xinlan Zhou] et al.  <a style="font-family: inherit;font-size: 12px;background-color: #ffffff" href="https://www.abstractsonline.com/pp8/#!/6812/presentation/4070" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
High-throughput unbiased microwell-based single-cell CNV detection reveals tumor clonal subtypes in hepatocellular carcinoma
<h6>[Liang Wu, Yuzhou Wang] et al.  <a style="font-family: inherit;font-size: 12px;background-color: #ffffff" href="https://www.abstractsonline.com/pp8/#!/6812/presentation/3524" target="_blank" rel="noopener noreferrer">Learn More</a></h6>
EPIC: MHC-I epitope prediction integrating mass spectrometry derived motifs and tissue-specific expression profiles
<h6>[Weipeng Hu] et al.  <a style="font-family: inherit;font-size: 12px;background-color: #ffffff" href="https://www.abstractsonline.com/pp8/#!/6812/presentation/6043" target="_blank" rel="noopener noreferrer">Learn More</a></h6>

BGI Excited to be at AACR 2019!

<h5 style="margin-bottom: 25px; font-size: 20px;">We’re getting ready to head to San Diego!</h5>
<h5 style="font-size: 20px;">Come say hello on booth #105 to learn how we can support your Plant and Animal research with our world-class sequencing services.</h5>
<h5 style="font-size: 20px;">We will be showcasing new products, including a greatly expanded line of services from our DNBseq™ technology platform, and host an educational seminar for your inspiration.</h5>
&nbsp;
<h2>Be Inspired!</h2>
<img class=" wp-image-6350 alignright" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/PAG-lightbulb.png" alt="BGI at PAG lightbulb" width="143" height="215" />
<h4 style="color: #c00000;">At our Workshop</h4>
<div class="page" title="Page 1">
<div class="layoutArea">

Attend our educational workshop to be inspired by new NGS technology and recent advances in plant and animal research from leaders in the field.

</div>
</div>
<h5></h5>
<h5></h5>
<h5>Examples of NGS-Enabled Plant Research:</h5>
<h5>Recent Advances and the Value of Big Data</h5>
<div class="page" title="Page 1">
<div class="layoutArea">

Monday, January 14, 4:00 - 6:10PM
Snacks and beverages will be provided.
Royal Palm salon 5-6

</div>
&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column" style="font-size: 16px;"><img class="size-full wp-image-8168 alignleft" style="width: 100px; height: 100px;" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/xxx.png" alt="" />
Shelley Lumba, PhD
Assistant Professor,University of Toronto,Toronto

<hr style="margin: 0; margin-top: -20px;" />

NGS Applications in Translational Research to Cannabis and African Parasitic Weeds

</div>
</div>
</div>
&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column" style="font-size: 16px;"><img class="size-medium wp-image-8169 alignleft" style="color: #333333; font-size: 14px; width: 100px; height: 100px;" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/xxx.png" alt="" />David Fang, PhD
Research Leader,ASDA-ARS, New Orleans

<hr style="margin: 0; margin-top: -20px;" />

Whole genome sequencing of a MAGIC population identified genomic loci and candidate genes for major fiber quality traits and Envoke® herbicide tolerance in cotton

</div>
</div>
</div>
&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column" style="font-size: 16px;"><img class=" wp-image-8170 alignleft" style="color: #333333; font-size: 14px; width: 100px; height: 100px;" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/xxx.png" alt="" />Zhikang Li, PhD
Professor,Institute of Crop Sciences, Chinese Academy of Agricultural Sciences

<hr style="margin: 0; margin-top: -20px;" />

Shaping the population and genomic architecture of Asian cultivated rice (Oryza sativa L.) through domestication and modern breeding

</div>
</div>
</div>
&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column" style="font-size: 16px;"><img class=" wp-image-8170 alignleft" style="color: #333333; font-size: 14px; width: 100px; height: 100px;" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/xxx.png" alt="" />Shifeng Chen, PhD
Senior Scientist,BGI Genomics

<hr style="margin: 0; margin-top: -20px;" />

The promise of Big Data in Plant Phylogenomics for Agriculture and medicinal plant research

</div>
</div>
</div>
&nbsp;
<h2 style="color: #c00000;">More Inspiration</h2>
<h4 style="color: #c00000;">from BGI Scientific Presentations at PAG</h4>
A chance for you to meet our scientists when they present their work, building on a rich tradition of scientific contribution to the field of Genomics.

Scientific Workshop
<table border="1">
<tbody>
<tr>
<td style="padding: 10px;">Pacific Salon 1Monday, Jan 14, 6:20PM</td>
<td style="padding: 10px;">Evolution of Marine Mammal Genome</td>
<td style="padding: 10px;">Xin Liu, BGI ResearchWesley Warren, McDonnell Genome Institute at Washington University</td>
</tr>
</tbody>
</table>
Other BGI Talks and Posters
<table style="text-align: center;" border="1">
<thead style="font-weight: bold;">
<tr>
<td style="padding: 10px;">Abstract</td>
<td style="padding: 10px;" width="100px">BGI Author</td>
<td style="padding: 10px;">Title</td>
</tr>
</thead>
<tbody>
<tr>
<td style="padding: 10px;">W375</td>
<td style="padding: 10px;">Guangyi Fan</td>
<td style="padding: 10px;">Chromosome Level Genome of Indo-Pacific Humpback Dolphin (Sousa Chinensis) reveal its Chromosome Evolution and Population Feature by Re-Sequencing</td>
</tr>
<tr>
<td style="padding: 10px;">W947</td>
<td style="padding: 10px;">Yu Guo</td>
<td style="padding: 10px;">Sequencing Reveals the Origins of Domesticated Barley in Tibet</td>
</tr>
<tr>
<td style="padding: 10px;">W920</td>
<td style="padding: 10px;">Shanlin Liu</td>
<td style="padding: 10px;">Genome-Wide Signature of Adaptive Evolution in the Rhinocerotidae</td>
</tr>
</tbody>
</table>
<h4></h4>
<h4></h4>
&nbsp;
<h4 style="color: #c00000;">We Sequence, You Discover.</h4>
We offer a complete line of NGS services to support your academic research or commercial plant and animal R&amp;D projects. From single sample to large-scale population studies, we are at your service!

</div>

BGI will be at PAG 2019 in San Diego

Last week at the 13th International Conference on Genomics (ICG-13) in Shenzhen, China, BGI announced a new sequencing system based on its DNBSEQ™ Technology. The newly unveiled MGISEQ-T7 is the most powerful sequencing system from BGI’s MGI subsidiary, with a daily output capability of 6Tb of data. The MGISEQ-T7 is able to complete 60 human genomes in a single day, with essentially error-free sequencing from BGI’s DNBSEQ™ sequencing technology. The quad-Flowcell system can run up to 4 high-density flow cells with different read lengths in a single run, adding operational flexibility to the uniquely high throughput. Read more <a href="https://www.prnewswire.com/news-releases/mgi-introduces-groundbreaking-ultra-high-throughput-sequencer-mgiseq-t7-300739020.html">here.</a>

BGI Unveils New High-Throughput Sequencing System.

BGI, Gencove Team Up To Provide Unique Whole Genome NGS Solutions To Rival Genotyping Arrays &nbsp; Cambridge, MA and New York, October 18, 2018 – BGI Americas, a genomics services leader, and Gencove, a leading genomics technology company, announced today that they have entered into an agreement to offer a new low-pass sequencing service to lower barriers to large-scale genomics projects. This service combines BGI’s DNBSEQ™ Next Generation Sequencing technology and Gencove’s ImputeSeq™ low-pass sequencing analysis pipeline. Genotyping array technology, widely used for genome-wide association studies and other large-scale genomics projects, is limited to a finite number of pre-selected genetic variants. In addition, these variants are often biased towards those most common in populations of European descent. BGI’s DNBSEQ technology has brought the price of generating sequencing data to a point where it is lower than that of genotyping arrays. At the same time, Gencove’s ImputeSeq™ pipeline turns low-pass data into high quality variant calls across the genome, along with ancestry and microbiome profiles for each sample. The powerful new NGS-based solution will provide scientists with more data, better variant calls without bias, and the ability to discover new rare variants, at a cost that is lower than that of genotyping arrays. In addition, the raw genome data will remain available for future re-analysis as science progresses. The solution will be available in the Americas as a complete turn-key service from both companies and will benefit scientists involved in genome-wide association studies, biobanks, and pharmacogenomics by allowing them to increase the power and scale of their work. According to Charles Bao, General Manager of BGI Americas Corporation, “This new service is the next step towards making NGS data more affordable through our DNBSEQ technology. Teaming up with Gencove allows us to provide a better tool for large genome-wide studies, allowing more precise analysis to advance the development of more precise healthcare. “ Joe Pickrell, CEO and co-founder of Gencove, added: “The DNBSEQ technology combined with Gencove’s analysis is a powerful tool for driving the adoption of sequencing to new applications and increasing the scale at which scientists can conduct research. “ About BGI Americas BGI Americas is a subsidiary of BGI Genomics, that provides a full menu of next generation sequencing and clinical testing services for academic research, drug development and diagnostics in the North and South American continents. The company operates service laboratories under global quality standards from laboratories in the US, Hong Kong and mainland China. BGI Genomics leverages its unequalled genomic research experience and massive sequencing capacity to provide customers with the highest quality data, fast turnaround at affordable prices. More information is available at <a href="http://www.bgi.com/">www.bgi.com</a> About Gencove Gencove is a spin-out of the New York Genome Center dedicated to making genomic data more accessible and interpretable through the development of molecular and computational tools. Gencove’s flagship product is its low-pass genome sequencing platform; the company operates a laboratory in New York and offers both low-pass sequencing and analytics software as a service, with customers that include top academic institutions, biotechnology and pharmaceutical companies.  More information is available at www.gencove.com. # # # Media contacts BGI Americas: Damon Zhang, <a href="mailto:Damon.zhang@bgi.com">Damon.zhang@bgi.com</a> (832) 373 2657 &nbsp; Gencove: Maria Vazquez <a href="mailto:maria.vazquez@gencove.com">maria.vazquez@gencove.com</a> (646) 583-3246

BGI and Gencove Team Up to Advance Genome-Wide Discovery

October 4, 2018 -- BGI has analyzed the world’s largest set of genome data from pregnant women, a total 141,431 expectant mothers from across China, in a groundbreaking study published today in the leading academic journal Cell. The genomic analyses from non-invasive prenatal testing (NIPT) revealed new genetic associations, patterns of viral infections, and history in Chinese populations. The study is the largest genomic study of the Chinese population to date and represents the first phase of BGI's Million Chinese Genome Project. “For the first time, we proved that NIPT data can be used in genome-wide association studies to understand the genetic architecture of complex traits and disease,” said Siyang Liu, senior research scientist in BGI and first author of the study.  “This brings up a new and promising model of investigating genetic mechanisms underlying traits related to maternal and child’s health.” The research has revealed novel genetic associations between genes and pregnancy-related traits, including the birth of twins and the woman’s age at pregnancy, one of the well-known measurements of fertility. The analysis also allowed researchers to reconstruct the recent movement and intermarriage of different ethnic groups in China, and promises to help identify genes that make people susceptible to viral infection. Read the complete Press Release here: <a href="https://www.bgi.com/wp-content/uploads/sites/2/2018/10/BGI-Publishes-140K-Genomes-Study-of-Chinese-Population-press-release-final-10.4.pdf">BGI Publishes 140K Genomes Study of Chinese Population press release final 10.4</a> &nbsp; &nbsp;

BGI Publishes Largest Ever Genomic Study of Chinese Population  Discoveries in more than 140,000 Genomes throughout China

<h5>We're getting ready to head to San Diego!</h5>
&nbsp;
<h5>Come say hello and learn how we can support your research with our world-class sequencing services.</h5>
<h5>We will be showcasing new products, including a greatly expanded line of WGS services from our DNBSEQ™ technology platform, host an educational seminar and offer special fall promotions for our services.</h5>
<h5>Scroll down for details and come see for yourself at booth #714.</h5>
<h1></h1>
&nbsp;
<h1>BE INSPIRED!</h1>
<img class=" wp-image-6350 alignright" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/PAG-lightbulb.png" alt="BGI at PAG lightbulb" width="143" height="215"/>AT OUR LUNCH SEMINAR.
<div class="page" title="Page 1">
<div class="layoutArea">

Attend our educational seminar and be inspired by new NGS technology applied to&nbsp;Research, Big Data population studies and Clinical applications, from leaders in genomics.

</div>
</div>
<h5></h5>
<h5>NGS 2.0 – Innovation Fuels Advances in Genomics Research and Population Studies</h5>
<div class="page" title="Page 1">
<div class="layoutArea">

Friday, October 19, 12:30 – 1:45PM, lunch will be provided.
Room 29CD, Upper Level, San Diego Convention Center

</div>
</div>
&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<h3>Talks and Speakers:</h3>
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">

<img class="size-full wp-image-8168 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/Picture1.png" alt="" width="112" height="139"/>The opportunity of the million genomes project in China and how to overcome big data challenges

Xin Jin, Ph.D.
Director of Big Data, BGI Genomics

&nbsp;
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">

<img class="size-medium wp-image-8169 alignleft" style="color: #333333;font-size: 14px" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/Picture2.png" alt="" width="114" height="152"/>Large Scale, Genome-wide Sequencing for the Diagnosis and Discovery of Genetic Disorders

Yaping Yang, Ph.D., FACMG
Professor, Department of Molecular and Human Genetics, Baylor College of Medicine

</div>
</div>
</div>
&nbsp;

</div>
</div>
</div>
</div>
</div>
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">

<img class="wp-image-8170 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/07/Picture3.png" alt="" width="114" height="147"/>

Sequencing and benchmarking of the GIAB Standards with the BGI sequencing platforms

Christopher Mason, Ph.D.
Associate Professor and WorldQuant Initiative, Director, Weill Cornell Medicine

</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<h1></h1>
&nbsp;
The opportunity of the million genomes project in China and how to overcome big data challenges – Xin Jin, Ph.D.
We analyze whole-genome sequencing data from 141,431 Chinese women, generated for non-invasive prenatal testing (NIPT). We use these data to characterize the population’s genetic structure and to investigate genetic associations with maternal and infectious traits. We show that the present-day distribution of alleles is a function of both ancient migration and very recent population movements. We reveal novel phenotype-genotype associations, including several replicated associations (height and BMI, maternal age and EMB, twin pregnancy and NRG1). Finally, we identify a unique pattern of circulating viral DNA in plasma with high prevalence of hepatitis B and other clinically relevant maternal infections. A GWAS for viral infections identifies a strong association between integrated herpesvirus 6 and MOV10L1, which affects piwi-interacting RNA (piRNA) processing and PIWI protein function. These findings demonstrate the value of accumulating NIPT data for worldwide medical and genetic analyses.

Large Scale, Genome-wide Sequencing for the Diagnosis and Discovery of Genetic Disorders - Yaping Yang, Ph.D.

Genome wide sequencing has become a powerful tool in diagnostic evaluations of genetic disorders. For example, clinical exome sequencing can identify contributing variants in approximately 30% of the individuals suspected of having neurologic genetic disorders. In addition, the accumulated clinical exome data is also a rich source for identifying the remaining Mendelian disorders that have yet to be elucidated. In this session, you will learn approaches to perform data mining of clinical exome data for the identification of novel disease genes.

Sequencing and benchmarking of the GIAB Standards with the BGI sequencing platforms – Christopher Mason, Ph.D.

Abstract to follow.

&nbsp;
<h1></h1>
<h1></h1>
<h1>New Products</h1>
Come check out our complete suite of WGS services from the proven DNBSEQ™ sequencing technology:
<ul>
 	<li>True PCR-free WGS for just $600</li>
 	<li>DNBSEQ™ Whole Genome Bisulfite Sequencing</li>
 	<li>Low-Pass Sequencing service with Gencove imputation and data analysis</li>
</ul>
&nbsp;
<h1></h1>
<h1>Amazingly Priced Services &amp; Promotions</h1>
Visit our booth #714 to learn about all our NGS services that make your research budget go further.

What’s more, special promotions for RNA Sequencing, Whole Exome Sequencing and Whole Genome Bisulfite Sequencing await you.

&nbsp;
<h1>Put booth #714 on your list for inspiration.</h1>
See you in San Diego!



&nbsp;

BGI at ASHG 2018, San Diego

<header> <h1 class="c-news__title"></h1> </header> <div class="entry-content"> <table border="0" width="100%" cellspacing="1" cellpadding="3"><tbody><tr class="ccbnBgTtl"><td valign="top"> <h3>Natera and BGI Genomics Announce Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI’s DNBseq™ Technology Platform</h3> </td></tr><tr class="ccbnBgTxt"><td valign="top">&nbsp; <div class="xn-content"> Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing SAN CARLOS, Calif.&nbsp;and&nbsp;SHENZHEN, China,&nbsp;March 11, 2019&nbsp;/PRNewswire/ —&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2489610013&amp;u=http%3A%2F%2Fwww.natera.com%2F&amp;a=Natera%2C+Inc." target="_blank" rel="nofollow noopener">Natera, Inc.</a>&nbsp;(NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=4138450103&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=BGI+Genomics+Co.%2C+Ltd.%2C" target="_blank" rel="nofollow noopener">BGI Genomics Co., Ltd.,</a>&nbsp;(300676.SZ), the largest cell-free DNA clinical testing laboratory in&nbsp;China&nbsp;and one of the world’s leading genomics companies, today announced a&nbsp;$50 million&nbsp;partnership to commercialize&nbsp;Natera’s&nbsp;Signatera™ MRD test in&nbsp;China, and to develop reproductive health tests in select markets on BGI’s sequencing instruments using the DNBseq™ NGS technology platform. The Natera Signatera MRD and molecular monitoring test will be offered in&nbsp;China, first through specialty hospital networks and then more broadly, once&nbsp;Natera&nbsp;and&nbsp;BGI Genomics&nbsp;gain&nbsp;China’s&nbsp;regulatory approval for use of the Signatera test on the DNBseq™ technology platform. DNBseq™ is the market name of BGI’s proprietary sequencing technology, which supports its portfolio of next-generation sequencing platforms.&nbsp;BGI Genomics’&nbsp;genetic testing leadership position in&nbsp;China, where it performs over 1 million cell-free DNA tests annually,1&nbsp;will accelerate&nbsp;Natera’s&nbsp;entry into this large and growing oncology market. Cancer is the leading cause of death in&nbsp;China&nbsp;with roughly 4.3 million new cancer cases and 2.8 million deaths reported annually.2&nbsp;The molecular diagnostics market in&nbsp;China&nbsp;is a rapidly growing multi-billion-dollar market, driven largely by the rising incidence of cancer and infectious diseases.3 “Natera&nbsp;shares our core vision of improving human health by offering innovative genetic testing solutions that allow for earlier and more effective diagnosis of disease,” said&nbsp;Yin Ye, CEO at&nbsp;BGI Genomics. “Natera’s&nbsp;decision to launch its Signatera test into&nbsp;China&nbsp;on BGI’s DNBseq™ technology platform is a testament to both the quality and versatility of our technology. We look forward to working together with&nbsp;Natera&nbsp;for the general benefit of people&nbsp;worldwide and to expanding access to the DNBseq™ technology platform to other customers globally.” “We are very impressed with BGI’s pace of innovation, its people, and its scale of operations in&nbsp;China,” said&nbsp;Steve Chapman, CEO at&nbsp;Natera. “BGI is a recognized world leader in next-generation sequencing and, we believe, the most qualified laboratory partner for us in&nbsp;China. This deal continues&nbsp;Natera’s&nbsp;commercialization success in oncology, augmenting over 30 pharmaceutical trials currently underway, and is a strong endorsement of&nbsp;Natera’s&nbsp;leading technology in oncology and reproductive health.” “We are excited for the opportunity to partner with an innovative leader like BGI to commercialize Signatera in&nbsp;China&nbsp;and expand the reach of&nbsp;Natera’s&nbsp;reproductive health technology in select markets, and we believe BGI has the capability to substantially reduce costs for offering our technology,” said&nbsp;John Fesko, Sr.&nbsp;Vice President of Business Development at&nbsp;Natera. “This deal complements our strategic partnerships with existing sequencing providers and does not alter our plans with them. This exciting alliance is key to our vision of being the application layer for genetic testing worldwide.” About BGI <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=3949147033&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=BGI" target="_blank" rel="nofollow noopener">BGI</a>&nbsp;was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications.&nbsp;BGI Genomics&nbsp;is an independent division of&nbsp;BGI Group, and was listed on the&nbsp;Shenzhen Chi-Next exchange in&nbsp;July 2017.&nbsp;BGI Genomics’&nbsp;goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI’s own DNBseq™ technology platforms, economies of scale, and expert bioinformatics resources.&nbsp;BGI Genomicsalso offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. Follow&nbsp;BGI Genomics&nbsp;on&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2839640756&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbgi-shenzhen%2F%3FviewAsMember%3Dtrue&amp;a=LinkedIn" target="_blank" rel="nofollow noopener">LinkedIn</a>&nbsp;and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=1067828996&amp;u=https%3A%2F%2Ftwitter.com%2FBGI_Genomics&amp;a=Twitter" target="_blank" rel="nofollow noopener">Twitter</a>. About&nbsp;DNBseq™&nbsp;Technology <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2184750478&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2Fdnbseq-ngs-technology%2F&amp;a=DNBseq%E2%84%A2%C2%A0" target="_blank" rel="nofollow noopener">DNBseq™&nbsp;</a>technology is a proprietary sequencing technology originally developed by MGI. DNBseq™ sequencing technology is powered by PCR-free Rolling Circle Replication, combinatorial Probe-Anchor Synthesis (cPAS) and DNA Nanoballs (DNB) technology. The cPAS chemistry works by linking a fluorescent probe to a DNA anchor on the DNB, followed by high-resolution digital imaging. This combination of linear amplification and DNB technology reduces the error rate while enhancing the signal. In addition, the size of the DNB is controlled in such a way that only one DNB is bound per active site in the flow cell. This patterned array technology not only provides sequencing accuracy, but it also increases the chip utilization and sample density. Unlike PCR amplification, amplification errors arising from Rolling Circle Amplification do not accumulate exponentially, allowing DNBseq™ platforms to deliver a high level of data clarity. NGS data from DNBseq™ technology is documented by a growing body of studies, with over 100 peer-reviewed publications to date. BGI has also published pilot data from its sequencing platforms running on DNBseq™ technology, including samples processed for human whole genome sequencing from the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2012495783&amp;u=https%3A%2F%2Fbiobank.ctsu.ox.ac.uk%2Fcrystal%2Frefer.cgi%3Fid%3D657&amp;a=UK+Biobank" target="_blank" rel="nofollow noopener">UK Biobank</a>&nbsp;as part of a proof of concept study. About Signatera™ <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2460634685&amp;u=https%3A%2F%2Fwww.natera.com%2Fsignatera%2Fdifference&amp;a=Signatera" target="_blank" rel="nofollow noopener">Signatera</a>&nbsp;is the first circulating tumor DNA (ctDNA) test custom-built for molecular treatment monitoring and molecular residual disease (MRD) assessment. The test is available for research use only until its clinical launch planned for Q2 2019. The Signatera methodology differs from currently available liquid biopsy tests, which test for a fixed panel of therapeutically relevant genes. Signatera provides each individual with a customized blood test tailored to match the clonal mutations found in that individual’s tumor tissue. This maximizes accuracy for detecting the presence or absence of MRD in a blood sample, even at levels down to a single mutant molecule in a tube of blood. Signatera RUO also allows researchers to track additional mutations of interest, up to several hundred mutations, for clinical studies. The body of evidence on the utility of Signatera is growing: <ul type="disc"> 	<li>A 2017 study demonstrated the Signatera RUO method’s ability to detect MRD, measure treatment response, and identify recurrence up to 11 months earlier than the standard of care for early stage non-small-cell lung cancer (NSCLC) with 93 percent sensitivity and zero false positives.4</li> 	<li>Data presented at the&nbsp;European Society for Medical Oncology&nbsp;2018&nbsp;Congress&nbsp;showed successful results from bladder and colorectal cancer studies, including median detection points of MRD that were 3.3 and 7.9 months, respectively, ahead of clinical relapse detection.5,6</li> 	<li>In two studies presented at the 2018 San Antonio Breast Cancer Symposium, Signatera RUO was able to detect MRD up to two years prior to clinical relapse and predict treatment response in a cross-section of breast cancer patients, including those who were HER-2 positive, hormone receptor-positive, and triple negative.7,8</li> </ul> Based on numerous studies across multiple cancer types, a positive Signatera RUO result without further treatment has predicted clinical relapse nearly 100 percent of the time.4-8 About&nbsp;Natera <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2958226392&amp;u=http%3A%2F%2Fwww.natera.com%2F&amp;a=Natera" target="_blank" rel="nofollow noopener">Natera</a>&nbsp;is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide.&nbsp;Nateraoperates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in&nbsp;San Carlos, Calif.&nbsp;It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that&nbsp;Natera’s&nbsp;plans, estimates, or expectations will be achieved. These forward-looking statements represent&nbsp;Natera’sexpectations as of the date of this press release, and&nbsp;Natera&nbsp;disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize product offerings,&nbsp;whether standard closing conditions can be met, our partners’ ability to obtain regulatory approvals required to offer our products, our ability to improve, and the effect of any improvements in, our cost of goods sold,&nbsp;our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers, or our expectations regarding our strategic operations. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in&nbsp;Natera’s&nbsp;recent filings on Forms 10-K and 10-Q and in other filings&nbsp;Natera&nbsp;makes with the&nbsp;SEC&nbsp;from time to time. These documents are available at&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=4189340854&amp;u=http%3A%2F%2Fwww.natera.com%2Finvestors&amp;a=www.natera.com%2Finvestors" target="_blank" rel="nofollow noopener">www.natera.com/investors&nbsp;</a>and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=1723542246&amp;u=http%3A%2F%2Fwww.sec.gov%2F&amp;a=www.sec.gov" target="_blank" rel="nofollow noopener">www.sec.gov</a>. Natera Contacts Investor Relations:&nbsp;Mike Brophy, CFO,&nbsp;Natera, 650-249-9090 Media:&nbsp;Andrea Sampson, Sullivan &amp; Sampson, 714-374–6174,&nbsp;<a href="mailto:asampson@sullivanpr.com" target="_blank" rel="nofollow noopener">asampson@sullivanpr.com</a> BGI Contacts Investor Relations:&nbsp;Qian Xu, Secretary Board of Directors, BGI, +86-755-36307888 Media:&nbsp;USA&nbsp;and EMEA,&nbsp;Matt Poulter, Senior Global Marketing Manager,&nbsp;BGI Genomics,&nbsp;<a href="mailto:matt.poulter@bgi.com" target="_blank" rel="nofollow noopener">matt.poulter@bgi.com</a> China&nbsp;and AP,&nbsp;Bicheng Yang, Director,&nbsp;Director Corporate Communications&nbsp;and Public Engagement,&nbsp;BGI Group,&nbsp;<a href="mailto:yangbicheng@genomics.cn" target="_blank" rel="nofollow noopener">yangbicheng@genomics.cn</a> References <ol type="1"> 	<li>BGI internal figures as of 2019.</li> 	<li>Chen W, Zheng R, Baade PD, et al. Cancer statistics in&nbsp;China, 2015.&nbsp;CA Cancer J Clin. 2016;66:115–132.</li> 	<li>China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA). 2018, Research and Markets Report, ID: 4607564.</li> 	<li>Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.</li> 	<li>Birkenkamp-Demtröder K, Christensen E, Sethi H, et al. Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer for Surveillance and Therapeutic Efficacy Monitoring. Poster presented at: European Society for Medical Oncology Annual Congress;&nbsp;October 20, 2018;&nbsp;Munich, Germany. Abstract 86P.</li> 	<li>Reinert T, Henriksen TV, Rasmussen MH, et al. Serial Circulating Tumor DNA Analysis for Detection of Residual Disease, Assessment of Adjuvant Therapy Efficacy and for Early Recurrence Detection in Colorectal Cancer. Poster presented at: European Society for Medical Oncology Annual Congress;&nbsp;October 21, 2018;&nbsp;Munich, Germany. Abstract 456PD.</li> 	<li>Magbanua M, Brown-Swigart L, Hirst G, et al. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL. Data presented at spotlight session: San Antonio Breast Conference Symposium;&nbsp;December 5, 2018. Abstract 1259.</li> 	<li>Coombes RC, Armstrong A, Ahmed S, Page K, et al. Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence. Poster presented at: San Antonio Breast Conference Symposium;&nbsp;December 7, 2018.&nbsp; Abstract 1266.</li> </ol> </div></td></tr></tbody></table> </div>

Natera and BGI Genomics Announce Partnership in Oncology Testing in China on DNBseq™ Technology Platform

<h5>Come say hello at booth #3555 and learn how we can support your cancer research with our world-class sequencing services.</h5>
<h5>We will be introducing new solutions for Biomarker Discovery &amp; Development and Immuno-Therapy.</h5>

<hr/>

<h5>New Solutions for Drug Development</h5>
Attend our educational seminar to be inspired by leaders in cancer genomics: BGISEQ-500 NGS technology applied in Cancer Research and a new Neoantigen Prediction solution.

&nbsp;
<h3><img class="wp-image-6791 alignnone" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/02/new-drug-table-1-1024x212.png" alt="" width="664" height="118"/></h3>

<hr/>

<h5>Be Inspired!&nbsp;At our Spotlight Theater Seminar<img class="wp-image-6350 alignright" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/PAG-lightbulb.png" alt="BGI at PAG lightbulb" width="139" height="228"/></h5>
Attend our educational seminar to be inspired by leaders in cancer genomics: BGISEQ-500 NGS technology applied in Cancer Research and a new Neoantigen Prediction solution.

New NGS Tools for Cancer Research and Immuno-Therapy.
Monday, April 16, 3:00 – 4:00PM
 Spotlight Theater C on the exhibit floor
<h3><img class="wp-image-6792 size-large alignnone" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/02/spotlight-tabel-02-1024x361.png" alt="" width="1024" height="361"/></h3>

<hr/>

<h5>More Inspiration,&nbsp;from BGI’s Scientific Presentations</h5>
A chance for you to meet scientists from BGI when they present their work, building on a rich tradition of scientific contribution to the field of Cancer Research.

Single-cell RNA-sequencing reveals the immune contexture of triple-negative breast cancer tumors
Si QIU, Scientist, BGI Research, Shenzhen, China
Session Category: Immunology
Session Title: &nbsp;Modifiers of the Tumor Microenvironment 2
Session Date &amp; Time: Monday Apr 16, 2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
Poster Board Number: 29

Dissecting the spatial heterogeneity of circulating tumor cells reveals CCL5-Treg-mediated immune evasion in hepatocellular carcinoma
Liang WU, Scientist, BGI Research, Shenzhen, China
Session Category: Clinical Research
Session Title: Liquid Biopsy 4
Session Date &amp; Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 27
Poster Board Number: 28

Analysis of the paired TCRα- and β-V(D)J full-length chains of single-cell sequence from human naïve and antigen-experienced T cells
Fei WANG, Scientist, BGI Research, Shenzhen, China
Session Category: Clinical Research
Session Title: Adoptive Cell Therapy 1
Session Date &amp;Time: Monday Apr 16, 2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 24
Poster Board Number: 9

<a href="http://www.abstractsonline.com/pp8/#!/4562/presentation/7077">A high-performance target enrichment strategy for liquid biopsy
</a>Jilong Liu, Research Scientist, BGI Research, Guangzhou, China
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Genomic Profiling of Tumors 1
Session Date &amp;Time: Tuesday, April 17, 2018, 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 17
Poster Board Number: 19

BGI at AACR 2018 in Chicago

BGI expands its long-read sequencing capacity with the purchase of 10 new PacBio Sequel systems. Customers will benefit from exceptional data quality and reduced turn-around timed for plant/animal/microbial sequencing, conservation biology and other long-read services. Featured today in GEN and on GenomeWeb. Read <img class="alignleft size-medium wp-image-6619" src="https://www.bgi.com/wp-content/uploads/sites/2/2018/01/Sequel-Image-300x172.jpg" alt="" width="300" height="172" />more <a href="http://www.pacb.com/press_releases/bgi-increases-long-read-sequencing-capacity-with-purchase-of-10-pacbio-sequel-systems/">here</a> .

BGI expands Long-Read sequencing capacity with 10 new Sequel systems

BGI Genomics, the industry's lowest-cost provider of WGS, launches two new ambitious plans at J.P. Morgan Healthcare Conference 2018 Jan 11, 2018 | BGI Genomics Today at the 36th J.P. Morgan Healthcare Conference, Ye Yin, CEO of BGI Genomics, announced that BGI Genomics has successfully sequenced the genome of over 10,000 human samples since it launched the industry's lowest priced Whole Genome Sequencing service at US$600, using the BGISEQ-500, BGI's own sequencing platform. Ye Yin went on to present two exiting new BGI initiatives: The 2020 Program and the Life Periodic Plan, both of which received strong interest from his audience. Over 10,000 human WGS samples have been sequenced with the BGISEQ-500 for just US$600 each, the industry's lowest price. BGI Genomics launched 100G high-quality WGS for the price of US$600 in 2016, still the lowest priced WGS available in the industry. A further 20,000 samples are currently being processed. Beginning in 1990, the first draft of the human genome took 13 years to complete, involved scientists from 6 countries at a cost of US$3.8 billion. With the rapid development of technology, the cost of sequencing has been driven down consistently. In 2016, BGI launched the BGISEQ-500 NGS platform. This technology enabled the $600 WGS product that is currently on the market. The BGISEQ-500 delivers high quality and high-throughput sequencing at a low cost, has accelerated the development of genomics, and has set the next benchmark for affordable genomics. BGI Genomic's launches two ambitious projects: 2020 Program and Life Periodic Plan At the conference, Ye Yin announced BGI Genomic’s 2020 Program. The ambitious program aims to perform human whole-genome sample sequencing, including sample preparation and data analysis, within 24-hours and below US$300. Ye Yin believes that this will be possible by 2020. To achieve this, BGI Genomics is collaborating with Intel and Alibaba Cloud to create the most radical innovation in genomics technology with advanced sequencing and computing equipment. BGI Online, BGI's bioinformatics cloud computing platform also plays an important role in the project. Just last week, BGI Genomics and Edico Genome completed a 100-person WGS project in just 120 minutes using Field Programmable Gate Array (FPGA) technology, representing a significant step towards BGI Genomic's goals. "Life Periodic Plan will be as significant as the periodic table" according to&nbsp;Ye Yin, CEO of BGI Genomics Ye Yin also launched BGI Genomic's Life Periodic Plan at the conference. Its objective is to data mine species through sequencing. This will facilitate the ambitious goal of digitizing all animals and plants on earth, and eventually elucidating the laws of life hidden within the data. The implementation of the Life Periodic Plan could help to protect endangered animals and plants, maintain ecological balance and the diversity of life on earth. Of the plant and animal species sequenced so far, 70% have been sequenced by BGI Genomics and its collaborators. The first phase of the Life Periodic Plan is targeted at the existing 27 orders and 157 families of Mammalia. To implement the first phase, BGI Genomics has asked for volunteers from within BGI Genomics and its collaborators to choose individual families to sequence. So far, more than 127 families have been claimed by group leaders. The project will be financed through crowdfunding. Group leaders will direct the genomics analysis, interpretation and knowledge dissemination of the species, to protect their species. The plant section of the Life Periodic Plan will be launched shortly.

BGI Genomics' CEO Yin Ye presents ambitious plans at the JP Morgan Healthcare Conference in San Francisco

BGI &amp; Sanguine Join Forces to Increase Speed and Efficiency of Precision Clinical Trial Recruitment SHENZHEN, China, CAMBRIDGE, Mass. and SHERMAN OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- BGI Genomics, a global leader in Next Generation Sequencing Services, and Sanguine BioSciences, Inc., a builder of data-integrated patient communities, have joined forces to develop a database of combined genomic and clinical data to increase the speed and efficiency of Precision Clinical Trial Recruitment. For their first project, Sanguine and BGI will collaborate to enable trial developers to access searchable Whole Genome and Electronic Medical Record (EMR) data of 1,000+ patients diagnosed with Rheumatoid Arthritis (RA). The combined offering will allow drug developers to significantly increase the homogeneity of their trial cohorts, reducing risk and cost and increasing the likelihood of success. Timothy J. Triche MD, PhD, Chairman of Sanguine's Board of Directors, said in a statement: "Selecting the right patient cohort(s), and then recruiting swiftly are the ingredients of a successful clinical trial. The healthcare community has seen time and time again that selecting the wrong patient cohort(s) is a death sentence for the trial. Today, there is no other company that enables specific individual requests based on both Whole Genome &amp; EMR data, and then works directly with those identified patients to enroll them into the trial. Together, Sanguine and BGI are making this a reality today, initially in Rheumatoid Arthritis." "BGI has been a credible partner to the biopharma industry, providing quality NGS services and a diverse menu of biomarker assays," said Charles Bao, Ph.D., General Manager of BGI Americas, a subsidiary of BGI Genomics. "The partnership with Sanguine will allow precise and efficient clinical trial enrollment, and will enhance BGI's overall solution to its biopharma partners. Whole genome sequencing provides the most comprehensive and unbiased genomic profiling that will maximize the value of Sanguine's patient database. The sequencing will be performed on our own BGISEQ NGS platform, marking the first time this high quality, low cost solution is used in a large-scale profiling project in the biopharma space." About Sanguine Sanguine is accelerating Precision Medicine by partnering with data-integrated patient communities. The Company has developed a disruptive, scalable Direct-to-Patient data collection and commercialization platform currently used by 20 out of the top 40 pharmaceutical companies and currently &gt;15,000 patients. About BGI Genomics BGI Genomics is the division of BGI Group that provides a diverse menu of next generation sequencing and clinical testing services to support academic research, drug development and diagnostics. The company operates service laboratories under global quality standards in the US, Denmark, Hong Kong and mainland China. BGI Genomics leverages its sophisticated genomic research experience and massive sequencing capacity to assist customers with fast turnaround, delivering high quality data at affordable prices. Contacts Sanguine BioSciences, Inc. Lindsey Burton Phone: (818) 606-0513 Email: <a href="mailto:lburton@sanguinebio.com">lburton@sanguinebio.com</a> Website: www.sanguinebio.com BGI Genomics Louis Sintasath Phone: (858) 344-8398 Email: <a href="mailto:louis.sintasath@bgi.com">louis.sintasath@bgi.com</a> Website: www.bgi.com &nbsp;

BGI & Sanguine Join Forces to Increase Speed and Efficiency of Precision Clinical Trial Recruitment

BGI and Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, Awarded Investment from Genome Canada and Ontario Genomics Shenzhen, China and Toronto, Canada, November 30, 2017 ‒ BGI and the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, today announced the signing of a Memorandum of Understanding (MOU) outlining their intention to collaborate on the development a genomics-based diagnostic test for the early identification of women at risk for pre-term birth and other pregnancy complications. The non-invasive test will be based on genomic information from easy to obtain blood samples. Preterm birth complications are the leading cause of death among children under 5 years of age. Of the 200 million women worldwide who become pregnant annually, 15 million will deliver preterm, and this number is rising. Each year, 1 million preterm babies die and millions more will experience serious, life-long medical and developmental disorders as a result. In Canada alone, the annual costs associated with preterm births are estimated to be $600 million. BGI, one of the largest genomic organizations in the world, is committed to reducing the rate of major disease by offering accurate and affordable genetic tests and molecular diagnostics services. Dr. Stephen Lye, Senior Investigator at the Toronto-based Lunenfeld-Tanenbaum Research Institute and research lead on this project, has identified gene expression signatures in maternal white blood cells that can predict which women who experience too-early symptoms of labor, will go on to experience preterm birth of their infants. The first phase of this international partnership was recently awarded a $4.6 CAD million Genomic Applications Partnership Program (GAPP) investment from Genome Canada and Ontario Genomics. It will focus on enhancing the diagnostic potential of these gene expression signatures with the goal of developing a simple genomic test to identify women in threatened preterm labour who will deliver preterm. Approximately 2 million women are hospitalized annually in North America for Threatened Pre-Term Labour. However, less than 20% of these women will deliver preterm, exposing 80% to unnecessary interventions and hospitalization. The second phase of this collaboration will focus on developing a screening test early in pregnancy to identify women at risk of a preterm birth with the potential of saving the Canadian healthcare system $200 CAD million per year, and of reducing the burden on neonatal ICUs. BGI intends to continue its research collaboration with the Lunenfeld-Tanenbaum Research Institute and expand its R&amp;D and business activities in Canada, which will generate downstream investment and create jobs for highly qualified personnel. As part of the collaboration, BGI will provide its BGISEQ-500Ô next generation sequencing system and will eventually expand the sequencing capacity with its newly introduced MGISEQ-2000Ô sequencing system. This will accommodate future joint research and Laboratory Developed Test (LDT) projects. Quotes “This collaboration promises to be a major step forward for the health of women and children worldwide. Agreements like this one show how much we can accomplish when we connect Ontario’s innovative researchers with leading global partners through international business missions to share ideas that can make a real impact in people’s lives,” said Kathleen Wynne, Premier of Ontario. We are pleased to support this international collaboration that will deliver multiple benefits for Canada, China and beyond – chief among them, helping to improve maternal and newborn health worldwide through a simple genomic test,”  said Marc LePage, President and CEO, Genome Canada. “Through this collaborative investment, we are enabling the development of diagnostics that will have a positive global impact on the personal, social and economic burden associated with preterm births,” said Bettina Hamelin, President and CEO, Ontario Genomics. Ning Li, Chief Development Officer at BGI said in a statement that “The results from the joint venture with Lunenfeld-Tanenbaum Research Institute will produce an important addition to our existing reproductive testing portfolio and contribute to the reduction of birth defects, improvement in maternal health in Canada, China and around the world”. “This investment has the potential to transform prenatal care for women at risk of pre-term birth. I am very grateful for this investment, and for this important collaboration with partners who are equally committed to providing exceptional care for this patient population,” says Dr. Stephen Lye, Senior Investigator, Lunenfeld-Tanenbaum Research Institute. About Lunenfeld-Tanenbaum Research Institute The Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, is a leading biomedical research centre, ranking amongst the top biomedical research institutes in the world. Established in 1985, the institute is profoundly advancing understanding of human biology in health and disease. Many of the breakthroughs that began as fundamental research have resulted in new and better ways to prevent, diagnose and treat prevalent conditions. The institute is affiliated with the University of Toronto and is focused on women's and infants' health, cancer biology, stem cell biology and regenerative medicine, neurobiology, diabetes, arthritis, health systems research, population health services and solutions, and systems biology. <a href="http://www.lunenfeld.ca">www.lunenfeld.ca</a>. About BGI BGI Group was established in 1999 with participation in the original Human Genome Project. Since then, BGI Group has grown in to one of the world’s largest genomics organizations, experienced in genomic research, commercial NGS services and sequencer manufacturing. One of the company objectives is reducing the rate of birth defects and maternal health by offering accurate and affordable genetic tests. <a href="http://www.bgi.com">www.bgi.com</a> About Genome Canada Genome Canada is a not-for-profit organization that aims to harness the transformative power of genomics for the benefit of all Canadians. We connect ideas and people across public and private sectors to find new uses for genomics, invest in large-scale science and technology to fuel innovation, and translate discoveries into solutions across key sectors of national importance, including health, agriculture, forestry, fisheries &amp; aquaculture, energy, mining, and the environment. <a href="http://www.genomecanada.ca">www.genomecanada.ca</a>. About Ontario Genomics Ontario Genomics is a not-for-profit organization funded by the Ontario government and the federal research funding agency, Genome Canada. Established in 2000, it is the only entity focused solely on stimulating, enabling and nurturing genomics innovation in the province of Ontario across all sectors of the bio-economy. Ontario Genomics connects ideas, people and organizations to invest in genomics-based solutions aimed at improving quality of life and driving economic growth. <a href="http://www.OntarioGenomics.ca">www.OntarioGenomics.ca</a>. For further information: Donna Takacs, Communications, Ontario Genomics, 416-275-4180; Sally Szuster, Senior Manager, Communications and Public Affairs, Sinai Health System, 416-586-4800 x 8713.

CANADA AND CHINA PARTNERING  TO DEVELOP DIAGNOSTICS TESTS FOR PRETERM BIRTH

Attending AMP? Make sure to meet BGI scientists who will report on NGS data analysis advances to benefit cancer diagnosis and treatment: A novel NGS method for the identification of Microsatellite Instability (MSI) is compared to the traditional PCR method and found to be more accurate. Poster ST20, Abstract 13264, Friday, November 17, 2:30-3:30PM A novel Homologous Recombination Deficiency (HRD) algorithm that does not require a control, to predict PARP inhibitor response in breast and ovarian cancer patients Poster TT37, Abstract 13465, Saturday, Nov. 18, 9:45-10:45AM

BGI Posters Presented at AMP 2017

<h3>Come say hello to us at booth #432 to see how we can help you with all your sequencing needs.</h3>

<hr />

<h3 style="text-align: left;">Be Inspired!</h3>
At our Dinner Workshop
<img class="wp-image-6350 alignright" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/PAG-lightbulb.png" alt="BGI at PAG lightbulb" width="139" height="228" />
Our educational workshop will inspire you with new BGISEQ-500 NGS technology applied to chromosome-level genome assembly and with recent plant and animal research presented by leaders in the field.
You will learn how transcriptomics enables new discovery to advance basic research and application in crops and how a novel molecular tool can increase protein content and disease resistance in crops. Another talk will demonstrate how genetic variation can contribute to rapid evolution of polygenic traits in honey bees.
Examples of Recent NGS-Enabled Plant and Animal Research: New Technology, Tools and Findings.

Monday, January 15, 6:20PM - 8:30PM
Appetizers and beverages will be provided.
Sunset Meeting House

<img class="size-full wp-image-6351 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/Ling-Li.png" alt="BGI at PAG" width="116" height="146" />

&nbsp;

Dr. Ling Li, Assistant Professor, Mississippi State University: A molecular tool to increase protein content and broad disease resistance in crops.
<table>
<tbody>
<tr>
<td width="144"></td>
</tr>
</tbody>
</table>
&nbsp;

<img class="size-full wp-image-6352 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/Dr-Avalos.png" alt="BGI at PAG" width="121" height="145" />

&nbsp;

Dr. Arián Avalos, Postdoctoral Associate, University of Illinois, Urbana-Champaign: A soft selective sweep during rapid evolution of gentle behavior in an Africanized honeybee.

&nbsp;

<img class="size-full wp-image-6353 alignleft" src="https://www.bgi.com/wp-content/uploads/sites/2/2017/11/Dr-Liu.png" alt="BGI at PAG" width="121" height="140" />

&nbsp;

Dr. Xin Liu, Executive Director, BGI Research: High quality plant and animal genome assemblies using the BGISEQ-500 sequencing platform.

&nbsp;

Link to BGI workshop page: <a href="https://pag.confex.com/pag/xxvi/meetingapp.cgi/Session/4893">https://pag.confex.com/pag/xxvi/meetingapp.cgi/Session/4893</a>

More Inspiration from BGI Scientific Presentations at PAG

BGI Scientists are presenting original research at PAG: A chance for you to meet scientists from BGI when they present their work, building on a rich tradition of scientific contribution to the field of Genomics:

The Genomes of African Orphan Crops

African Orphan Crops workshop,

Wednesday, Jan. 17, 1:30-3:40 – Towne Meeting House

<a href="https://pag.confex.com/pag/xxvi/meetingapp.cgi/Paper/28348"> Xin Liu, BGI Research, Shenzhen, China</a>

<a href="https://pag.confex.com/pag/xxvi/meetingapp.cgi/Paper/28348">Paper/28348</a>

The Pomegranate Genome and the Genomics of Punicalagin Biosynthesis

Fruit/Nuts workshop,

Saturday, January 13, 2018 – Pacific Salon 3

<a href="https://pag.confex.com/pag/xxvi/meetingapp.cgi/Paper/29781"> Zhen Yue, BGI Genomics</a>, Shenzhen, China

<a href="https://pag.confex.com/pag/xxvi/meetingapp.cgi/Paper/29781">Paper/29781</a>

BGI will be in San Diego at PAG XXVI

<h1>BGI’s MGI Tech Launches Two New NGS Platforms</h1> Early Evaluators Report Faster Sequencing and Consistent Quality at a Lower Cost SHENZHEN, China (October 31, 2017) -- MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200, at the 12th International Conference on Genomics (ICG-12) in Shenzhen. The products were unveiled at the conference, held at the China National GeneBank from Oct. 26 - 29 with the theme “Omics for All – Global Partnership.” MGI also launched a modular NGS workstation, MGIFLP, as well as a robotic ultrasound system, MGIUS-R3. Before the product launch, BGI President Jian Wang gave the opening address. He said he hoped the new products could be affordable and benefit people all over the world, summing up his intention to “lower the price, save the life.” MGI Vice-President Hui Jiang said the new sequencers will deliver consistent high quality sequencing data faster and at a lower price. MGISEQ 200/2000 are upgrades to BGISEQ 50/500 with technological improvements. “MGISEQ-2000 and MGISEQ-200 can complete one run with PE100 read length in less than 48 hours, which provides partners high-quality service and data even more rapidly to benefit patients,” Jiang said. “We have made significant improvements in the industrial design of the sequencers and optimized the chemistry, which will allow our customers to operate the sequencers in their labs at a lower cost,” said Jian Liu, MGI Vice President. MGISEQ-2000 and MGISEQ-200 can run with at least four different read lengths, providing flexibility to cover a wide variety of applications across genomic research, clinical diagnosis, agriculture, forensics and environmental engineering. “With our R&amp;D team’s great efforts, we managed to make sequencing more affordable and of better quality and performance,” he said. Several partners involved in early testing of the new technology said it demonstrates significant improvements over existing technology. MGI Tech’s overall goal is to make the MGISEQ a versatile and open sequencing platform, said MGI CEO Feng Mu. MGI plans to release sequencing adapters and the test data to encourage users to develop their own applications on the MGISEQ platform. “This will help us to speed up technology development and production and to provide better tools and services to our customers,” Mu said. “Our goal is to innovate new technologies to help people live a healthy life. That’s why ‘Omics for All” is the important theme of this year’s ICG.” MGISEQ-2000 and MGISEQ-200 will be available for orders beginning from Dec. 25, 2017, and will start shipment from Feb. 14, 2018, initially in China. About MGI MGI (MGI Tech Co., Limited) is a part of BGI Group, one of the world's largest genomics organizations. As the equipment supporting platform of BGI, MGI is dedicated to developing, manufacturing and distributing instruments, reagents and devices/assays through innovation and collaboration. Since its acquisition of CGI (Complete Genomics Inc.)), MGI has built upon its technologies to rapidly develop a new series of genetic sequencers, including BGISEQ-1000, BGISEQ-500, and BGISEQ-50. MGI's mission is to "Make a Great Instrument and Make It Smart" to provide a real-time, digitized panoramic view of living things and advance life science to service genomics, proteomics and beyond.

BGI’s MGI Tech Launches Two New NGS Platforms

September 7th, 2017, Hong Kong, China - Global genomics company, BGI, today announced that it has obtained Clinical Laboratory Improvement Amendments (CLIA) certificate of registration for its Hong Kong based laboratory. BGI said that the CLIA-certificate of registration is an important step in expanding its offerings to include clinical sequencing services for analysis of specific diseases including cancer and mendelian diseases. In addition, it will provide a stronger footing for genomics-based clinical trial testing as part of BGI’s CRO pharma solutions that support drug discovery and development for its global biopharmaceutical clients. ‘BGI's objective is to offer the broadest array of high quality clinical diagnostics as well as solutions for more efficient research and drug discovery’ Liu Na, Vice President of BGI Genomics, said in a statement. BGI's existing services portfolio includes a wide variety of sequencing and analytical and bioinformatics services for DNA and RNA as well as a broad genetic screening portfolio covering reproductive health and oncology. BGI’s Hong Kong laboratory was established in 2010. It received accreditation by College of American Pathology (CAP) in 2013, and currently serves as BGI’s largest sequencing and logistics center for its international customers. ‘We are excited about the addition of the CLIA-certificate of registration at our Hong Kong laboratory’ added Li Ning, Chief Development Officer of BGI Genomics. ‘As well as demonstrating that we are committed to the highest operational and quality standards, this certification is also an important milestone in realizing our vision to offer precision medicine to the global market to benefit all patients, wherever they are.’ About BGI BGI Group was established in 1999 with participation in the original Human Genome Project. Since then, BGI Group has grown in to one of the world’s largest genomics organizations, experienced in genomic research, commercial NGS services and sequencer manufacturing. BGI Group is committed to providing solutions to address the research, pharmaceutical, and clinical markets and is dedicated to improving human health and empowering large-scale human, plant and animal genomics research.

BGI Receives CLIA Certificate of Registration

BGI will be at the SynBioBeta conference from 3 - 5 October in San Fransisco, CA. Come by to say hello and to find out about our genome synthesis and editing capabilities.

BGI will be at SynBioBeta SF 2017

SHENZHEN, China, July 14, 2017 -- BGI Genomics, an independent division of BGI Group, today announced pricing of its initial public offering of 40.1 million shares at a list price of RMB 13.64 per share. BGI Genomics has been listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange. The shares began trading on July 14 under the code 300676. The IPO was approved by the China Securities Regulatory Commission (CSRC) in May. BGI Genomics’ IPO prospectus was first announced on the CSRC website in December 2015 and was updated in March 2017. For the listing ceremony, BGI Genomics invited a group of patients and caregivers to ring the opening bell, signifying the successful launch of BGI Genomics in the Chinese capital market. The event marks a major step for BGI Genomics towards realizing its vision of “Trans-omics for a better life.” “In the genomics field, we aim to dominate the market, creating a bright future for all by bringing both social and economic benefits,” BGI Genomics’ President Wang Jian said in a statement. “Benefitting from our innovations in scientific research, the industry will become more active; by serving people's lives as the starting point, the industry will also become more competitive and scalable.” Wang, who co-founded BGI Group in 1999, vowed not to sell any of his holdings in the next five years, adding he would remain invested over the long term to drive the goal of reducing gene-related disabilities in China. “This IPO is a historic day for BGI,” said Yin Ye, CEO of BGI Genomics. “The capital raised will allow us to invest in the development of new services, top talent and lab infrastructure to benefit our global customers and to support our continued growth and innovation.” About BGI Genomics BGI Genomics is a part of BGI Group, one of the world’s largest genomics organizations. BGI Group was founded in 1999 with the vision of using genomics to benefit humanity and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI Group has a proven track record of innovative, high profile research, which has generated over 2,000 publications. BGI Genomics provides a wide range of commercial next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. BGI Genomics’ mission is to leverage its genomics expertise in order to advance life science research and to improve human health by providing high quality, affordable genomics powered health solutions that are available for everybody. BGI Genomics has particular strengths in prenatal screening, hereditary cancer screening, testing for rare disease and in aiding precision medicine research. Numerous scientific partners, healthcare providers and pharmaceutical companies have come to rely on BGI Genomics’ world leading bio-informatics research and development, large scale computing infrastructure and proprietary sequencing platforms. BGI Genomics is headquartered in Shenzhen, China, with branches and medical laboratories in major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI Genomics also has offices and laboratories located in Europe, North America and the Asia Pacific region.

BGI Genomics Announces Pricing of Initial Public Offering

Budapest, Hungary – University of Debrecen (UD), Hungary and BGI Group signed a Memorandum of Understanding, Tuesday 20th June, regarding cooperation on the establishment of a local NGS sequencing hub for local population cohort studies and diagnostic testing, and wider collaboration in the research and development of genetic and genomic sciences. The MOU was signed by Prof Dr Bartha Elek, Deputy Rector of Education, UD, and Dr. Ning Li, Chief Development Officer of BGI Group Community on Precision Medicine. The signing took place during the CEEC-China Health Ministers’ Meeting, Budapest, Hungary, which aims to facilitate greater cooperation, knowledge sharing and investment in the field of public health. The conference itself can be seen in the context of China’s Belt - Road initiative, which aims to foster economic development along the old Silk Road linking it to Europe. BGI Group has already built close ties with various countries and regions along ‘the Belt and Road’, such as Laos and South Africa, in the fields of scientific research, industrial development and people’s livelihood. According to the agreement, UD and BGI Group will establish joint scientific and innovation research proposals, joint R&amp;D projects and work together developing national and international research and innovation projects. UD and BGI Group will also explore the possibility of establishing a sequencing hub for local population cohort studies and diagnostic testing. The lab will be staffed by UD, with BGI Group providing its sequencing expertise for the successful establishment of the laboratory, and sequencing platforms and ongoing support for the operation of the laboratory. The University of Debrecen, as a leading and prominent institution of Hungarian higher education and in line with the spirit of the Magna Charta of European Universities, is dedicated to developing and improving universal scholarship and Hungarian society by providing high-quality, versatile and interdisciplinary educational as well as research and development programs. The main focus of the UD’s activities is directed at the health industry. UD has established a center for clinical genomics and personalized medicine, and many of its research groups are involved in genomic, transcriptomic and proteomic research and development. BGI Group was established in 1999 with participation in the original Human Genome Project. Since then, BGI Group has grown in to one of the world’s largest genomics organizations, experienced in genomic research, commercial NGS services and sequencer manufacturing. BGI Group is committed to providing solutions to address the research, pharmaceutical, and clinical markets and is dedicated to improving human health and empowering large-scale human, plant and animal genomics research. Dr Ning Li commented, “UD is the leading genomics institution in Hungary. We believe that by combining their local strengths and BGI Group’s sequencing expertise, international network and sequencing platforms, this MOU establishes the beginning of a long-term strategic partnership between UD and BGI Group, which will lead to our two institutions jointly addressing key issues in human health’. &nbsp; Media Contact BGI Genomics: Matt Poulter matt.poulter@bgi.com, Marketing Manager, Copenhagen, Denmark &nbsp; &nbsp;

University of Debrecen, Hungary and BGI Group sign MOU

BGI will be at the FMF World Congress, 25-29 June, Ljubljana, Slovenia. Come and say hello and learn about our range of solutions for reproductive health.
<div class="panel-body"></div>

BGI will be at the FMF World Congress

SHENZHEN, China and BOSTON, May 24, 2017 /PRNewswire/ -- Today, at Bio-IT World Conference &amp; Expo held in Boston, BGI announced that it will work with the Broad Institute, Intel and Alibaba Cloud to provide cloud-based free access to the latest version of the Genome Analysis Tool Kit (GATK4) software package on the BGI Online platform. With this agreement, the GATK Best Practices pipeline will be freely available to users of BGI Online in China around the world. The agreement also includes support of the well-established Workflow Definition Language (WDL) and the workflow execution engine Cromwell in the future version of BGI Online. "As one of the world's largest genome centers, we are delighted to see users in China and around the world get access to state-of-the-art genome analysis tools through the BGI Online platform," said Xin Jin, Deputy Director of Research and Development Center at BGI and director of the BGI Online platform. "We are processing millions of samples each year through BGISEQ-500 sequencers. By providing the cloud-based solution, we can greatly expand access and accelerate both scientific research and clinical applications with cutting-edge genomics technology." "In our global effort to drive breakthroughs in human health, high-quality data is paramount," said Eric Banks, Senior Director of Data Sciences and Data Engineering at the Broad Institute. "We want to help ensure that every researcher, scientist, and analyst has access to the best genomic analysis tools. We are pleased that GATK best practices will be used in the BGI Online platform." "BGI Online offering the newest version of GATK, including optimizations developed through Intel's collaboration with the Broad Institute, means two of the world's top genomics centers will use common open source tools," said Jason Waxman, corporate vice president of the Intel Data Center Solutions Group. "This is a big step toward making state-of-the-art genomic data analysis available worldwide." "As one of the world's leading cloud computing company, Alibaba Cloud looks forward to leveraging our data intelligence and computing power, and accelerating the development of bioinformatics. We are excited to be part of this collative effort in bringing GATK4 to Chinese users and making genome analysis technology more inclusive," said Jin Li, Senior Director at Alibaba Cloud. About BGI Online BGI Online is a powerful and secure cloud platform for genomics data analysis. The platform exploits the powerful computing and unlimited storage capabilities of Amazon Web Services and Alibaba Cloud. BGI Online provides easier and more effective solutions to institutions from data storage, automated analysis, and data delivery to project partnership and bioinformatics methods development. For more information please visit www.bgionline.com (Global) and www.bgionline.cn (China).

BGI to work with Broad Institute, Intel & Alibaba Cloud to provide free access to GATK4 on BGI Online

PHILADELPHIA, May 9, 2017 /PRNewswire-USNewswire/ -- The Children's Brain Tumor Tissue Consortium (CBTTC) has announced the addition of two new satellite member institutions located in China. The addition of The Beijing Tiantan Hospital Neurosurgery Center (BTHNC), located in Beijing and The China National GeneBank (CNGB), established by BGI in Shenzhen, increases the total membership of the CBTTC to 15 core and satellite member institutions located throughout Europe, Asia and the United States. CNBG/BGI and the BTHNC have agreed to contribute genomic data collected from specimens of extracted pediatric brain tumor tissue, which will be uploaded into CAVATICA, a cloud-based platform developed by the CBTTC for collaboratively accessing, sharing and analyzing pediatric cancer data. In addition, BGI and CNBG will lead the recruitment of additional Chinese hospitals and will coordinate the execution of the CBTTC's protocols from sample collection to big data analysis and clinical treatment, for CBTTC member sites in China. "The new CBTTC member sites at Beijing Tiantan Hospital Neurosurgery Center and the China National GeneBank represent a giant leap forward in the collaborative, global effort to find cures and better treatments for pediatric cancer," said Adam Resnick, PhD, Scientific Chair of the CBTTC. "The China National GeneBank is proud to join CBTTC," said Xun Xu, Ph.D., Director of BGI Research and Executive Director of China National GeneBank. "We are looking forward to contributing our big data, genomic research capabilities and network of health care providers to advance the important work of the consortium in improving the outcomes and quality of life for pediatric brain cancer patients." About Beijing Tiantan Hospital Neurosurgery Center BTHNC joins the CBTTC as the largest and most-renowned neurosurgical and center in China. Founded by Dr. Wang Chungcheng, a pioneer of neurosurgery in China in the early 1980s, Beijing Tiantan Hospital Neurosurgery Center provides a full range of adult and pediatric neurological surgery specialty services and performs more than 7,000 brain surgeries per year. About BGI and the China National GeneBank BGI was established in 1999 as Beijing Genomics Institute to participate in the original Human Genome Project. Since then, BGI has grown in to one of the world's largest genomics organizations, experienced in genomic research, commercial NGS services and sequencer manufacturing. BGI, now headquartered in Shenzhen, is committed to improving human health and enabling large-scale plant and animal genomics research by providing solutions for research, pharmaceutical, and clinical markets. Built and operated by BGI-Shenzhen, the China National GeneBank (CNGB) is the first national gene bank integrating a large-scale bio-repository and an omics database. It was established by the Chinese government, with the mission of collecting, preserving and exploiting genomics resources, and to build a network fostering global communication and collaboration on biodiversity conservation and genetic resources utilization. In addition, CNGB is supported by BGI's high-throughput sequencing and bio-informatics capacity, and it will not only provide a repository system for biological collection, but more importantly develop a novel platform to further understand genomic mechanisms of life. Visit www.bgi.com and www.cngb.org. About the Children's Brain Tumor Tissue Consortium The Children's Brain Tumor Tissue Consortium is a multi-institutional, collaborative research partnership dedicated to improving treatments and outcomes for children diagnosed with brain tumors.  The nucleus of the CBTTC is a state-of-the-art biorepository and informatics portal, which allows researchers from all over the world to access high-quality genomic and clinical tumor data. The CBTTC is currently composed of 15 member institutions from around the world. For more information, visit cbttc.org. Contact: Adam Resnick, PhD, Children's Hospital of Philadelphia, resnick@email.chop.edu, 301-728-4653

Children's Brain Tumor Tissue Consortium Announces Two New Satellite Members

BGI, a leading global genomics organization, announced plans to create a West Coast Innovation Center to develop technologies and collaborative projects in life science, global health and related fields. The BGI Global Innovation Center will be co-located in Seattle, Wash. and San Jose, Calif. to build an ecosystem of innovation in the two high-technology clusters and promote cross-sector collaboration. Genomics are driving the most important discoveries of our time, delivering life-saving solutions across the globe. This includes securing our food sources, the preservation of biodiversity in the face of climate change, stemming the spread of devastating pandemics and revolutionizing cures for cancer. Dr. Jian Wang, a pioneer in genomic science, co-founder and president of BGI, visited the West Coast to launch the center, while joining 130 of the world’s top business and technology leaders at the Microsoft CEO Summit. Wang also met with Washington Governor Jay Inslee, University of Washington President Ana Mari Cauce and UW Medicine CEO Paul Ramsey and Dr. Linda Buck, Nobel Laureate and researcher at Fred Hutchinson Cancer Research Center. “The Center demonstrates BGI’s commitment to international collaboration and to aligning interests and partners to drive innovation,” said Wang, adding that BGI intended to support a number of research initiatives, such as precision medicine and population health efforts at the University of Washington. <div class="detail-content"> “With the partnership between UW Medicine and BGI, more innovations in research, education and healthcare will be developed between Seattle and Shenzhen to benefit the health of people worldwide,” Wang stated. </div>

BGI Announces Global Innovation Center on West Coast

BGI and Allen Institute Sign Scientific Memorandum of Understanding BGI, a global genomics company, and the Allen Institute, a nonprofit medical research organization, have signed a memorandum of understanding to discuss and explore possible scientific collaborations using genomics-based research. The two organizations expect to explore comprehensive sequencing technologies and possible collaborative research projects in areas such as bioinformatics and data mining. The research projects envisioned involve defining cell types in the brain and understanding neurodegenerative or developmental diseases and disorders. The relationship may also include educational exchanges between BGI, headquartered in Shenzhen, China, and the Allen Institute, based in Seattle, USA.

BGI and Allen Institute Sign Scientific Memorandum of Understanding

BGI will be at the ESHG Annual Meeting 2017
BGI will be attending the European Society of Human Genetics 2017 Annual Conference in Copenhagen, Denmark May 27-30.
We'll be at booth number 420.
Please drop by to say hello or to tell us about your project.

BGI will be at the ESHG Annual Meeting 2017

<div data-canvas-width="205.1626666666667"> NGS based Gene Expression analysis has been well documented in the literature and offers distinct benefits over traditional microarray data. BGISEQ-500 Gene Expression service now offers these benefits at the same price levels as microarray data: a great value! BGI now offers RNA-Seq(Quantification) Gene Expression Sequencing services based on its own BGISEQ-500 sequencing system, based on cPAS and DNA NanoBall (DNB) technology developed by MGI. </div> BGISEQ-500 Gene Expression Sequencing data correlates very well with TaqMan qPCR data and offers nearly unlimited bioinformatics analysis options. <div data-canvas-width="138.77599999999998">XXX&nbsp;</div> <div data-canvas-width="577.2622222222221"> <div data-canvas-width="138.77599999999998">BGISEQ-500 Gene Expression Sequencing includes:</div> <ul> 	<li>50bp Single-end sequencing reads</li> 	<li>Standard output 20 Million reads per sample</li> 	<li>Clean filtered sequencing data delivered in standard FASTQ file format</li> 	<li>Customized Gene Expression bioinformatics analysis</li> 	<li>Cloud-based data storage and delivery system</li> </ul> </div> <div data-canvas-width="114.11822222222223"></div> <div data-canvas-width="578.4951111111109"></div> <div data-canvas-width="138.77599999999998"> Learn More about Gene expression Sequencing performance and how BGI can put your research in overdrive. &nbsp; </div> <h4>Contact Us Today for a No Obligation Quote</h4> <div>XXXX</div> <div data-canvas-width="114.11822222222223"></div> <div data-canvas-width="114.11822222222223"></div>

Gene Expression Sequencing at Array Prices!

BGI will be attending the Royal College of Obstetrics and Gynaecology 2017 Annual Conference in Cape Town, South Africa, 20-22 March.

We'll be at booth 52. Come and say hello and learn more about our wide range of genomics solutions across reproductive healthcare.

To schedule an appointment, please email us at info@bgi-international.com.

&nbsp;

&nbsp;

BGI will be at RCOG 2017

<h1>Gene Expression: Array Out – NGS In</h1> BGI brings you Gene Expression services at a new level of value. It has been well documented that gene expression data from RNA sequencing yields well-correlated expression data with higher sensitivity and a wider dynamic range. BGI introduces a cost-effective sequencing alternative to traditional micro-array technology, with BGISEQ-500 RNA Expression sequencing. Confidence - Great correlation with micro array data. More data - From raw FastQ data to expression bioinformatics. Lasting data - Analyze, re-analyze your raw data as new insights develop. Higher performance - Higher sensitivity and greater dynamic range. Lower cost - an introductory cost of $249 per sample. Contact us for more information about the possibilities of Gene Expression Sequencing! &nbsp; [form form-1] Service available from our mainland China sequencing laboratory.

Gene Expression: Array Out – NGS In!

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/11/Screen-Shot-2016-11-21-at-11.09.18.png"><img class="alignnone size-full wp-image-3700" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/11/Screen-Shot-2016-11-21-at-11.09.18.png" alt="BGI at London Festival of Genomics" width="668" height="340" /></a>

BGI is delighted to be attending the Festival of Genomics, London. Our Sequencing experts will be on-hand to answer all your questions on our NGS services. Please stop by our booth No. 61 to learn how we can help you generate the highest quality NGS data without the headaches.

&nbsp;

Join BGI at the London Festival of Genomics!

BGI will join world leaders and host a session at the upcoming Precision Medicine World Conference, this coming January in Mountain View, California. BGI executives will explore the possibilities of the information from a low-cost genome for patients and society.&nbsp;&nbsp;
<div class=" et_pb_row et_pb_row_9 et_pb_row_fullwidth">
<div class=" et_pb_row et_pb_row_10">
<div class="et_pb_column et_pb_column_4_4 et_pb_column_13">
<div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_23">
<div class="insert-page insert-page-5398 " data-post-id="5398">
<div class="et_pb_section et_pb_section_3 et_pb_with_background et_section_regular">
<div class="et_pb_row et_pb_row_12 et_pb_row_1-4_3-4">
<div class="et_pb_column et_pb_column_3_4 et_pb_column_16">
<div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_22">

Healthcare in the Era of the Digitized Life&nbsp;</div><div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_22">Genetic testing at extremely low costs, combined with imaging and other technologies, is digitizing human life, enabling more comprehensive diagnosis of disease risks and status. A new paradigm of healthcare is emerging with unprecedented power to allow human beings to live healthier and longer lives.

&nbsp;

</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>&nbsp;<div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_7">Implications of $100 Whole Genome Sequencing&nbsp;</div><div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_7">We explore the healthcare impact of a $100 genome. Whole Genome Sequencing at consumer pricing will give healthcare providers a wealth of information on genetic links, risk factors of diseases, drug targets and drug reactions. The availability of precision medicine will benefit patients and society while lowering cost.&nbsp; &nbsp;</div><div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_8"><div class=" et_pb_row et_pb_row_6">
<div class="et_pb_column et_pb_column_4_4 et_pb_column_8">
<div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_16">
<div class="insert-page insert-page-5394 " data-post-id="5394">
<div class="et_pb_section et_pb_section_2 et_pb_with_background et_section_regular">
<div class="et_pb_column et_pb_column_3_4 et_pb_column_11">
<div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_15"> </div><div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_15">

Efficient WGS as Foundation for Precision Medicine&nbsp;</div><div class="et_pb_text et_pb_module et_pb_bg_layout_light et_pb_text_align_left et_pb_text_15">A complete, accurate and phased WGS is critical to precision medicine. We describe an efficient massively parallel sequencing method using PCR-free process on patterned DNA-nanoball arrays, generating &gt;1Tb (10 genomes) per microscope slide. When combined with co-barcoded reads, this platform generates the phased $100-WGS with quality needed for precision medicine.

Read more:&nbsp;http://www.pmwcintl.com/2017sv/sessionthemes-newhealthcareparadigm/

&nbsp;

&nbsp;

</div>
</div>
<div class=" et_pb_row et_pb_row_9 et_pb_row_fullwidth"></div>
</div>
</div>
</div>
</div>
</div>
<div class=" et_pb_row et_pb_row_10"></div>
</div>

BGI and Precision Medicine in Mountain View

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/08/BGI_ExomePromotion.png"><img class="alignnone size-full wp-image-3619" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/08/BGI_ExomePromotion.png" alt="BGI exome promotion" width="800" height="160" /></a>
<h2>FREE Bioinformatic Analysis FROM $499</h2>
Do more with less: To celebrate the opening of the new academic year, BGI is introducing a unique opportunity get more bang for your buck with a limited-time Exome promotion.
<h2>What</h2>
<ul>
 	<li>Free Bioinformatic analysis: Complete SNP and Indel analysis.</li>
 	<li>100x coverage, 10G data guaranteed.</li>
 	<li>Service from our CAP accredited, 21CFR part 11 compliant laboratory in Hong Kong.</li>
 	<li>With Agilent Sureselect V3, V4, V5 and Roche Nimblegen SeqCap EZ V2, V3 enrichment kits.</li>
</ul>
<h2>When</h2>
Until October 31, BGI offers special pricing for Whole Exome Services, with the quality and care from our CAP laboratory in Hong Kong.
<h2>Act Now</h2>
Contact your local BGI sequencing expert to learn about the details, based on your Exome sequencing project needs.

[form form-1]

&nbsp;

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/illumina.jpg"><img class="alignnone size-full wp-image-127" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/illumina.jpg" alt="Illumina CSP" width="137" height="48" /></a>      <a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/agilent.jpg"><img class="alignnone wp-image-128" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/agilent.jpg" alt="Agilent CSP" width="55" height="49" /></a>

Back-to-School Exome Promotion

&nbsp;
<h2>FREE Bioinformatic Analysis FROM $499</h2>
Do more with less: To celebrate the opening of the new academic year, BGI is introducing a unique opportunity get more bang for your buck with a limited-time Exome promotion.
<h2>What</h2>
<ul>
 	<li>Free Bioinformatic analysis: Complete SNP and Indel analysis.</li>
 	<li>100x coverage, 10G data guaranteed.</li>
 	<li>Service from our CAP accredited, 21CFR part 11 compliant laboratory in Hong Kong.</li>
 	<li>With Agilent Sureselect V3, V4, V5 and Roche Nimblegen SeqCap EZ V2, V3 enrichment kits.</li>
</ul>
<h2>When</h2>
Until October 31, BGI offers special pricing for Whole Exome Services, with the quality and care from our CAP laboratory in Hong Kong.
<h2>Act Now</h2>
Contact your local BGI sequencing expert to learn about the details, based on your Exome sequencing project needs.

[form form-1]

&nbsp;

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/illumina.jpg"><img class="alignnone size-full wp-image-127" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/illumina.jpg" alt="Illumina CSP" width="137" height="48" /></a>      <a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/agilent.jpg"><img class="alignnone wp-image-128" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/04/agilent.jpg" alt="Agilent CSP" width="55" height="49" /></a>

<h1>Enter Our ‘Unlock the Code’ Competition and Win $5,000 of FREE NGS Services!</h1>
A unique chance at the ASHG conference to help unlock the potential of your genomics research.

Sign up at <a href="http://www.bgi.com/us/unlockthecode">www.bgi.com/us/unlockthecode</a> and get your unique code.

Come to our booth #323-325 to see if your code unlocks our genomics treasure chest to win $5,000 of FREE NGS services, from one of our ISO, CAP or CLIA certified laboratories around the world.
Terms and conditions apply.

&nbsp;

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/09/DNA_Safe_Small.png"><img class="alignnone wp-image-3664" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/09/DNA_Safe_Small.png" alt="Unlock the Code" width="500" height="291" /></a>

Enter Our Competition and Win $5000 of NGS Services!

BGISEQ-500:

BGISEQ-500测序平台——集DNA纳米球技术（DNB）、联合探针锚定聚合技术（cPAS）、阵列式芯片（Pattern Array）、科学级CMOS成像系统（sCMOS）等众多黑科技于一身！

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Screen-Shot-2016-07-04-at-12.33.32.png"><img class="wp-image-3331 aligncenter" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Screen-Shot-2016-07-04-at-12.33.32.png" alt="BGISEQ-500 ChIP seq" width="324" height="214" /></a>

ChIP-Seq优势:

1.样品起始量低至5ng

2.交付快至25个工作日

3.同样的服务质量，最低仅需市场价的1/3

4.同样的测序量，更多的有效数据产出

5.独特的cPAS技术，让测序更精准

6.与HiSeq平台一致性相关系数高达0.97，准确性值得信赖

7.测序重复性高达0.98，与同类平台重复性相当

8.可对全基因组范围内的蛋白质结合位点进行高效而准确的鉴定

9.全面的信息分析，让蛋白位点无处可逃

10.与RNA-seq联合分析，让发文更简单

活动一 
<ul>
 	<li>劲爆活动价——1999  元/样本</li>
 	<li>每个客户限量4个，共100个样本</li>
 	<li>建库+测序（20M Clean reads）+信息分析</li>
</ul>
活动时间：即日起至2016年7月30日，逾期恢复原价。

活动二 
<ul>
 	<li>ChIP-Seq+RNA-Seq组合测序策略，附赠价值1000元的联合分析</li>
 	<li>要求：分别购买ChIP-Seq和RNA-Seq</li>
</ul>
活动时间：即日起至2016年7月30日

（两个活动具体送样要求详询华大当地科技代表，本次活动最终解释权归华大基因股份有限公司所有）

<a href="http://survey.bgitechsolutions.cn/m/8923292.aspx">点击报名</a>

联系我们：

电话：400-706-6615

邮箱：<a href="mailto:info@bgitechsolutions.com">info@bgitechsolutions.com</a>

ChIP-Seq新品发布，期末钜惠，等你来!

<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Header.png"><img class="alignnone size-full wp-image-3326" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Header.png" alt="BGI RNA Sequencing" width="1119" height="226"/></a>

RNA-Sequencing for quantification has emerged as the method of choice for measuring the gene expression levels of organisms, particularly adding value to cancer and stem cell research as well as biomarker discovery.&nbsp;Compared to traditional array-based gene expression assays, RNA-Sequencing reveals very high sensitivities for a wide range of transcripts that cannot be readily obtained using microarrays.

Enjoy BGI’s expert RNA-Sequencing services for unbiased detection, at a broader dynamic range than array technology and with higher sensitivity for low-abundance transcripts, without the need to invest in NGS infrastructure.

Quality is in Our DNA

• Comprehensive QC processes perform quality checks at various stages of the project, from sample receipt to data analysis, to assure consistent high quality results.

• Projects are executed by experienced NGS scientists and are monitored by assigned Project Managers to assure the highest quality of data and service.

Personalized Support from Sample to Result

• BGI offers professional project management and local account support by highly qualified personnel.

• From experiment design to raw data and Bioinformatic analysis, BGI will be with you all the way.

• BGI will support your research with swift turn-around-times and fees that fit your budget, without compromising on quality, because your research deserves the best.

BGI Accepts A Wide Range of Sample Types
<div data-canvas-width="660.8324447096809">Our laboratories are specialized in handling a wide variety of sample types, including normal&nbsp;human or animal tissue, whole blood, cell line and fresh frozen samples. We also process&nbsp;your plant, fungi, or insect samples and can custom-design RNA extraction processes to fit&nbsp;your specific needs, including single cell RNA-Sequencing protocols.</div>
<div data-canvas-width="660.8324447096809">_________________________________________________________________________________</div>
<div data-canvas-width="660.8324447096809"></div>
<div data-canvas-width="660.8324447096809"></div>
</div>
</div>
<div data-canvas-width="660.8324447096809"><a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Graphic-table-smaples-RNA.png"><img class="alignnone size-full wp-image-3322" src="http://www.bgi.com/wp-content/uploads/sites/2/2016/06/Graphic-table-smaples-RNA.png" alt="BGI RNA Seq samples " width="827" height="290"/></a></div>
<div data-canvas-width="660.8324447096809">________________________________________________________________________________</div>
</div>
<div data-canvas-width="492.39914018875294">
<div data-canvas-width="376.2810757539361"></div>
<div data-canvas-width="376.2810757539361">Fast Turn-Around Sample Processing</div>
<div data-canvas-width="660.9501831889746">BGI RNA-Sequencing projects are executed using the HiSeq4000 platform. The BGI bioinformatics group performs the data quality&nbsp;control and bioinformatics analysis per your requirements.</div>
<div data-canvas-width="668.7209228223543"></div>
<div data-canvas-width="668.7209228223543">Typical turn-around-times are as quick&nbsp;as 50 days from the time you ship your sample, to result. Expedited services are available.&nbsp;For actual service fees and process time based on your samples, research and bioinformatics&nbsp;needs, please consult your local specialist.</div>
<div data-canvas-width="668.7209228223543">&nbsp;</div>
</div>
<div data-canvas-width="668.7209228223543">&nbsp;_________________________________________________________________________________</div>
<div data-canvas-width="668.7209228223543">Don't hesitate to contact us for more information.</div>
<div data-canvas-width="668.7209228223543">_________________________________________________________________________________</div>
<div data-canvas-width="668.7209228223543">[form form-1]</div>

RNA Services – Quality Data, Fast and Affordable

今年的ICG-11将以崭新的会议场所、创新的学术氛围和革新的交流 方式,恭候全球的科学泰斗、科研翘楚、学界新星和业界元老、管理精英、投资大腕、创业新人、 极客创客的再次光临和对话。 今年的ICG-11主题为“共为、共赢 — 全球合作(Omics for All --- Global Partnership)”。 会议将承继“共需、共有、共为、共享”的“HGP精神”,共建omics的国际联盟和共同体;共话omics奠定的“精准”基础;共创生命经济和生物产业；共商医学和健康、农业和扶贫、绿色生态 创建、大数据和基因库、先进智造等全方位的创新韬略。

ICG-11

BGI will be exhibiting at the ESHG Conference taking place 21st-24th May in Barcelona, Spain. Come and say hello to us at booth 620 and learn more about our global genomics services. Or, sign up for our seminar taking place on Saturday 21st May in room 120|121, 12:15pm, and hear about recent advances in next generation sequencing technology with success stories in clinical and research applications from some of our clients.

For advance registration for our seminar, please send an email to info@bgi.com with the title 'ESHG Seminar Registration' in the subject field.

Seating is limited and space is allocated on a first come first served basis. Boxed lunches will be served for all participants.

For more information regarding talk titles and speakers, please click on the link below.

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2016/04/ESHG-SeminaA4Advert-04-16.pdf" rel="">BGI Seminar at ESHG</a>

&nbsp;

BGI Will Be Exhibiting At ESHG.

BGI will be exhibiting at the American Society of Clinical Oncology conference (ASCO) taking place in Chicago, June 3rd-7th.
Email us at info@bgi.com to arrange a meeting with a representative or to learn more about our ongoing oncology research or cancel panels.

June 3rd-7th, ASCO, Chicago, USA

BGI will be exhibiting at the ASHG conference taking place in Vancouver, Canada, October 18th-22nd.
Stay tuned for more information or email us at info@bgi.com.

October 18th-22nd, ASHG, Vancouver, Canada

The International Plant &amp; Animal Genome XXIV brings together over 3,000 leading genetic scientists and researchers in plant and animal research, with over 130 exhibits, 150 workshops, 1100 posters and over 1800 abstracts. BGI will be exhibiting at the conference. Follow us on Twitter at @BGI_Genomics for our latest product updates and conference news.

2016 9-13 January. San Diego. PAG XXIV

Exome Seq Pricing Promotion!

[av_layerslider id='39']

[av_three_fifth first]

[av_textblock size='' font_color='' color='']
<h1>Whole Genome Sequencing on the Revolocity™ System</h1>The Revolocity™&nbsp;system is the first fully automated, integrated high-capacity sequencing system for whole genome sequencing (WGS) applications.

At BGI, we know that not every partner needs to acquire this population-scale sequencing system. We’re therefore proud to announce our whole genome sequencing services on the Revolocity™ platform, providing you with affordable access to high quality whole genomes at 50X mean coverage.

- 50X genome
- High quality SNP, CNV, Indel and SV data
- Sequencing at our California facility
- Standard file formats
- Comprehensive bioinformatics included
<h1>Contact Us Now with Your Project Requirements or For More Information!</h1>
<a href="http://www.bgi.com/about-us/introduction-int/">Learn more about BGI</a>.
[/av_textblock]

[/av_three_fifth][av_two_fifth]
[av_textblock size='' font_color='' color='']
<h2 style="color: #003a8f; margin-bottom: -10px;">Contact Us For More Information!</h2>
[/av_textblock]

[av_contact email='matt.poulter@gmail.com, dsiu@completegenomics.com, matt.poulter@genomics.cn, gaoqiang@genomics.cn' title='' button='Submit' on_send='' sent='Thank you, your message has been sent. We will contact you shortly.' link='manually,http://' subject='BGI WGS Revolocity info request' autorespond='' captcha='' color='']
[av_contact_field label='Name' type='text' check='is_empty' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='Company' type='text' options='' check='is_empty' width='' multi_select=''][/av_contact_field]
[av_contact_field label='Location' type='text' options='' check='is_empty' width='' multi_select=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' check='is_email' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width='' multi_select=''][/av_contact_field]
[av_contact_field label='Message' type='textarea' check='is_empty' options='' multi_select='' width=''][/av_contact_field]
[/av_contact]
[/av_two_fifth]

Whole Genome Sequencing on the Revolocity™ Platform

The ACMG Annual Clinical Genetics Meeting provides genetics professionals with the opportunity to learn how genetics and genomics are being integrated into medical or clinical practice. BGI will be exhibiting, come and say hello!

2016 8-12 March. Tampa. ACMG

Ground-breaking pricing has always been in BGI’s DNA. Now we are proud to bring you industry leading quality too. With our CAP compliant facility in Hong Kong, US FDA 21 CFR Part 11 compliant processes and 24/7 worldwide technical support by NGS technical specialists and bioinformaticians, we offer exome sequencing solutions for a wide variety of research and clinical needs.

- 50X coverage from USD250.

- 75X, 100X or higher coverage options available with data from our CAP compliant facility in Hong Kong.

- Choose from BGI Capture or Agilent Capture v5 kits

- Per sample yield guarantee options

- Worldwide shipping with 24/7 technical support

- Fast turnaround times
<h2>Contact Us Now to Take Advantage of Our Pricing Promotion!</h2>
Please contact us at info@bgi-international.com with the reference 'Autumn Promotion' in the subject line of your email.

Exome Sequencing - More For Less!

[av_textblock size='' font_color='' color='']
<h1>Don't Miss BGI's Workshop&nbsp;at the International Plant and Animal Genome Conference&nbsp;</h1>
We are pleased to invite you to attend the BGI Workshop at the&nbsp;2016 PAG conference in San Diego. &nbsp;The workshop takes place on Monday the 11th of January at 6.10pm in the Sunset Room. Drinks and refreshments will be provided.

We will cover both plant and animal collaborative projects&nbsp;and provide an update on the BGI 10K Genome Sequencing Initiative. The workshop also provides a good&nbsp;opportunity&nbsp;to meet our&nbsp;experienced US-based project&nbsp;support team should you have any&nbsp;prospective projects you would like to discuss.

If you are unable to attend our workshop, please come and speak to us at booth 323 in the Grand Exhibit Hall.
<h1>Register Now As Space Is Limited!</h1>
<h2></h2>
[/av_textblock]

[av_contact email='matt.poulter@gmail.com' title='' button='Submit' on_send='' sent='Thank you, we have received your email. ' link='manually,http://' subject='PAG Registration Request' autorespond='' captcha='' form_align='' color='']
[av_contact_field label='Name' type='text' check='is_empty' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' check='is_email' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='Company Name' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width=''][/av_contact_field]
[av_contact_field label='Message' type='textarea' options='' check='' width=''][/av_contact_field]
[/av_contact]

Register Now For BGI's Workshop at PAG 2016

The European Human Genetics Conference (now in its 49th year) is a forum for all workers in human and medical genetics to review advances and develop research collaborations. BGI will be exhibiting, come and say hello!

2016 May 21-24. Barcelona. ESHG

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/09/Workshop_Banner-01.png"><img class="alignnone size-full wp-image-2099" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/09/Workshop_Banner-01.png" alt="BGI ASHG symposium" width="700" height="280" /></a>

华大基因欢迎您注册会议：

会议主题：新型测序平台开启大型测序及临床测序应用—流行病研究及治疗的成功案例

会议时间：2015年10月8日周四13:00

会议地点：巴尔地摩会展中心3楼327/328/329厅

嘉宾：

Daniel Siu：华大基因海外业务发展副总裁

I-Ming Wang：默克研究实验室遗传学与药物部首席科学家

Brien Riley：弗吉尼亚联邦大学分子实验室主任

名额有限，先到先得！

[av_contact email='matt.poulter@genomics.cn' title='注册表格' button='Submit' on_send='' sent='Thank you for your interest. We've received your registration.' link='manually,http://' subject='' autorespond='Thank you for your interest in BGI's symposium, we look forward to meeting you. If for any reason you shouldn't be able to make it, please drop us a quick message so we can reallocate your seat. BGI Symposium: New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications 10/08/2015 Thursday 1:00PM-2:30PM Baltimore Convention Center Room 327/328/329, Level 3 ' captcha='' color='']
[av_contact_field label='Name' type='text' options='' multi_select='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Job Title' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Company Name' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Country' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' options='' multi_select='' check='is_email' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width=''][/av_contact_field]
[av_contact_field label='Area of Interest' type='text' options='' check='is_empty' width=''][/av_contact_field]
[/av_contact]

欢迎注册《美国人类遗传学会年度会议（ASHG）》，会议于2015年10月8日13:00在巴尔地摩举行

<a href="http://www.bgi.com/wp-content/uploads/sites/2/2015/09/Workshop_Banner-01.png"><img class="alignnone size-full wp-image-2099" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/09/Workshop_Banner-01.png" alt="BGI ASHG symposium" width="700" height="280" /></a>

BGI Invites You to its Symposium at ASHG 2015:

New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications
- with success stories in therapeutic and epidemiology research from our clients

to be held Thursday, October 8th, 1pm at the Baltimore Convention Center Room 327/328/329, Level 3

Speakers:

- Daniel Siu, Vice President Global Business Development, BGI

- I-Ming Wang, Principal Scientist, Department of Genetics and Pharmacogenomics at Merck Research Labs

- Brien Riley, Director of the Molecular Laboratory at Virginia Commonwealth University

Limited seating is available, registrations are available on a first come first served basis.

[av_contact email='matt.poulter@gmail.com' title='Registration Form' button='Submit' on_send='' sent='Thank you for your interest. We've received your registration.' link='manually,http://' subject='' autorespond='Thank you for your interest in BGI's symposium, we look forward to meeting you. If for any reason you shouldn't be able to make it, please drop us a quick message so we can reallocate your seat. BGI Symposium: New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications 10/08/2015 Thursday 1:00PM-2:30PM Baltimore Convention Center Room 327/328/329, Level 3 ' captcha='' color='']
[av_contact_field label='Name' type='text' options='' multi_select='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Job Title' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Company Name' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Country' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' options='' multi_select='' check='is_email' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width=''][/av_contact_field]
[av_contact_field label='Area of Interest' type='text' options='' check='is_empty' width=''][/av_contact_field]
[/av_contact]

Save the Date! Register Now For BGI's Symposium Thursday, October 8th, 1pm at ASHG 2015, Baltimore

ASHG 2015 will be held in Baltimore, Maryland from Tuesday, October 6 through Saturday, October 10, 2015. The meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics: at invited, platform, and poster sessions; on the trade show floor; and at interactive workshops and events. Visit BGI's booth to find out more about our genetic test products and sequencing services.

BGI Invites You&nbsp;to its Symposium:

New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications
- with success stories in therapeutic and epidemiology research from our clients

to be held Thursday, October 8th, 1pm at the&nbsp;Baltimore Convention Center&nbsp;Room 327/328/329, Level 3

Speakers:

- Daniel Siu, Vice President Business Development, BGI

- I-Ming Wan, Principal scientist, Department of Genetics and Pharmacogenomics at Merck Research Labs

- Brien Riley, Director of the Molecular Laboratory at Virginia Commonwealth University

Limited seating is available, registrations are available on a first come first served basis.

[av_contact email='matt.poulter@genomics.cn' title='Registration Form' button='Submit' on_send='' sent='Thank you for your interest. We've received your registration.' link='manually,http://' subject='' autorespond='Thank you for your interest in BGI's symposium, we look forward to meeting you. If for any reason you shouldn't be able to make it, please drop us a quick message so we can reallocate your seat. BGI Symposium: New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications 10/08/2015 Thursday 1:00PM-2:30PM Baltimore Convention Center Room 327/328/329, Level 3 ' captcha='' color='']
[av_contact_field label='Name' type='text' options='' multi_select='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Job Title' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Company Name' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Country' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' options='' multi_select='' check='is_email' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width=''][/av_contact_field]
[av_contact_field label='Area of Interest' type='text' options='' check='is_empty' width=''][/av_contact_field]
[/av_contact]

6-10 October. Baltimore. ASHG 2015

华大基因欢迎您注册会议：

会议主题：新型测序平台开启大型测序及临床测序应用—流行病研究及治疗的成功案例

会议时间：2015年10月8日周四13:00

会议地点：巴尔地摩会展中心3楼327/328/329厅

嘉宾：

Daniel Siu：华大基因海外业务发展副总裁

I-Ming Wang：默克研究实验室遗传学与药物部首席科学家

Brien Riley：弗吉尼亚联邦大学分子实验室主任

名额有限，先到先得！

[av_contact email='matt.poulter@genomics.cn' title='Registration Form' button='Submit' on_send='' sent='Thank you for your interest. We've received your registration.' link='manually,http://' subject='' autorespond='Thank you for your interest in BGI's symposium, we look forward to meeting you. If for any reason you shouldn't be able to make it, please drop us a quick message so we can reallocate your seat. BGI Symposium: New Sequencing Platforms Enabling Large-scale and Clinical Sequencing Applications 10/08/2015 Thursday 1:00PM-2:30PM Baltimore Convention Center Room 327/328/329, Level 3 ' captcha='' color='']
[av_contact_field label='Name' type='text' options='' multi_select='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Job Title' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Company Name' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='Country' type='text' options='' check='is_empty' width=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' options='' multi_select='' check='is_email' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width=''][/av_contact_field]
[av_contact_field label='Area of Interest' type='text' options='' check='is_empty' width=''][/av_contact_field]
[/av_contact]

10/6-10. Baltimore. 美国人类遗传学会年度会议（ASHG 2015)

<img class="alignnone wp-image-1751 size-full" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/06/millet-bgi.png" alt="millet-bgi" width="900" height="518"/> In 2012, BGI was proud to sign a memorandum of understanding with the Bill and Melinda Gates Foundation with the goal of achieving common objectives in health and agricultural development, and meaningfully contributing to the achievement of one or more of the Millennium Development Goals. Since that date BGI has gone on to sequence the genomes of many critical plant and animal species and human diseases, and contribute its expertise and technology to important&nbsp;human development initiatives across the globe. BGI has paid particular focus to the issue of food scarcity, a problem that is set to become more critical as the world’s population increases. BGI has initiated or participated in the sequencing of 70% of the 188 plants, which are closely associated with the necessity of feeding our human population. Utilizing our advanced technology platforms and molecular breeding expertise, BGI has also developed a new variety of millet, the ‘Shen Nong Millet’. Millet has been planted by humans for thousands of years and contains abundant protein, vitamins, coarse fiber and essential amino acids. The ‘Shen Nong Millet’ is more resilient to climatic extremes and can therefore be planted in a wider range of regions while producing significantly higher yields than traditional varieties. Crucially, the ‘Shen Nong Millet’ also requires far less water resources to grow than other millet or crop varieties, a factor of critical importance in areas of the world suffering from food scarcity as a result of low rainfall. The BGI Farm, China. <img class="alignleft wp-image-1748 size-full" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/06/bgi-millet.png" alt="bgi-millet" width="347" height="212"/> <img class="alignleft size-full wp-image-1749" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/06/bgi-millet-2.png" alt="bgi-millet-2" width="347" height="212"/>

How we came to develop a new variety of millet, the ‘Shen Nong Millet’

<img class="alignnone wp-image-612 size-full" src="http://www.bgi.com/wp-content/uploads/sites/2/2015/05/BGIA-Spotlight-Page-Banner-BGIonline1.jpg" alt="BGIA-Spotlight-Page-Banner-BGIonline1" width="700" height="223"/>
BGI has developed a powerful and highly secure cloud-based genomic computingBGI-online-icon-v1-blue-1 platform, known as BGI Online, aims to provide easier and more effective solutions for a wide range of problems faced by bioinformaticians. With more robust software, a high level of data security, and well-designed data logistics, BGI Online liberates researchers from the constraints of limited storage space, high labor costs, data delivery, and endless command lines in data analysis.

The advantages of BGI Online:
Powerful, Efficient, and Economical
One-Stop Solution for NGS Research
Collaboration with Anyone, Anywhere
Unparalleled Safety and Security
<h3>Powerful, Efficient, and Economical</h3>
BGI Online has an integrated infrastructure with high-performance computing servers, massive data storage capabilities, and secure networking interconnection.

No need to set up and maintain hardware– anytime, anywhere
Utilize unlimited resources dynamically and Multi-tier, flexible storage
Seamless integration via automated API
Powerful metadata system for convenient data/sample management
Data Level Parallelism (DLP), Automatic monitoring, Smart rerun

One-Stop Solution for NGS Data Analysis
With BGI Online, users can easily combine public bioinformatics tools and our proprietary tools and resources with their own custom tools and data sets to create pipelines that fit their specific needs.

Ready-to-run Pipelines
- Analyze your data according to best practices- 5 open genomics pipelines (WGS, WES, RNA-Seq, RNA-ref, single-gene genetic disease); 30+ genomics tools
- Sophisticated expert support
Customized Bioinformatics Analysis
- Full customization for parameters and pipelines
- Drag-and-drop pipeline construction via an intuitive visual editor
Downstream Integration
- Visualization
- Clinical reporting
Developer-Friendly
- Docker-based software development kit (SDK) provides easy and efficient wrapping of tools
- Supports all major sequencing technologies and all program languages

Collaboration with Anyone, Anywhere
BGI Online users can instantly and securely share data and analysis tools on a global scale, facilitating communication with their collaborators.

Multiple users can participate in the same project with different access roles: Payer, Uploader, Analyst, and Manager, etc.
Data and tools can be shared among users
All activities are recorded and audited
Leverage pre-collected public data sets and applications
Publish your data or applications to get rewarded
Learn from other users via the BBS discussion forum

Unparalleled Safety and Security
BGI Online provides the best-in-class safety performance, ensuring the highest level of data security in the industry and compliance with clinical and diagnostic standards.

HIPAA ∧EU Data Protection Directive compliant
Fine-grained project/user privileges
Secure (SSL) data transfer throughout the platform
AES256 data encryption at rest

GET STARTED TODAY
Go to www.bgionline.com to sign up for your free BGI Online account. Every new user gets 30,000 free credits to explore the BGI Online cloud analysis platform.

BGI online - Analyse, store, and share your genomics data securely

BGI will be attending the&nbsp;14th World Congress in Fetal Medicine on the 21- 25 June on Crete.

Vestibulum lacinia tempor lacinia. Pellentesque volutpat lectus semper orci gravida auctor. Maecenas mollis quam sagittis commodo euismod. Aliquam et lectus sit amet lacus placerat dapibus. Curabitur tristique dolor urna, in porttitor ante tempus ut. Duis hendrerit vulputate risus, at luctus mi condimentum nec. Morbi semper sem sed lacinia consequat.

21-25 June - 14th World Congress in Fetal Medicine

Read about BGI News and our latest goings on, including company news and recent genomics publications.

News and Events